<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00474526</url>
  </required_header>
  <id_info>
    <org_study_id>V59P14</org_study_id>
    <nct_id>NCT00474526</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants</brief_title>
  <official_title>A Phase 3, Open-Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and immune response of the Novartis Meningococcal ACWY
      conjugate vaccine when administered with routine infant vaccinations to healthy infants.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects With hSBA Titer &gt;=1:8 - US Subjects</measure>
    <time_frame>13 months of age (one month post-toddler vaccination)</time_frame>
    <description>Immunogenicity as measured by percentage of subjects with hSBA titer &gt;=1:8 directed against N. meningitidis serogroups A, C, W and Y; after four doses of MenACWY-CRM at 2, 4, and 6 and 12 months of age</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean hSBA Titers - US Subjects</measure>
    <time_frame>13 months of age (one month post-toddler vaccination)</time_frame>
    <description>Immunogenicity as measured by Geometric Mean hSBA Titers directed against N. meningitidis serogroups A, C, W and Y; comparison of four doses of MenACWY-CRM at 2, 4, and 6 and 12 months of age versus a single dose at 12 months of age.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Solicited Local and Systemic Reactions Post First Vaccination - Infant Series</measure>
    <time_frame>7 days after vaccination</time_frame>
    <description>Solicited local and systemic reactions post first vaccination of infant series were compared in subjects receiving Infant Vaccines only and subjects receiving MenACWY-CRM concomitantly with Infant Vaccines.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Solicited Local and Systemic Reactions Post Second Vaccination - Infant Series</measure>
    <time_frame>7 days after vaccination</time_frame>
    <description>Solicited local and systemic reactions post second vaccination of infant series were compared in subjects receiving Infant Vaccines only and subjects receiving MenACWY-CRM concomitantly with Infant Vaccines.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Solicited Local and Systemic Reactions Post Third Vaccination - Infant Series</measure>
    <time_frame>7 days after vaccination</time_frame>
    <description>Solicited local and systemic reactions post third vaccination of infant series were compared in subjects receiving Infant Vaccines only and subjects receiving MenACWY-CRM concomitantly with Infant Vaccines.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Solicited Local and Systemic Reactions After Vaccination at 12 Months of Age</measure>
    <time_frame>7 days after vaccination</time_frame>
    <description>Solicited local and systemic reactions after receiving MenACWY-CRM vaccination at 12 months of age were compared in subjects receiving Infant Vaccines only and subjects receiving MenACWY-CRM concomitantly with Infant Vaccines.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Solicited Local and Systemic Reactions Post First Vaccination - Toddler Series</measure>
    <time_frame>7 days post vaccination</time_frame>
    <description>Solicited local and systemic reactions post first vaccination of toddler series were compared in subjects receiving Infant Vaccines only and subjects receiving MenACWY-CRM concomitantly with Infant Vaccines.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Solicited Local and Systemic Reactions Post Second Vaccination - Toddler Series</measure>
    <time_frame>7 days post vaccination</time_frame>
    <description>Solicited local and systemic reactions post second vaccination of toddler series at 15 months of age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Solicited Local and Systemic Reactions Post First Vaccination - Infant Series</measure>
    <time_frame>7 days post-vaccination</time_frame>
    <description>Solicited local and systemic reactions reported post first vaccination was compared in subjects receiving MenACWY versus Hib Vaccines.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Solicited Local and Systemic Reactions Post Second Vaccination - Infant Series</measure>
    <time_frame>7 days post-vaccination</time_frame>
    <description>Solicited local and systemic reactions reported post second vaccination was compared in subjects receiving MenACWY versus Hib Vaccines.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Solicited Local and Systemic Reactions Post Third Vaccination - Infant Series</measure>
    <time_frame>7 days post-vaccination</time_frame>
    <description>Solicited local and systemic reactions reported post third vaccination was compared in subjects receiving MenACWY versus Hib Vaccines.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean hSBA Titers Post-infant Series - US Subjects</measure>
    <time_frame>7 months of age (one month post-infant series)</time_frame>
    <description>Geometric Mean hSBA Titers directed against N. meningitidis serogroups A, C, W and Y was measured after three doses at 2, 4, and 6 months of age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean hSBA Titers Post-infant Series - LA Subjects</measure>
    <time_frame>7 months of age (one month post-infant series)</time_frame>
    <description>Geometric Mean hSBA Titers directed against N. meningitidis serogroups A, C, W and Y was measured after two doses of MenACWY at 2 and 6 months (LA1) versus three doses at 2, 4, and 6 (LA3) months of age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With hSBA Titer &gt;=1:8 - US Subjects</measure>
    <time_frame>7 months of age (one month post-infant series)</time_frame>
    <description>Immunogenicity as measured by percentage of subjects with hSBA titer &gt;=1:8 directed against N. meningitidis serogroups A, C, W and Y; after three doses of MenACWY at 2, 4, and 6 months of age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With hSBA Titer &gt;=1:4 - US Subjects</measure>
    <time_frame>7 months of age (one month post-infant series)</time_frame>
    <description>Immunogenicity as measured by percentage of subjects with hSBA titer &gt;=1:4 directed against N. meningitidis serogroups A, C, W and Y; after three doses of MenACWY at 2, 4, and 6 months of age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With hSBA Titer &gt;=1:8 - LA Subjects</measure>
    <time_frame>7 months of age (one month post-infant series)</time_frame>
    <description>Immunogenicity as measured by percentage of subjects with hSBA titer &gt;=1:8 directed against N. meningitidis serogroups A, C, W and Y; after two doses of MenACWY at 2 and 6 months (LA1) versus three doses at 2, 4, and 6 months of age (LA3) .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With hSBA Titer &gt;=1:4 - LA Subjects</measure>
    <time_frame>7 months of age (one month post-infant series)</time_frame>
    <description>Immunogenicity as measured by percentage of subjects with hSBA titer &gt;=1:4 directed against N. meningitidis serogroups A, C, W and Y; after two doses of MenACWY at 2 and 6 months (LA1) versus three doses at 2, 4, and 6 months of age (LA3) .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentrations or Titers of DTaP, HBV, Hib, Pneumococcal and Polio Antigens at 1 Month After Infant Series Vaccination - US Subjects</measure>
    <time_frame>7 months of age (one month post-infant series)</time_frame>
    <description>Immunogenicity as measured by antibody GMCs / GMTs directed against DTaP, HBV, Hib, pneumococcal and polio antigens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroresponse Rates to DTaP, HBV, Hib, Pneumococcal and Polio Antigens at 1 Month After Infant Series Vaccination - US Subjects</measure>
    <time_frame>7 months of age (one month post-infant series)</time_frame>
    <description>Immunogenicity as measured by percentage of subjects with predefined seroprotective antibody titers against DTaP, HBV, Hib, pneumococcal and polio antigens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentrations or Titers of DTaP, HBV, Hib, Pneumococcal and Polio Antigens at 1 Month After Infant Series Vaccination - LA Subjects</measure>
    <time_frame>7 months of age (one month post-infant series)</time_frame>
    <description>Immunogenicity as measured by antibody GMCs / GMTs directed against DTaP, HBV, Hib, pneumococcal and polio antigens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroresponse Rates to DTaP, HBV, Hib, Pneumococcal and Polio Antigens at 1 Month After Infant Series Vaccination - LA Subjects</measure>
    <time_frame>7 months of age (one month post-infant series)</time_frame>
    <description>Immunogenicity as measured by percentage of subjects with predefined seroprotective antibody titers against DTaP, HBV, Hib, pneumococcal and polio antigens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Persistence Antibodies hSBA ≥1:4 at 12 Months of Age- US Subject</measure>
    <time_frame>12 Months of Age (one month pre-toddler vaccination)</time_frame>
    <description>Persistence of Antibodies as measured by the percentage of subjects with serum bactericidal activity using human complement (hSBA) ≥ 1:4, directed against N.meningitidis serogroups A, C, W and Y.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Persistence Antibodies hSBA ≥1:8 at 12 Months of Age- US Subject</measure>
    <time_frame>12 Months of Age (one month pre-toddler vaccination)</time_frame>
    <description>Persistence of Antibodies as measured by the percentage of subjects with serum bactericidal activity using human complement (hSBA) ≥ 1:8, directed against N.meningitidis serogroups A, C, W and Y.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistence Antibodies Geometric Mean Titers - US Subject</measure>
    <time_frame>12 Months of Age (one month pre-toddler vaccination)</time_frame>
    <description>Geometric Mean hSBA Titers directed against N. meningitides serogroups A, C, W and Y was measured at 12 Months of Age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Persistence Antibodies hSBA ≥1:4 at 12 or 16 Months of Age- LA Subject</measure>
    <time_frame>12 or 16 Months of Age (one month pre-toddler vaccination)</time_frame>
    <description>Persistence of Antibodies as measured by the percentage of subjects with serum bactericidal activity using human complement (hSBA) ≥ 1:4, directed against N.meningitidis serogroups A, C, W and Y.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Persistence Antibodies hSBA ≥1:8 at 12 or 16 Months of Age- LA Subject</measure>
    <time_frame>12 or 16 Months of Age (one month pre-toddler vaccination)</time_frame>
    <description>Persistence of Antibodies as measured by the percentage of subjects with serum bactericidal activity using human complement (hSBA) ≥ 1:8, directed against N.meningitidis serogroups A, C, W and Y.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistence Antibodies Geometric Mean Titers - LA Subjects</measure>
    <time_frame>12 or 16 Months of Age (one month pre-toddler vaccination)</time_frame>
    <description>Geometric Mean hSBA Titers directed against N. meningitidis serogroups A, C, W and Y was measured at 12 or 16 Months of Age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects (95% CI) With hSBA ≥ 1:4 at 1 Month After Toddler MenACWY Vaccination - US Subjects</measure>
    <time_frame>13 months of age (one month post-toddler vaccination)</time_frame>
    <description>Immunogenicity as measured by the percentage of subjects with serum bactericidal activity using human complement (hSBA) ≥ 1:4 , directed against N.meningitidis serogroups A, C, W and Y.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects (95% CI) With hSBA ≥ 1:8 at 1 Month After Toddler MenACWY Vaccination - US Subjects</measure>
    <time_frame>13 months of age (one month post-toddler vaccination)</time_frame>
    <description>Immunogenicity as measured by the percentage of subjects with serum bactericidal activity using human complement (hSBA) ≥ 1:8 , directed against N.meningitidis serogroups A, C, W and Y.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects (95% CI) With hSBA ≥ 1:16 at 1 Month After Toddler MenACWY Vaccination - US Subjects</measure>
    <time_frame>13 months of age (one month post-toddler vaccination)</time_frame>
    <description>Immunogenicity as measured by the percentage of subjects with serum bactericidal activity using human complement (hSBA) ≥ 1:16 , directed against N.meningitidis serogroups A, C, W and Y.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean hSBA Titers at 1 Month After Toddler MenACWY Vaccination - US Subjects</measure>
    <time_frame>13 months of age (one month post-toddler vaccination)</time_frame>
    <description>Immunogenicity as measured by Geometric Mean hSBA Titers directed against N. meningitidis serogroups A, C, W and Y; comparison of four doses of MenACWY-CRM at 2, 4, and 6 and 12 months of age versus a single dose at 12 months of age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects (95% CI) With hSBA ≥1:4 at 1 Month After Toddler MenACWY Vaccination - LA Subjects</measure>
    <time_frame>13 or 17 Months of Age (one month post-toddler vaccination)</time_frame>
    <description>Immunogenicity as measured by the percentage of subjects with serum bactericidal activity using human complement (hSBA) ≥ 1:4, directed against N. meningitidis serogroups A, C, W and Y.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects (95% CI) With hSBA ≥1:8 at 1 Month After Toddler MenACWY Vaccination - LA Subjects</measure>
    <time_frame>13 or 17 Months of Age (one month post-toddler vaccination)</time_frame>
    <description>Immunogenicity as measured by the percentage of subjects with serum bactericidal activity using human complement (hSBA) ≥ 1:8, directed against N. meningitidis serogroups A, C, W and Y.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With hSBA ≥ 1:16 at 1 Month After Toddler MenACWY Vaccination - LA Subjects</measure>
    <time_frame>13 or 17 Months of Age (one month post-toddler vaccination)</time_frame>
    <description>Immunogenicity as measured by the percentage of subjects with serum bactericidal activity using human complement (hSBA) ≥ 1:16, directed against N. meningitidis serogroups A, C, W and Y.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean hSBA Titers at 1 Month After Toddler MenACWY Vaccination - LA Subjects</measure>
    <time_frame>13 or 17 Months of Age (one month post-toddler vaccination)</time_frame>
    <description>Immunogenicity as measured by Serum bactericidal activity using human complement (hSBA) GMTs, directed against N. meningitidis serogroups A, C, W and Y.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentrations of Pneumococcal Antibodies at 1 Month After Toddler Vaccination - US Subjects</measure>
    <time_frame>13 months of age (one month post-toddler vaccination)</time_frame>
    <description>Immunogenicity as measured by antibody GMTs, directed against pneumococcal antigens PnC 4, PnC 6B, PnC 9V, PnC 14, PnC 18C, PnC 19F and PnC 23F.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Pneumococcal Antibody GMCs ≥1.0 μg/mL at 1 Month After Toddler Vaccination - US Subjects</measure>
    <time_frame>13 months of age (one month post-toddler vaccination)</time_frame>
    <description>Immunogenicity as measured by Percentage of Subjects with Pneumococcal Antibody GMCs ≥1.0 μg/mL directed against pneumococcal antigens PnC 4, PnC 6B, PnC 9V, PnC 14, PnC 18C, PnC 19F and PnC 23F.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentrations of Pneumococcal Antibodies at 1 Month After Toddler Vaccination - LA Subjects</measure>
    <time_frame>13 months of age (one month post-toddler vaccination)</time_frame>
    <description>Immunogenicity as measured by antibody GMTs, directed against pneumococcal antigens PnC 4, PnC 6B, PnC 9V, PnC 14, PnC 18C, PnC 19F and PnC 23F.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Pneumococcal Antibody Concentration ≥1.0 μg/mL at 1 Month After Toddler Vaccination - LA Subjects</measure>
    <time_frame>13 months of age (one month post-toddler vaccination)</time_frame>
    <description>Immunogenicity as measured by Percentage of Subjects with Pneumococcal Antibody GMCs ≥1.0 μg/mL directed against pneumococcal antigens PnC 4, PnC 6B, PnC 9V, PnC 14, PnC 18C, PnC 19F and PnC 23F</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentrations or Titers of DTaP and Hib Antigens at 1 Month After Toddler Vaccination - LA Subjects</measure>
    <time_frame>17 months of age (one month post-toddler vaccination)</time_frame>
    <description>Immunogenicity as measured by antibody GMCs/GMTs, directed against DTaP and Hib Antigens</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroresponse Rates to DTaP and Hib Antigens at 1 Month After Toddler Vaccination - LA Subjects</measure>
    <time_frame>17 months of age (one month post-toddler vaccination)</time_frame>
    <description>Immunogenicity as measured by Percentage of Subjects with predefined seroprotective antibody titers against DTaP and Hib Antigens</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With hSBA ≥1:8 at 1 Month After 1st (LA2) or 2nd (LA4) Toddler MenACWY Vaccination - LA Subjects</measure>
    <time_frame>12 or 15 months of age (one month post 1st or 2nd toddler vaccination)</time_frame>
    <description>Immunogenicity as measured by the percentage of subjects with serum bactericidal activity using human complement (hSBA) ≥ 1:8, directed against N.meningitidis serogroups A, C, W and Y.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean hSBA Titers at 1 Month After 1st (LA2) or 2nd (LA4) Toddler MenACWY Vaccination - LA Subjects</measure>
    <time_frame>12 or 15 months of age (one month post 1st or 2nd toddler vaccination)</time_frame>
    <description>Immunogenicity as measured by Serum bactericidal activity using human complement (hSBA) GMTs, directed against N. meningitidis serogroups A, C, W and Y.</description>
  </secondary_outcome>
  <number_of_arms>17</number_of_arms>
  <enrollment type="Actual">4545</enrollment>
  <condition>Meningitis, Meningococcal</condition>
  <arm_group>
    <arm_group_label>US1A (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Received vaccines:
MenACWY: 2, 4, 6, and 12 months
DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months
Pneumococcal, HAV, and MMR-V: 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>US1B (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Received vaccines:
MenACWY: 2, 4, 6, and 13 months
DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months
Pneumococcal, HAV, and MMR-V: 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>US2 (Infant Vaccines Only)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Received vaccines:
MenACWY: 12 and 15 months
DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months
Pneumococcal, HAV, and MMR-V: 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>US3 (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Received vaccines:
MenACWY: 2, 4, 6, and 12 months
DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months
Pneumococcal, HAV, and MMR-V: 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>US4A (Infant Vaccines Only)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Received vaccines:
MenACWY: 12 and 15 months
DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months
Pneumococcal, HAV, and MMR-V: 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>US4B (Infant Vaccines Only)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Received vaccines:
MenACWY: 13 and 15 months DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months
Pneumococcal, HAV, and MMR-V: 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>US4C (Infant Vaccines Only)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Received vaccines:
MenACWY: 18 months
DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months
Pneumococcal, HAV, and MMR-V: 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LA1A (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Received vaccines:
MenACWY: 2, 6, and 12 months
DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months Pneumococcal, HAV, and MMR-V: 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LA1B (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Received vaccines:
MenACWY: 2, 6, and 13 months
DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months
Pneumococcal, HAV, and MMR-V: 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LA2 (Infant Vaccines Only)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Received vaccines:
MenACWY: 12 and 15 months
DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months
Pneumococcal, HAV, and MMR-V: 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LA3A (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Received vaccines:
MenACWY: 2, 4, 6, and 16 months
DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months
DTaP, Hib: 16 months
Pneumococcal, HAV, and MMR-V: 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LA3B (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Received vaccines:
MenACWY: 2, 4, 6, and 17 months
DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months
DTaP, Hib: 16 months
Pneumococcal, HAV, and MMR-V: 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LA4 (Infant Vaccines Only)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Received vaccines:
MenACWY: 12 and 15 months
DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months
DTaP, Hib: 15 months
Pneumococcal, HAV, and MMR-V: 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LA5 (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Received vaccines:
MenACWY: 2, 4, 6, and 12 months
DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months
Pneumococcal, HAV, and MMR-V: 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LA6A (Infant Vaccines Only)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Received vaccines:
MenACWY: 12, and 15 months
DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months
Pneumococcal, HAV, and MMR-V: 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LA6B (Infant Vaccines Only)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Received vaccines:
MenACWY: 13 and 15 months
DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months
Pneumococcal, HAV, and MMR-V: 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LA6C (Infant Vaccines Only)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Received vaccines:
MenACWY: 18 months
DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months
Pneumococcal, HAV, and MMR-V: 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningococcal ACWY Conjugate Vaccine</intervention_name>
    <arm_group_label>US1A (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_label>US1B (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_label>US2 (Infant Vaccines Only)</arm_group_label>
    <arm_group_label>US3 (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_label>US4A (Infant Vaccines Only)</arm_group_label>
    <arm_group_label>US4B (Infant Vaccines Only)</arm_group_label>
    <arm_group_label>US4C (Infant Vaccines Only)</arm_group_label>
    <arm_group_label>LA1A (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_label>LA1B (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_label>LA2 (Infant Vaccines Only)</arm_group_label>
    <arm_group_label>LA3A (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_label>LA3B (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_label>LA4 (Infant Vaccines Only)</arm_group_label>
    <arm_group_label>LA5 (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_label>LA6A (Infant Vaccines Only)</arm_group_label>
    <arm_group_label>LA6B (Infant Vaccines Only)</arm_group_label>
    <arm_group_label>LA6C (Infant Vaccines Only)</arm_group_label>
    <other_name>Menveo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DTaP-IPV-HBV</intervention_name>
    <arm_group_label>US1A (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_label>US1B (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_label>US2 (Infant Vaccines Only)</arm_group_label>
    <arm_group_label>US3 (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_label>US4A (Infant Vaccines Only)</arm_group_label>
    <arm_group_label>US4B (Infant Vaccines Only)</arm_group_label>
    <arm_group_label>US4C (Infant Vaccines Only)</arm_group_label>
    <arm_group_label>LA1A (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_label>LA1B (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_label>LA2 (Infant Vaccines Only)</arm_group_label>
    <arm_group_label>LA3A (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_label>LA3B (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_label>LA4 (Infant Vaccines Only)</arm_group_label>
    <arm_group_label>LA5 (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_label>LA6A (Infant Vaccines Only)</arm_group_label>
    <arm_group_label>LA6B (Infant Vaccines Only)</arm_group_label>
    <arm_group_label>LA6C (Infant Vaccines Only)</arm_group_label>
    <other_name>Pediarix® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine Combined</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hib</intervention_name>
    <arm_group_label>US1A (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_label>US1B (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_label>US2 (Infant Vaccines Only)</arm_group_label>
    <arm_group_label>US3 (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_label>US4A (Infant Vaccines Only)</arm_group_label>
    <arm_group_label>US4B (Infant Vaccines Only)</arm_group_label>
    <arm_group_label>US4C (Infant Vaccines Only)</arm_group_label>
    <arm_group_label>LA1A (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_label>LA1B (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_label>LA2 (Infant Vaccines Only)</arm_group_label>
    <arm_group_label>LA3A (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_label>LA3B (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_label>LA4 (Infant Vaccines Only)</arm_group_label>
    <arm_group_label>LA5 (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_label>LA6A (Infant Vaccines Only)</arm_group_label>
    <arm_group_label>LA6B (Infant Vaccines Only)</arm_group_label>
    <arm_group_label>LA6C (Infant Vaccines Only)</arm_group_label>
    <other_name>ActHIB® (Haemophilus influenzae type b Conjugate Vaccine)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rotavirus</intervention_name>
    <arm_group_label>US1A (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_label>US1B (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_label>US2 (Infant Vaccines Only)</arm_group_label>
    <arm_group_label>US3 (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_label>US4A (Infant Vaccines Only)</arm_group_label>
    <arm_group_label>US4B (Infant Vaccines Only)</arm_group_label>
    <arm_group_label>US4C (Infant Vaccines Only)</arm_group_label>
    <arm_group_label>LA1A (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_label>LA1B (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_label>LA2 (Infant Vaccines Only)</arm_group_label>
    <arm_group_label>LA3A (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_label>LA3B (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_label>LA4 (Infant Vaccines Only)</arm_group_label>
    <arm_group_label>LA5 (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_label>LA6A (Infant Vaccines Only)</arm_group_label>
    <arm_group_label>LA6B (Infant Vaccines Only)</arm_group_label>
    <arm_group_label>LA6C (Infant Vaccines Only)</arm_group_label>
    <other_name>RotaTeq® Rotavirus Vaccine, Live, Oral, Pentavalent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pneumococcal 7-valent Conjugate Vaccine</intervention_name>
    <arm_group_label>US1A (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_label>US1B (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_label>US2 (Infant Vaccines Only)</arm_group_label>
    <arm_group_label>US3 (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_label>US4B (Infant Vaccines Only)</arm_group_label>
    <arm_group_label>US4C (Infant Vaccines Only)</arm_group_label>
    <arm_group_label>LA1A (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_label>LA1B (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_label>LA2 (Infant Vaccines Only)</arm_group_label>
    <arm_group_label>LA3A (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_label>LA3B (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_label>LA4 (Infant Vaccines Only)</arm_group_label>
    <arm_group_label>LA5 (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_label>LA6A (Infant Vaccines Only)</arm_group_label>
    <arm_group_label>LA6B (Infant Vaccines Only)</arm_group_label>
    <arm_group_label>LA6C (Infant Vaccines Only)</arm_group_label>
    <other_name>Prevnar®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HAV</intervention_name>
    <arm_group_label>US1A (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_label>US1B (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_label>US2 (Infant Vaccines Only)</arm_group_label>
    <arm_group_label>US3 (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_label>US4A (Infant Vaccines Only)</arm_group_label>
    <arm_group_label>US4B (Infant Vaccines Only)</arm_group_label>
    <arm_group_label>US4C (Infant Vaccines Only)</arm_group_label>
    <arm_group_label>LA1A (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_label>LA1B (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_label>LA2 (Infant Vaccines Only)</arm_group_label>
    <arm_group_label>LA3A (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_label>LA3B (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_label>LA4 (Infant Vaccines Only)</arm_group_label>
    <arm_group_label>LA5 (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_label>LA6A (Infant Vaccines Only)</arm_group_label>
    <arm_group_label>LA6B (Infant Vaccines Only)</arm_group_label>
    <arm_group_label>LA6C (Infant Vaccines Only)</arm_group_label>
    <other_name>Havrix® (Hepatitis A Vaccine, Inactivated)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MMR-V</intervention_name>
    <arm_group_label>US1A (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_label>US1B (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_label>US2 (Infant Vaccines Only)</arm_group_label>
    <arm_group_label>US3 (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_label>US4A (Infant Vaccines Only)</arm_group_label>
    <arm_group_label>US4B (Infant Vaccines Only)</arm_group_label>
    <arm_group_label>US4C (Infant Vaccines Only)</arm_group_label>
    <arm_group_label>LA1A (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_label>LA1B (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_label>LA2 (Infant Vaccines Only)</arm_group_label>
    <arm_group_label>LA3A (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_label>LA3B (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_label>LA4 (Infant Vaccines Only)</arm_group_label>
    <arm_group_label>LA5 (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_label>LA6A (Infant Vaccines Only)</arm_group_label>
    <arm_group_label>LA6B (Infant Vaccines Only)</arm_group_label>
    <other_name>ProQuad™ (Measles, Mumps, Rubella and Varicella vaccine)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DTaP</intervention_name>
    <arm_group_label>LA3A (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_label>LA3B (MenACWY-CRM + Infant Vaccines)</arm_group_label>
    <arm_group_label>LA4 (Infant Vaccines Only)</arm_group_label>
    <other_name>Infanrix® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy term 2-month-old infants for whom a parent/legal representative has given
             written informed consent.

        Exclusion Criteria:

          -  Subjects with a previous or suspected disease caused by Neisseria meningitidis,
             Corynebacterium diphtheriae, Clostridium tetani, Poliovirus, Hepatitis B, Haemophilus
             influenzae type b (Hib), Pneumococcus or Bordetella pertussis; previous immunization
             with a meningococcal vaccine or vaccine containing meningococcal antigen(s) or prior
             vaccination with Diptheria, Tetanus, Pertussis (acellular or whole cell), inactivated
             polio vaccineIPV or oral polio vaccineOPV, H. influenzae type b (Hib) or Pneumococcus;
             who have had household contact with and/or intimate exposure to an individual with
             laboratory confirmed N. meningitidis (serogroups A, C, W-135, or Y), B. pertussis,
             Hib, C. diphtheriae, Polio, or pneumococcal infection at any time since birth; Any
             serious acute, chronic or progressive disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>2 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis - Vaccines</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Vaccines &amp; Diagnostics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Growing Up Pediatrics</name>
      <address>
        <city>Bessemer</city>
        <state>Alabama</state>
        <zip>35022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alabama Clinical Therapeutics, LLC</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>03523</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Growing Up Pediatrics</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Health Research Center, LLC</name>
      <address>
        <city>Downey</city>
        <state>California</state>
        <zip>90241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Med Group - Vaccine Study Ctr</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Trials, LLC</name>
      <address>
        <city>Paramount</city>
        <state>California</state>
        <zip>90723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Pleasanton</name>
      <address>
        <city>Pleasanton</city>
        <state>California</state>
        <zip>94588</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Richmond</name>
      <address>
        <city>Richmond</city>
        <state>California</state>
        <zip>94801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Santa Clara</name>
      <address>
        <city>Santa Clara</city>
        <state>California</state>
        <zip>95051</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Center for Vaccine Research</name>
      <address>
        <city>Torrence</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Longmont Medical Research Network</name>
      <address>
        <city>Longmont</city>
        <state>Colorado</state>
        <zip>80501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614-3394</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kentucky Pediatric/Adult Research Inc.</name>
      <address>
        <city>Bardstown</city>
        <state>Kentucky</state>
        <zip>40004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Annapolis Pediatrics</name>
      <address>
        <city>Annapolis</city>
        <state>Maryland</state>
        <zip>21401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Vaccine Development</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Pediatric Center</name>
      <address>
        <city>Frederick</city>
        <state>Maryland</state>
        <zip>21702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston University Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Associates of Fall River</name>
      <address>
        <city>Fall River</city>
        <state>Massachusetts</state>
        <zip>02724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Creighton University</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Physicians Dundee</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akron Children's Hospital</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louis P. Brine, Jr., MD, Beeghley Medical Park</name>
      <address>
        <city>Boardman</city>
        <state>Ohio</state>
        <zip>44512</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Senders Pediatric Research at Dr. Senders and Associates</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carnegie Pediatrics</name>
      <address>
        <city>Carnegie</city>
        <state>Pennsylvania</state>
        <zip>15106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Health Care - West</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC/Community Medicine, Inc.</name>
      <address>
        <city>Greenville</city>
        <state>Pennsylvania</state>
        <zip>16125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Healthcare Partners</name>
      <address>
        <city>Grove City</city>
        <state>Pennsylvania</state>
        <zip>16127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pennridge Pediatric Associates</name>
      <address>
        <city>Harleyville</city>
        <state>Pennsylvania</state>
        <zip>19438</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Associates of Latrobe</name>
      <address>
        <city>Latrobe</city>
        <state>Pennsylvania</state>
        <zip>15650</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Medical Associates</name>
      <address>
        <city>Norristown</city>
        <state>Pennsylvania</state>
        <zip>19401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Squirrel Hill Office</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Alliance, Greentree Division</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Hills Pediatrics</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Alliance, Southwestern</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Physicians Research, Inc</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatrics Medical Associates</name>
      <address>
        <city>Rydal</city>
        <state>Pennsylvania</state>
        <zip>19046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pennridge Pediatric Associates</name>
      <address>
        <city>Sellersville</city>
        <state>Pennsylvania</state>
        <zip>18960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laurel Pediatrics</name>
      <address>
        <city>Uniontown</city>
        <state>Pennsylvania</state>
        <zip>15401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCP - Pittsburgh Pediatrics</name>
      <address>
        <city>Wexford</city>
        <state>Pennsylvania</state>
        <zip>15090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Goodlettsville Pediatrics</name>
      <address>
        <city>Madison</city>
        <state>Tennessee</state>
        <zip>37115-2154</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Across America</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercury Pharma Services</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scott and White Hospital</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wee Care Pediatrics</name>
      <address>
        <city>Layton</city>
        <state>Utah</state>
        <zip>84041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utah Valley Pediatrics - Timpanogos</name>
      <address>
        <city>Orem</city>
        <state>Utah</state>
        <zip>84057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foothill Family Clinic</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Copperview Medical Center</name>
      <address>
        <city>South Jordan</city>
        <state>Utah</state>
        <zip>84095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monroe Medical Foundation</name>
      <address>
        <city>Monroe</city>
        <state>Wisconsin</state>
        <zip>53566</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CEDEPAP Rio IV</name>
      <address>
        <city>Alvear 1439 PB Dpto, rio IV, Cordoba</city>
        <state>Cordoba</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospitales Materno Neonatal,</name>
      <address>
        <city>Castro Barros 650 - Barrio San Martin, Cordoba</city>
        <state>Cordoba</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Luis Pasteur,</name>
      <address>
        <city>Mendoza n°2152, Villa Maria, Cordoba,</city>
        <state>Cordoba</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Buenos Aires, Argentina</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1406DGI</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CdePAP, Centro De Desarrollo De Proyectos Avanzados Roma 1465,</name>
      <address>
        <city>Cordoba</city>
        <zip>X5000BJH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Estudios Infect</name>
      <address>
        <city>Scalabrini Ortiz 676, Buenos Aires, Buenos Aires,</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siloe</name>
      <address>
        <city>Calle 1 #50-51</city>
        <state>Cali</state>
        <zip>405</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comfenalco</name>
      <address>
        <city>Calle 6#5-42</city>
        <state>Cali</state>
        <zip>405</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital C H Trujillo</name>
      <address>
        <city>Calle 72U 28 F-00</city>
        <state>Cali</state>
        <zip>405</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corporation Cientifica</name>
      <address>
        <city>Ped Calle 5B5 No.37 BIS-28</city>
        <state>Cali</state>
        <zip>405</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Colombia</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Klein NP, Reisinger KS, Johnston W, Odrljin T, Gill CJ, Bedell L, Dull P. Safety and immunogenicity of a novel quadrivalent meningococcal CRM-conjugate vaccine given concomitantly with routine vaccinations in infants. Pediatr Infect Dis J. 2012 Jan;31(1):64-71. doi: 10.1097/INF.0b013e31823dce5c. Erratum in: Pediatr Infect Dis J. 2012 Oct;31(10):1105.</citation>
    <PMID>22094635</PMID>
  </results_reference>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2007</study_first_submitted>
  <study_first_submitted_qc>May 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2007</study_first_posted>
  <results_first_submitted>May 27, 2013</results_first_submitted>
  <results_first_submitted_qc>February 24, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 24, 2014</results_first_posted>
  <disposition_first_submitted>April 16, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>April 16, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 20, 2010</disposition_first_posted>
  <last_update_submitted>February 24, 2014</last_update_submitted>
  <last_update_submitted_qc>February 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Meningococcal</keyword>
  <keyword>meningitis</keyword>
  <keyword>vaccine</keyword>
  <keyword>infants</keyword>
  <keyword>Meningococcal meningitis</keyword>
  <keyword>Meningococcal disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningitis</mesh_term>
    <mesh_term>Meningitis, Meningococcal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>US1A (MenACWY-CRM + Infant Vaccines)</title>
          <description>US infants received MenACWY at 2, 4 and 6 months of age along with routine infant vaccines, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccine. These infants received a fourth dose of MenACWY concomitantly with pneumococcal, HAV, and MMR-V vaccines at 12 months of age.</description>
        </group>
        <group group_id="P2">
          <title>US1B (MenACWY-CRM + Infant Vaccines)</title>
          <description>US infants received MenACWY at 2, 4 and 6 months of age along with routine infant vaccines, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines. These infants received pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months; and a fourth dose of MenACWY at 13 months of age.</description>
        </group>
        <group group_id="P3">
          <title>US2 (Infant Vaccines Only)</title>
          <description>US infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. These infants received one dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months; and a second dose of MenACWY at 15 months of age.</description>
        </group>
        <group group_id="P4">
          <title>US3 (MenACWY-CRM + Infant Vaccines)</title>
          <description>US infants received MenACWY at 2, 4 and 6 months of age along with routine infant vaccines, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccine. These infants received fourth dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months of age.</description>
        </group>
        <group group_id="P5">
          <title>US4A (Infant Vaccines Only)</title>
          <description>US infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. These infants received one dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months; and a second dose of MenACWY at 15 months of age.</description>
        </group>
        <group group_id="P6">
          <title>US4B (Infant Vaccines Only)</title>
          <description>US infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. These subjects received concomitant pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months; and one dose of MenACWY at 13 and a second dose of MenACWY at 15 months of age.</description>
        </group>
        <group group_id="P7">
          <title>US4C (Infant Vaccines Only)</title>
          <description>US infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines, at 2, 4 and 6 months of age. These subjects received concomitant pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months and one dose of MenACWY at 18 months of age.</description>
        </group>
        <group group_id="P8">
          <title>LA1A (MenACWY-CRM + Infant Vaccines)</title>
          <description>LA infants received MenACWY at 2 and 6 months of age; and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. These subjects received a third dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months of age.</description>
        </group>
        <group group_id="P9">
          <title>LA1B (MenACWY-CRM + Infant Vaccines)</title>
          <description>LA infants received MenACWY at 2 and 6 months of age and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. These subjects received pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months and a third dose of MenACWY at 13 months of age.</description>
        </group>
        <group group_id="P10">
          <title>LA2 (Infant Vaccines Only)</title>
          <description>LA infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. These infants received one dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months; and a second dose of MenACWY at 15 months of age.</description>
        </group>
        <group group_id="P11">
          <title>LA3A (MenACWY-CRM + Infant Vaccines)</title>
          <description>LA infants received MenACWY at 2, 4 and 6 months of age; and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, pneumococcal conjugate vaccine, and rotavirus vaccine. Around 12 months of age, these infants were recommended to receive pneumococcal conjugate vaccine, HAV, and MMR-V. At 16 months of age, these subjects received the fourth dose of MenACWY along with concomitant DTaP and Hib.</description>
        </group>
        <group group_id="P12">
          <title>LA3B (MenACWY-CRM + Infant Vaccines)</title>
          <description>LA infants received MenACWY at 2, 4 and 6 months of age; and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, pneumococcal conjugate vaccine, and rotavirus vaccine. Around 12 months of age, received pneumococcal conjugate vaccine, HAV, and MMR-V. At 16 months of age, these subjects received DTaP and Hib. At 17 months of age, these subjects received the fourth dose of MenACWY.</description>
        </group>
        <group group_id="P13">
          <title>LA4 (Infant Vaccines Only)</title>
          <description>LA infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, pneumococcal conjugate vaccine, and rotavirus vaccine at 2, 4 and 6 months of age. These infants received one dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months and a second dose of MenACWY along with DTaP and Hib vaccines at 15 months of age.</description>
        </group>
        <group group_id="P14">
          <title>LA5 (MenACWY-CRM + Infant Vaccines)</title>
          <description>LA infants received MenACWY at 2, 4 and 6 months of age; and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines. At 12 months of age, these subjects received the fourth dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V.</description>
        </group>
        <group group_id="P15">
          <title>LA6A (Infant Vaccines Only)</title>
          <description>LA infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, rotavirus, and pneumococcal conjugate vaccines, at 2, 4 and 6 months of age. These infants received concomitant pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months; and one dose of MenACWY at 12 and a second dose of MenACWY at 15 months of age.</description>
        </group>
        <group group_id="P16">
          <title>LA6B (Infant Vaccines Only)</title>
          <description>LA infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, rotavirus, and pneumococcal conjugate vaccines, at 2, 4 and 6 months of age. These infants received concomitant pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months; and one dose of MenACWY at 13 and a second dose of MenACWY at 15 months of age.</description>
        </group>
        <group group_id="P17">
          <title>LA6C (Infant Vaccines Only)</title>
          <description>LA infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, rotavirus, and pneumococcal conjugate vaccines, at 2, 4 and 6 months of age. These infants received concomitant pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months; and one dose of MenACWY at 18 months of age</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="154"/>
                <participants group_id="P2" count="166"/>
                <participants group_id="P3" count="159"/>
                <participants group_id="P4" count="680"/>
                <participants group_id="P5" count="76"/>
                <participants group_id="P6" count="70"/>
                <participants group_id="P7" count="203"/>
                <participants group_id="P8" count="151"/>
                <participants group_id="P9" count="150"/>
                <participants group_id="P10" count="148"/>
                <participants group_id="P11" count="151"/>
                <participants group_id="P12" count="150"/>
                <participants group_id="P13" count="150"/>
                <participants group_id="P14" count="1426"/>
                <participants group_id="P15" count="358"/>
                <participants group_id="P16" count="170"/>
                <participants group_id="P17" count="183"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="121"/>
                <participants group_id="P2" count="120"/>
                <participants group_id="P3" count="110"/>
                <participants group_id="P4" count="561"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="54"/>
                <participants group_id="P7" count="178"/>
                <participants group_id="P8" count="145"/>
                <participants group_id="P9" count="144"/>
                <participants group_id="P10" count="121"/>
                <participants group_id="P11" count="141"/>
                <participants group_id="P12" count="139"/>
                <participants group_id="P13" count="135"/>
                <participants group_id="P14" count="1270"/>
                <participants group_id="P15" count="281"/>
                <participants group_id="P16" count="152"/>
                <participants group_id="P17" count="174"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="46"/>
                <participants group_id="P3" count="49"/>
                <participants group_id="P4" count="119"/>
                <participants group_id="P5" count="68"/>
                <participants group_id="P6" count="16"/>
                <participants group_id="P7" count="25"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="27"/>
                <participants group_id="P11" count="10"/>
                <participants group_id="P12" count="11"/>
                <participants group_id="P13" count="15"/>
                <participants group_id="P14" count="156"/>
                <participants group_id="P15" count="77"/>
                <participants group_id="P16" count="18"/>
                <participants group_id="P17" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>ADMINISTRATIVE REASON</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="20"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="1"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="2"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="1"/>
                <participants group_id="P16" count="1"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="3"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>INAPPROPRIATE ENROLLMENT</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="2"/>
                <participants group_id="P15" count="2"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="29"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="8"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="6"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="4"/>
                <participants group_id="P13" count="6"/>
                <participants group_id="P14" count="74"/>
                <participants group_id="P15" count="29"/>
                <participants group_id="P16" count="4"/>
                <participants group_id="P17" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="4"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="2"/>
                <participants group_id="P13" count="4"/>
                <participants group_id="P14" count="19"/>
                <participants group_id="P15" count="9"/>
                <participants group_id="P16" count="6"/>
                <participants group_id="P17" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>UNABLE TO CLASSIFY</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="3"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="20"/>
                <participants group_id="P15" count="12"/>
                <participants group_id="P16" count="6"/>
                <participants group_id="P17" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="52"/>
                <participants group_id="P5" count="38"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="12"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="13"/>
                <participants group_id="P11" count="5"/>
                <participants group_id="P12" count="4"/>
                <participants group_id="P13" count="4"/>
                <participants group_id="P14" count="37"/>
                <participants group_id="P15" count="22"/>
                <participants group_id="P16" count="1"/>
                <participants group_id="P17" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>US1A (MenACWY-CRM + Infant Vaccines)</title>
          <description>US infants received MenACWY at 2, 4 and 6 months of age along with routine infant vaccines, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccine. These infants received a fourth dose of MenACWY concomitantly with pneumococcal, HAV, and MMR-V vaccines at 12 months of age.</description>
        </group>
        <group group_id="B2">
          <title>US1B (MenACWY-CRM + Infant Vaccines)</title>
          <description>US infants received MenACWY at 2, 4 and 6 months of age along with routine infant vaccines, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines. These infants received pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months; and a fourth dose of MenACWY at 13 months of age.</description>
        </group>
        <group group_id="B3">
          <title>US2 (Infant Vaccines Only)</title>
          <description>US infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. These infants received one dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months; and a second dose of MenACWY at 15 months of age.</description>
        </group>
        <group group_id="B4">
          <title>US3 (MenACWY-CRM + Infant Vaccines)</title>
          <description>US infants received MenACWY at 2, 4 and 6 months of age along with routine infant vaccines, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccine. These infants received fourth dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months of age.</description>
        </group>
        <group group_id="B5">
          <title>US4A (Infant Vaccines Only)</title>
          <description>US infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. These infants received one dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months; and a second dose of MenACWY at 15 months of age.</description>
        </group>
        <group group_id="B6">
          <title>US4B (Infant Vaccines Only)</title>
          <description>US infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. These subjects received concomitant pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months; and one dose of MenACWY at 13 and a second dose of MenACWY at 15 months of age.</description>
        </group>
        <group group_id="B7">
          <title>US4C (Infant Vaccines Only)</title>
          <description>US infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines, at 2, 4 and 6 months of age. These subjects received concomitant pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months and one dose of MenACWY at 18 months of age.</description>
        </group>
        <group group_id="B8">
          <title>LA1A (MenACWY-CRM + Infant Vaccines)</title>
          <description>LA infants received MenACWY at 2 and 6 months of age; and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. These subjects received a third dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months of age.</description>
        </group>
        <group group_id="B9">
          <title>LA1B (MenACWY-CRM + Infant Vaccines)</title>
          <description>LA infants received MenACWY at 2 and 6 months of age and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. These subjects received pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months and a third dose of MenACWY at 13 months of age.</description>
        </group>
        <group group_id="B10">
          <title>LA2 (Infant Vaccines Only)</title>
          <description>LA infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. These infants received one dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months; and a second dose of MenACWY at 15 months of age.</description>
        </group>
        <group group_id="B11">
          <title>LA3A (MenACWY-CRM + Infant Vaccines)</title>
          <description>LA infants received MenACWY at 2, 4 and 6 months of age; and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, pneumococcal conjugate vaccine, and rotavirus vaccine. Around 12 months of age, these infants were recommended to receive pneumococcal conjugate vaccine, HAV, and MMR-V. At 16 months of age, these subjects received the fourth dose of MenACWY along with concomitant DTaP and Hib.</description>
        </group>
        <group group_id="B12">
          <title>LA3B (MenACWY-CRM + Infant Vaccines)</title>
          <description>LA infants received MenACWY at 2, 4 and 6 months of age; and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, pneumococcal conjugate vaccine, and rotavirus vaccine. Around 12 months of age, received pneumococcal conjugate vaccine, HAV, and MMR-V. At 16 months of age, these subjects received DTaP and Hib. At 17 months of age, these subjects received the fourth dose of MenACWY.</description>
        </group>
        <group group_id="B13">
          <title>LA4 (Infant Vaccines Only)</title>
          <description>LA infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, pneumococcal conjugate vaccine, and rotavirus vaccine at 2, 4 and 6 months of age. These infants received one dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months and a second dose of MenACWY along with DTaP and Hib vaccines at 15 months of age.</description>
        </group>
        <group group_id="B14">
          <title>LA5 (MenACWY-CRM + Infant Vaccines)</title>
          <description>LA infants received MenACWY at 2, 4 and 6 months of age; and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines. At 12 months of age, these subjects received the fourth dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V.</description>
        </group>
        <group group_id="B15">
          <title>LA6A (Infant Vaccines Only)</title>
          <description>LA infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, rotavirus, and pneumococcal conjugate vaccines, at 2, 4 and 6 months of age. These infants received concomitant pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months; and one dose of MenACWY at 12 and a second dose of MenACWY at 15 months of age.</description>
        </group>
        <group group_id="B16">
          <title>LA6B (Infant Vaccines Only)</title>
          <description>LA infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, rotavirus, and pneumococcal conjugate vaccines, at 2, 4 and 6 months of age. These infants received concomitant pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months; and one dose of MenACWY at 13 and a second dose of MenACWY at 15 months of age.</description>
        </group>
        <group group_id="B17">
          <title>LA6C (Infant Vaccines Only)</title>
          <description>LA infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, rotavirus, and pneumococcal conjugate vaccines, at 2, 4 and 6 months of age. These infants received concomitant pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months; and one dose of MenACWY at 18 months of age</description>
        </group>
        <group group_id="B18">
          <title>TOTAL</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="154"/>
            <count group_id="B2" value="166"/>
            <count group_id="B3" value="159"/>
            <count group_id="B4" value="680"/>
            <count group_id="B5" value="76"/>
            <count group_id="B6" value="70"/>
            <count group_id="B7" value="203"/>
            <count group_id="B8" value="151"/>
            <count group_id="B9" value="150"/>
            <count group_id="B10" value="148"/>
            <count group_id="B11" value="151"/>
            <count group_id="B12" value="150"/>
            <count group_id="B13" value="150"/>
            <count group_id="B14" value="1426"/>
            <count group_id="B15" value="358"/>
            <count group_id="B16" value="170"/>
            <count group_id="B17" value="183"/>
            <count group_id="B18" value="4545"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.1" spread="7.2"/>
                    <measurement group_id="B2" value="65.8" spread="6.6"/>
                    <measurement group_id="B3" value="65.7" spread="6.5"/>
                    <measurement group_id="B4" value="65.0" spread="6.0"/>
                    <measurement group_id="B5" value="66.1" spread="6.2"/>
                    <measurement group_id="B6" value="65.0" spread="6.5"/>
                    <measurement group_id="B7" value="65.9" spread="6.5"/>
                    <measurement group_id="B8" value="68.0" spread="7.7"/>
                    <measurement group_id="B9" value="68.6" spread="8.9"/>
                    <measurement group_id="B10" value="67.8" spread="8.3"/>
                    <measurement group_id="B11" value="67.0" spread="7.9"/>
                    <measurement group_id="B12" value="68.4" spread="8.7"/>
                    <measurement group_id="B13" value="67.5" spread="8.0"/>
                    <measurement group_id="B14" value="65.0" spread="9.4"/>
                    <measurement group_id="B15" value="67.7" spread="9.7"/>
                    <measurement group_id="B16" value="59.5" spread="6.2"/>
                    <measurement group_id="B17" value="65.0" spread="7.9"/>
                    <measurement group_id="B18" value="65.7" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="71"/>
                    <measurement group_id="B4" value="340"/>
                    <measurement group_id="B5" value="39"/>
                    <measurement group_id="B6" value="29"/>
                    <measurement group_id="B7" value="103"/>
                    <measurement group_id="B8" value="79"/>
                    <measurement group_id="B9" value="82"/>
                    <measurement group_id="B10" value="72"/>
                    <measurement group_id="B11" value="72"/>
                    <measurement group_id="B12" value="75"/>
                    <measurement group_id="B13" value="81"/>
                    <measurement group_id="B14" value="682"/>
                    <measurement group_id="B15" value="178"/>
                    <measurement group_id="B16" value="89"/>
                    <measurement group_id="B17" value="91"/>
                    <measurement group_id="B18" value="2223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="88"/>
                    <measurement group_id="B4" value="340"/>
                    <measurement group_id="B5" value="37"/>
                    <measurement group_id="B6" value="41"/>
                    <measurement group_id="B7" value="100"/>
                    <measurement group_id="B8" value="72"/>
                    <measurement group_id="B9" value="68"/>
                    <measurement group_id="B10" value="76"/>
                    <measurement group_id="B11" value="79"/>
                    <measurement group_id="B12" value="75"/>
                    <measurement group_id="B13" value="69"/>
                    <measurement group_id="B14" value="744"/>
                    <measurement group_id="B15" value="180"/>
                    <measurement group_id="B16" value="81"/>
                    <measurement group_id="B17" value="92"/>
                    <measurement group_id="B18" value="2322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With hSBA Titer &gt;=1:8 - US Subjects</title>
        <description>Immunogenicity as measured by percentage of subjects with hSBA titer &gt;=1:8 directed against N. meningitidis serogroups A, C, W and Y; after four doses of MenACWY-CRM at 2, 4, and 6 and 12 months of age</description>
        <time_frame>13 months of age (one month post-toddler vaccination)</time_frame>
        <population>The analysis was done on per protocol population
Per protocol was defined as subjects who:
received all the relevant doses of vaccine correctly
provided evaluable serum samples at the relevant time points
had no major protocol deviation as defined prior to database lock</population>
        <group_list>
          <group group_id="O1">
            <title>US1A (MenACWY- CRM + Infant Vaccines)</title>
            <description>US infants received one dose of MenACWY at 2, 4 and 6 months of age and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, pneumococcal conjugate vaccine, and rotavirus vaccine.At 12 months of age received fourth dose of MenACWY along with concomitant pneumococcal,HAV, and MMR-V vaccines.</description>
          </group>
          <group group_id="O2">
            <title>US2 (Infant Vaccine Only)</title>
            <description>received as part of routine infant vaccination schedule DTaP-IPV-HBV,Hib, pneumococcal conjugate vaccine, and rotavirus vaccine at 2, 4 and 6 months of age. At 12 months of age, these subjects received a dose of MenACWY along with concomitant pneumococcal conjugate vaccine, HAV, and MMR-V. At 15 months of age, these subjects received a second dose of MenACWY.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With hSBA Titer &gt;=1:8 - US Subjects</title>
          <description>Immunogenicity as measured by percentage of subjects with hSBA titer &gt;=1:8 directed against N. meningitidis serogroups A, C, W and Y; after four doses of MenACWY-CRM at 2, 4, and 6 and 12 months of age</description>
          <population>The analysis was done on per protocol population
Per protocol was defined as subjects who:
received all the relevant doses of vaccine correctly
provided evaluable serum samples at the relevant time points
had no major protocol deviation as defined prior to database lock</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A (84, 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" lower_limit="87" upper_limit="98"/>
                    <measurement group_id="O2" value="72" lower_limit="60" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C (86, 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="92" upper_limit="100"/>
                    <measurement group_id="O2" value="90" lower_limit="81" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W (85, 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O2" value="58" lower_limit="45" upper_limit="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Y (84, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O2" value="56" lower_limit="43" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Solicited Local and Systemic Reactions Post First Vaccination – Infant Series</title>
        <description>Solicited local and systemic reactions post first vaccination of infant series were compared in subjects receiving Infant Vaccines only and subjects receiving MenACWY-CRM concomitantly with Infant Vaccines.</description>
        <time_frame>7 days after vaccination</time_frame>
        <population>The population used in analysis was the safety set Safety population was defined as: all subjects in the exposed population who provided post-baseline safety data. If a subject received an entirely wrong vaccine schedule (e.g., US3 instead of US4), the subject would be analyzed for safety according to the group the subject actually followed.</population>
        <group_list>
          <group group_id="O1">
            <title>US1A (MenACWY-CRM + Infant Vaccines)</title>
            <description>US infants received MenACWY at 2, 4 and 6 months of age along with routine infant vaccines, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccine. These infants received a fourth dose of MenACWY concomitantly with pneumococcal, HAV, and MMR-V vaccines at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>US1B (MenACWY-CRM + Infant Vaccines )</title>
            <description>US infants received MenACWY at 2, 4 and 6 months of age along with routine infant vaccines, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines. These infants received pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months; and a fourth dose of MenACWY at 13 months of age.</description>
          </group>
          <group group_id="O3">
            <title>US1 (MenACWY-CRM + Infant Vaccines)</title>
            <description>US infants received one dose of MenACWY at 2, 4 and 6 months of age; and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines. Group US1 was randomized into US1A and US1B subgroups.</description>
          </group>
          <group group_id="O4">
            <title>US2 (Infant Vaccines Only)</title>
            <description>US infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. These infants received one dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months; and a second dose of MenACWY at 15 months of age.</description>
          </group>
          <group group_id="O5">
            <title>US3 (MenACWY-CRM + Infant Vaccines)</title>
            <description>US infants received MenACWY at 2, 4 and 6 months of age along with routine infant vaccines, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccine. These infants received fourth dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months of age.</description>
          </group>
          <group group_id="O6">
            <title>US4 (Infant Vaccines Only )</title>
            <description>US infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. These infants received concomitant pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months of age. These infants were randomized in subgroup US4A, US4B and US4C.</description>
          </group>
          <group group_id="O7">
            <title>LA1 (MenACWY-CRM + Infant Vaccines)</title>
            <description>LA infants received MenACWY at 2 and 6 months of age and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. Group LA1 was randomized into LA1A and LA 1B subgroups.</description>
          </group>
          <group group_id="O8">
            <title>LA2 (Infant Vaccines Only)</title>
            <description>LA infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. These infants received one dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months; and a second dose of MenACWY at 15 months of age.</description>
          </group>
          <group group_id="O9">
            <title>LA3 (MenACWY-CRM + Infant Vaccines)</title>
            <description>LA infants received MenACWY at 2, 4 and 6 months of age; and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, pneumococcal conjugate vaccine, and rotavirus vaccine. Group LA3 was further randomized into LA3A and LA3B subgroups.</description>
          </group>
          <group group_id="O10">
            <title>LA4 (Infant Vaccines Only)</title>
            <description>LA infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, pneumococcal conjugate vaccine, and rotavirus vaccine at 2, 4 and 6 months of age. These infants received one dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months and a second dose of MenACWY along with DTaP and Hib vaccines at 15 months of age.</description>
          </group>
          <group group_id="O11">
            <title>LA5 (MenACWY-CRM + Infant Vaccines)</title>
            <description>LA infants received MenACWY at 2, 4 and 6 months of age; and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines. At 12 months of age, these subjects received the fourth dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V.</description>
          </group>
          <group group_id="O12">
            <title>LA6 (Infant Vaccines Only)</title>
            <description>LA infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, rotavirus, and pneumococcal conjugate vaccines, at 2, 4 and 6 months of age. These infants received concomitant pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months of age. Group LA6 was further randomized into LA6A and LA6B and LA6C subgroups.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Solicited Local and Systemic Reactions Post First Vaccination – Infant Series</title>
          <description>Solicited local and systemic reactions post first vaccination of infant series were compared in subjects receiving Infant Vaccines only and subjects receiving MenACWY-CRM concomitantly with Infant Vaccines.</description>
          <population>The population used in analysis was the safety set Safety population was defined as: all subjects in the exposed population who provided post-baseline safety data. If a subject received an entirely wrong vaccine schedule (e.g., US3 instead of US4), the subject would be analyzed for safety according to the group the subject actually followed.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="165"/>
                <count group_id="O3" value="318"/>
                <count group_id="O4" value="159"/>
                <count group_id="O5" value="677"/>
                <count group_id="O6" value="345"/>
                <count group_id="O7" value="301"/>
                <count group_id="O8" value="148"/>
                <count group_id="O9" value="301"/>
                <count group_id="O10" value="150"/>
                <count group_id="O11" value="1424"/>
                <count group_id="O12" value="709"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Erythema (mm) - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="23"/>
                    <measurement group_id="O5" value="66"/>
                    <measurement group_id="O6" value="54"/>
                    <measurement group_id="O7" value="86"/>
                    <measurement group_id="O8" value="62"/>
                    <measurement group_id="O9" value="86"/>
                    <measurement group_id="O10" value="65"/>
                    <measurement group_id="O11" value="542"/>
                    <measurement group_id="O12" value="273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema (mm) - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration (mm) - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="25"/>
                    <measurement group_id="O5" value="61"/>
                    <measurement group_id="O6" value="44"/>
                    <measurement group_id="O7" value="74"/>
                    <measurement group_id="O8" value="56"/>
                    <measurement group_id="O9" value="72"/>
                    <measurement group_id="O10" value="53"/>
                    <measurement group_id="O11" value="249"/>
                    <measurement group_id="O12" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration (mm) - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="2"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="76"/>
                    <measurement group_id="O3" value="140"/>
                    <measurement group_id="O4" value="69"/>
                    <measurement group_id="O5" value="324"/>
                    <measurement group_id="O6" value="161"/>
                    <measurement group_id="O7" value="154"/>
                    <measurement group_id="O8" value="96"/>
                    <measurement group_id="O9" value="170"/>
                    <measurement group_id="O10" value="95"/>
                    <measurement group_id="O11" value="916"/>
                    <measurement group_id="O12" value="501"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="25"/>
                    <measurement group_id="O6" value="19"/>
                    <measurement group_id="O7" value="30"/>
                    <measurement group_id="O8" value="19"/>
                    <measurement group_id="O9" value="22"/>
                    <measurement group_id="O10" value="20"/>
                    <measurement group_id="O11" value="92"/>
                    <measurement group_id="O12" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body Temp. ( &gt;= 38° C )</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="32"/>
                    <measurement group_id="O6" value="21"/>
                    <measurement group_id="O7" value="15"/>
                    <measurement group_id="O8" value="12"/>
                    <measurement group_id="O9" value="18"/>
                    <measurement group_id="O10" value="5"/>
                    <measurement group_id="O11" value="211"/>
                    <measurement group_id="O12" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Eating Habits - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="88"/>
                    <measurement group_id="O4" value="34"/>
                    <measurement group_id="O5" value="171"/>
                    <measurement group_id="O6" value="96"/>
                    <measurement group_id="O7" value="37"/>
                    <measurement group_id="O8" value="30"/>
                    <measurement group_id="O9" value="44"/>
                    <measurement group_id="O10" value="16"/>
                    <measurement group_id="O11" value="250"/>
                    <measurement group_id="O12" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Eating Habits - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="6"/>
                    <measurement group_id="O12" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="47"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="107"/>
                    <measurement group_id="O6" value="46"/>
                    <measurement group_id="O7" value="42"/>
                    <measurement group_id="O8" value="20"/>
                    <measurement group_id="O9" value="44"/>
                    <measurement group_id="O10" value="22"/>
                    <measurement group_id="O11" value="222"/>
                    <measurement group_id="O12" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="2"/>
                    <measurement group_id="O12" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="107"/>
                    <measurement group_id="O3" value="189"/>
                    <measurement group_id="O4" value="96"/>
                    <measurement group_id="O5" value="419"/>
                    <measurement group_id="O6" value="211"/>
                    <measurement group_id="O7" value="121"/>
                    <measurement group_id="O8" value="62"/>
                    <measurement group_id="O9" value="99"/>
                    <measurement group_id="O10" value="59"/>
                    <measurement group_id="O11" value="508"/>
                    <measurement group_id="O12" value="240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="24"/>
                    <measurement group_id="O6" value="12"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="4"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="22"/>
                    <measurement group_id="O12" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Persistent Crying - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="74"/>
                    <measurement group_id="O3" value="117"/>
                    <measurement group_id="O4" value="49"/>
                    <measurement group_id="O5" value="252"/>
                    <measurement group_id="O6" value="125"/>
                    <measurement group_id="O7" value="95"/>
                    <measurement group_id="O8" value="53"/>
                    <measurement group_id="O9" value="87"/>
                    <measurement group_id="O10" value="43"/>
                    <measurement group_id="O11" value="479"/>
                    <measurement group_id="O12" value="258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Persistent Crying - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="11"/>
                    <measurement group_id="O10" value="8"/>
                    <measurement group_id="O11" value="29"/>
                    <measurement group_id="O12" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="11"/>
                    <measurement group_id="O7" value="11"/>
                    <measurement group_id="O8" value="6"/>
                    <measurement group_id="O9" value="12"/>
                    <measurement group_id="O10" value="4"/>
                    <measurement group_id="O11" value="98"/>
                    <measurement group_id="O12" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="4"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="54"/>
                    <measurement group_id="O12" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="104"/>
                    <measurement group_id="O3" value="187"/>
                    <measurement group_id="O4" value="76"/>
                    <measurement group_id="O5" value="354"/>
                    <measurement group_id="O6" value="173"/>
                    <measurement group_id="O7" value="106"/>
                    <measurement group_id="O8" value="53"/>
                    <measurement group_id="O9" value="93"/>
                    <measurement group_id="O10" value="52"/>
                    <measurement group_id="O11" value="727"/>
                    <measurement group_id="O12" value="381"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="14"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="6"/>
                    <measurement group_id="O10" value="4"/>
                    <measurement group_id="O11" value="21"/>
                    <measurement group_id="O12" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="33"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="67"/>
                    <measurement group_id="O6" value="36"/>
                    <measurement group_id="O7" value="25"/>
                    <measurement group_id="O8" value="9"/>
                    <measurement group_id="O9" value="29"/>
                    <measurement group_id="O10" value="17"/>
                    <measurement group_id="O11" value="215"/>
                    <measurement group_id="O12" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="2"/>
                    <measurement group_id="O12" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Analgesic / Antipyretic medication used</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="120"/>
                    <measurement group_id="O3" value="225"/>
                    <measurement group_id="O4" value="110"/>
                    <measurement group_id="O5" value="447"/>
                    <measurement group_id="O6" value="223"/>
                    <measurement group_id="O7" value="155"/>
                    <measurement group_id="O8" value="75"/>
                    <measurement group_id="O9" value="159"/>
                    <measurement group_id="O10" value="80"/>
                    <measurement group_id="O11" value="996"/>
                    <measurement group_id="O12" value="510"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Solicited Local and Systemic Reactions Post Second Vaccination – Infant Series</title>
        <description>Solicited local and systemic reactions post second vaccination of infant series were compared in subjects receiving Infant Vaccines only and subjects receiving MenACWY-CRM concomitantly with Infant Vaccines.</description>
        <time_frame>7 days after vaccination</time_frame>
        <population>The population used in analysis was the safety set: The total number of subjects analyzed was less than the safety set due to subject withdrawals. LA1 and LA 2 groups are not included here as they did not receive MenACWY at 4 months of age.</population>
        <group_list>
          <group group_id="O1">
            <title>US1A (MenACWY-CRM + Infant Vaccines)</title>
            <description>US infants received MenACWY at 2, 4 and 6 months of age along with routine infant vaccines, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccine. These infants received a fourth dose of MenACWY concomitantly with pneumococcal, HAV, and MMR-V vaccines at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>US1B (MenACWY-CRM + Infant Vaccines)</title>
            <description>US infants received MenACWY at 2, 4 and 6 months of age along with routine infant vaccines, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines. These infants received pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months; and a fourth dose of MenACWY at 13 months of age.</description>
          </group>
          <group group_id="O3">
            <title>US1 (MenACWY-CRM + Infant Vaccines)</title>
            <description>US infants received one dose of MenACWY at 2, 4 and 6 months of age; and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines. Group US1 was randomized into US1A and US1B subgroups.</description>
          </group>
          <group group_id="O4">
            <title>US2 (Infant Vaccines Only)</title>
            <description>US infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. These infants received one dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months; and a second dose of MenACWY at 15 months of age.</description>
          </group>
          <group group_id="O5">
            <title>US3 (MenACWY-CRM + Infant Vaccines)</title>
            <description>US infants received MenACWY at 2, 4 and 6 months of age along with routine infant vaccines, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccine. These infants received fourth dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months of age.</description>
          </group>
          <group group_id="O6">
            <title>US4 (Infant Vaccines Only)</title>
            <description>US infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. These infants received concomitant pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months of age. These infants were randomized in subgroup US4A, US4B and US4C.</description>
          </group>
          <group group_id="O7">
            <title>LA3 (MenACWY-CRM + Infant Vaccines)</title>
            <description>LA infants received MenACWY at 2, 4 and 6 months of age; and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, pneumococcal conjugate vaccine, and rotavirus vaccine. Group LA3 was further randomized into LA3A and LA3B subgroups.</description>
          </group>
          <group group_id="O8">
            <title>LA4 (Infant Vaccines Only)</title>
            <description>LA infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, pneumococcal conjugate vaccine, and rotavirus vaccine at 2, 4 and 6 months of age. These infants received one dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months and a second dose of MenACWY along with DTaP and Hib vaccines at 15 months of age.</description>
          </group>
          <group group_id="O9">
            <title>LA5 (MenACWY-CRM + Infant Vaccines)</title>
            <description>LA infants received MenACWY at 2, 4 and 6 months of age; and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines. At 12 months of age, these subjects received the fourth dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V.</description>
          </group>
          <group group_id="O10">
            <title>LA6 (Infant Vaccines Only)</title>
            <description>LA infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, rotavirus, and pneumococcal conjugate vaccines, at 2, 4 and 6 months of age. These infants received concomitant pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months of age. Group LA6 was further randomized into LA6A and LA6B and LA6C subgroups.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Solicited Local and Systemic Reactions Post Second Vaccination – Infant Series</title>
          <description>Solicited local and systemic reactions post second vaccination of infant series were compared in subjects receiving Infant Vaccines only and subjects receiving MenACWY-CRM concomitantly with Infant Vaccines.</description>
          <population>The population used in analysis was the safety set: The total number of subjects analyzed was less than the safety set due to subject withdrawals. LA1 and LA 2 groups are not included here as they did not receive MenACWY at 4 months of age.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="291"/>
                <count group_id="O4" value="151"/>
                <count group_id="O5" value="645"/>
                <count group_id="O6" value="325"/>
                <count group_id="O7" value="301"/>
                <count group_id="O8" value="150"/>
                <count group_id="O9" value="1424"/>
                <count group_id="O10" value="709"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Erythema (mm) – Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="33"/>
                    <measurement group_id="O4" value="35"/>
                    <measurement group_id="O5" value="75"/>
                    <measurement group_id="O6" value="60"/>
                    <measurement group_id="O7" value="92"/>
                    <measurement group_id="O8" value="45"/>
                    <measurement group_id="O9" value="583"/>
                    <measurement group_id="O10" value="311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema (mm) – Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration (mm) - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="27"/>
                    <measurement group_id="O5" value="45"/>
                    <measurement group_id="O6" value="48"/>
                    <measurement group_id="O7" value="73"/>
                    <measurement group_id="O8" value="36"/>
                    <measurement group_id="O9" value="194"/>
                    <measurement group_id="O10" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration (mm) - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="59"/>
                    <measurement group_id="O3" value="118"/>
                    <measurement group_id="O4" value="56"/>
                    <measurement group_id="O5" value="230"/>
                    <measurement group_id="O6" value="137"/>
                    <measurement group_id="O7" value="115"/>
                    <measurement group_id="O8" value="59"/>
                    <measurement group_id="O9" value="726"/>
                    <measurement group_id="O10" value="401"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="13"/>
                    <measurement group_id="O6" value="11"/>
                    <measurement group_id="O7" value="13"/>
                    <measurement group_id="O8" value="5"/>
                    <measurement group_id="O9" value="49"/>
                    <measurement group_id="O10" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body Temp. ( &gt;= 38° C )</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="49"/>
                    <measurement group_id="O6" value="28"/>
                    <measurement group_id="O7" value="23"/>
                    <measurement group_id="O8" value="13"/>
                    <measurement group_id="O9" value="223"/>
                    <measurement group_id="O10" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Eating Habits - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="46"/>
                    <measurement group_id="O4" value="20"/>
                    <measurement group_id="O5" value="122"/>
                    <measurement group_id="O6" value="64"/>
                    <measurement group_id="O7" value="28"/>
                    <measurement group_id="O8" value="12"/>
                    <measurement group_id="O9" value="160"/>
                    <measurement group_id="O10" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Eating Habits - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="6"/>
                    <measurement group_id="O10" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="53"/>
                    <measurement group_id="O6" value="35"/>
                    <measurement group_id="O7" value="28"/>
                    <measurement group_id="O8" value="14"/>
                    <measurement group_id="O9" value="149"/>
                    <measurement group_id="O10" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="4"/>
                    <measurement group_id="O10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="80"/>
                    <measurement group_id="O3" value="163"/>
                    <measurement group_id="O4" value="83"/>
                    <measurement group_id="O5" value="342"/>
                    <measurement group_id="O6" value="182"/>
                    <measurement group_id="O7" value="82"/>
                    <measurement group_id="O8" value="41"/>
                    <measurement group_id="O9" value="414"/>
                    <measurement group_id="O10" value="209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="14"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="13"/>
                    <measurement group_id="O10" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Persistent Crying - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="83"/>
                    <measurement group_id="O4" value="34"/>
                    <measurement group_id="O5" value="178"/>
                    <measurement group_id="O6" value="107"/>
                    <measurement group_id="O7" value="42"/>
                    <measurement group_id="O8" value="22"/>
                    <measurement group_id="O9" value="294"/>
                    <measurement group_id="O10" value="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Persistent Crying - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="14"/>
                    <measurement group_id="O10" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="24"/>
                    <measurement group_id="O6" value="13"/>
                    <measurement group_id="O7" value="13"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="97"/>
                    <measurement group_id="O10" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="52"/>
                    <measurement group_id="O10" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="56"/>
                    <measurement group_id="O3" value="125"/>
                    <measurement group_id="O4" value="47"/>
                    <measurement group_id="O5" value="238"/>
                    <measurement group_id="O6" value="131"/>
                    <measurement group_id="O7" value="62"/>
                    <measurement group_id="O8" value="26"/>
                    <measurement group_id="O9" value="485"/>
                    <measurement group_id="O10" value="237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="13"/>
                    <measurement group_id="O10" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="49"/>
                    <measurement group_id="O6" value="27"/>
                    <measurement group_id="O7" value="20"/>
                    <measurement group_id="O8" value="10"/>
                    <measurement group_id="O9" value="136"/>
                    <measurement group_id="O10" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Analgesic / Antipyretic medication used</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="91"/>
                    <measurement group_id="O3" value="185"/>
                    <measurement group_id="O4" value="96"/>
                    <measurement group_id="O5" value="385"/>
                    <measurement group_id="O6" value="201"/>
                    <measurement group_id="O7" value="131"/>
                    <measurement group_id="O8" value="61"/>
                    <measurement group_id="O9" value="857"/>
                    <measurement group_id="O10" value="430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean hSBA Titers – US Subjects</title>
        <description>Immunogenicity as measured by Geometric Mean hSBA Titers directed against N. meningitidis serogroups A, C, W and Y; comparison of four doses of MenACWY-CRM at 2, 4, and 6 and 12 months of age versus a single dose at 12 months of age.</description>
        <time_frame>13 months of age (one month post-toddler vaccination)</time_frame>
        <population>The analysis was done on per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>US1A (MenACWY- CRM + Infant Vaccines )</title>
            <description>US infants received one dose of MenACWY at 2, 4 and 6 months of age and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, pneumococcal conjugate vaccine, and rotavirus vaccine.At 12 months of age received fourth dose of MenACWY along with concomitant pneumococcal,HAV, and MMR-V vaccines.</description>
          </group>
          <group group_id="O2">
            <title>US2 (Infant Vaccine Only)</title>
            <description>received as part of routine infant vaccination schedule DTaP-IPV-HBV,Hib, pneumococcal conjugate vaccine, and rotavirus vaccine at 2, 4 and 6 months of age. At 12 months of age, these subjects received a dose of MenACWY along with concomitant pneumococcal conjugate vaccine, HAV, and MMR-V. At 15 months of age, these subjects received a second dose of MenACWY.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean hSBA Titers – US Subjects</title>
          <description>Immunogenicity as measured by Geometric Mean hSBA Titers directed against N. meningitidis serogroups A, C, W and Y; comparison of four doses of MenACWY-CRM at 2, 4, and 6 and 12 months of age versus a single dose at 12 months of age.</description>
          <population>The analysis was done on per protocol population</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A Pre-vaccination (84, 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.51" lower_limit="2.14" upper_limit="2.96"/>
                    <measurement group_id="O2" value="2.14" lower_limit="1.8" upper_limit="2.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A Post-vaccination (84, 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77" lower_limit="55" upper_limit="109"/>
                    <measurement group_id="O2" value="17" lower_limit="12" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C Pre-vaccination (86, 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.72" lower_limit="5.9" upper_limit="10"/>
                    <measurement group_id="O2" value="2.26" lower_limit="1.69" upper_limit="3.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C Post-vaccination (86, 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="227" lower_limit="155" upper_limit="332"/>
                    <measurement group_id="O2" value="35" lower_limit="23" upper_limit="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W Pre-vaccination (85, 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="11" upper_limit="18"/>
                    <measurement group_id="O2" value="2.21" lower_limit="1.69" upper_limit="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W Post-vaccination (85, 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="416" lower_limit="288" upper_limit="602"/>
                    <measurement group_id="O2" value="11" lower_limit="7.59" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Y Pre-vaccination (84, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="8.76" upper_limit="15"/>
                    <measurement group_id="O2" value="2.14" lower_limit="1.6" upper_limit="2.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Y Post-vaccination (84, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="395" lower_limit="269" upper_limit="580"/>
                    <measurement group_id="O2" value="10" lower_limit="6.72" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Using the MenACWY GMTs, immunogenicity of the fourth dose at 1 month after the 12-month vaccination in those subjects receiving MenACWY at 2, 4, and 6 months was considered superior to the immune response of a single dose given at 12-months of age if the lower limit of the two-sided 95% CI of the ratio of the two GMTs was &gt;= 2.0.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of GMTs</param_type>
            <param_value>4.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.04</ci_lower_limit>
            <ci_upper_limit>6.74</ci_upper_limit>
            <estimate_desc>A (Post-vaccination GMT; group ratio US1A:US2)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Using the MenACWY GMTs, immunogenicity of the fourth dose at 1 month after the 12-month vaccination in those subjects receiving MenACWY at 2, 4, and 6 months was considered superior to the immune response of a single dose given at 12-months of age if the lower limit of the two-sided 95% CI of the ratio of the two GMTs was &gt;= 2.0.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of GMTs</param_type>
            <param_value>6.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.16</ci_lower_limit>
            <ci_upper_limit>9.79</ci_upper_limit>
            <estimate_desc>C (Post-vaccination GMT; group ratio US1A:US2)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Using the MenACWY GMTs, immunogenicity of the fourth dose at 1 month after the 12-month vaccination in those subjects receiving MenACWY at 2, 4, and 6 months was considered superior to the immune response of a single dose given at 12-months of age if the lower limit of the two-sided 95% CI of the ratio of the two GMTs was &gt;= 2.0.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of GMTs</param_type>
            <param_value>37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>24</ci_lower_limit>
            <ci_upper_limit>58</ci_upper_limit>
            <estimate_desc>W (Post-vaccination GMT; group ratio US1A:US2)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Using the MenACWY GMTs, immunogenicity of the fourth dose at 1 month after the 12-month vaccination in those subjects receiving MenACWY at 2, 4, and 6 months was considered superior to the immune response of a single dose given at 12-months of age if the lower limit of the two-sided 95% CI of the ratio of the two GMTs was &gt;= 2.0.
Ratio of GMTs</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of GMTs</param_type>
            <param_value>38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>24</ci_lower_limit>
            <ci_upper_limit>60</ci_upper_limit>
            <estimate_desc>Y (Post-vaccination GMT; group ratio US1A:US2)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Solicited Local and Systemic Reactions Post Third Vaccination – Infant Series</title>
        <description>Solicited local and systemic reactions post third vaccination of infant series were compared in subjects receiving Infant Vaccines only and subjects receiving MenACWY-CRM concomitantly with Infant Vaccines.</description>
        <time_frame>7 days after vaccination</time_frame>
        <population>The population used in analysis was the safety set: The total number of subjects analyzed was less than the safety set due to subject withdrawals.</population>
        <group_list>
          <group group_id="O1">
            <title>US1A (MenACWY-CRM + Infant Vaccines)</title>
            <description>US infants received MenACWY at 2, 4 and 6 months of age along with routine infant vaccines, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccine. These infants received a fourth dose of MenACWY concomitantly with pneumococcal, HAV, and MMR-V vaccines at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>US1B (MenACWY-CRM + Infant Vaccines)</title>
            <description>US infants received MenACWY at 2, 4 and 6 months of age along with routine infant vaccines, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines. These infants received pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months; and a fourth dose of MenACWY at 13 months of age.</description>
          </group>
          <group group_id="O3">
            <title>US1 (MenACWY-CRM + Infant Vaccines)</title>
            <description>US infants received one dose of MenACWY at 2, 4 and 6 months of age; and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines. Group US1 was randomized into US1A and US1B subgroups.</description>
          </group>
          <group group_id="O4">
            <title>US2 (Infant Vaccines Only)</title>
            <description>US infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. These infants received one dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months; and a second dose of MenACWY at 15 months of age.</description>
          </group>
          <group group_id="O5">
            <title>US3 (MenACWY-CRM + Infant Vaccines)</title>
            <description>US infants received MenACWY at 2, 4 and 6 months of age along with routine infant vaccines, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccine. These infants received fourth dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months of age.</description>
          </group>
          <group group_id="O6">
            <title>US4 (Infant Vaccines Only)</title>
            <description>US infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. These infants received concomitant pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months of age. These infants were randomized in subgroup US4A, US4B and US4C.</description>
          </group>
          <group group_id="O7">
            <title>LA1 (MenACWY-CRM + Infant Vaccines)</title>
            <description>LA infants received MenACWY at 2 and 6 months of age and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. Group LA1 was randomized into LA1A and LA 1B subgroups.</description>
          </group>
          <group group_id="O8">
            <title>LA2 (Infant Vaccines Only)</title>
            <description>LA infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. These infants received one dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months; and a second dose of MenACWY at 15 months of age.</description>
          </group>
          <group group_id="O9">
            <title>LA3 (MenACWY-CRM + Infant Vaccines)</title>
            <description>LA infants received MenACWY at 2, 4 and 6 months of age; and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, pneumococcal conjugate vaccine, and rotavirus vaccine. Group LA3 was further randomized into LA3A and LA3B subgroups.</description>
          </group>
          <group group_id="O10">
            <title>LA4 (Infant Vaccines Only)</title>
            <description>LA infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, pneumococcal conjugate vaccine, and rotavirus vaccine at 2, 4 and 6 months of age. These infants received one dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months and a second dose of MenACWY along with DTaP and Hib vaccines at 15 months of age.</description>
          </group>
          <group group_id="O11">
            <title>LA5 (MenACWY-CRM + Infant Vaccines)</title>
            <description>LA infants received MenACWY at 2, 4 and 6 months of age; and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines. At 12 months of age, these subjects received the fourth dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V.</description>
          </group>
          <group group_id="O12">
            <title>LA6 (Infant Vaccines Only)</title>
            <description>LA infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, rotavirus, and pneumococcal conjugate vaccines, at 2, 4 and 6 months of age. These infants received concomitant pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months of age. Group LA6 was further randomized into LA6A and LA6B and LA6C subgroups.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Solicited Local and Systemic Reactions Post Third Vaccination – Infant Series</title>
          <description>Solicited local and systemic reactions post third vaccination of infant series were compared in subjects receiving Infant Vaccines only and subjects receiving MenACWY-CRM concomitantly with Infant Vaccines.</description>
          <population>The population used in analysis was the safety set: The total number of subjects analyzed was less than the safety set due to subject withdrawals.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="283"/>
                <count group_id="O4" value="143"/>
                <count group_id="O5" value="627"/>
                <count group_id="O6" value="311"/>
                <count group_id="O7" value="297"/>
                <count group_id="O8" value="131"/>
                <count group_id="O9" value="290"/>
                <count group_id="O10" value="147"/>
                <count group_id="O11" value="1357"/>
                <count group_id="O12" value="679"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Erythema (mm) - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="28"/>
                    <measurement group_id="O5" value="92"/>
                    <measurement group_id="O6" value="67"/>
                    <measurement group_id="O7" value="69"/>
                    <measurement group_id="O8" value="27"/>
                    <measurement group_id="O9" value="64"/>
                    <measurement group_id="O10" value="38"/>
                    <measurement group_id="O11" value="485"/>
                    <measurement group_id="O12" value="273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema (mm) - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration (mm) - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="29"/>
                    <measurement group_id="O5" value="59"/>
                    <measurement group_id="O6" value="53"/>
                    <measurement group_id="O7" value="54"/>
                    <measurement group_id="O8" value="25"/>
                    <measurement group_id="O9" value="64"/>
                    <measurement group_id="O10" value="32"/>
                    <measurement group_id="O11" value="125"/>
                    <measurement group_id="O12" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration (mm) - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="82"/>
                    <measurement group_id="O4" value="45"/>
                    <measurement group_id="O5" value="189"/>
                    <measurement group_id="O6" value="92"/>
                    <measurement group_id="O7" value="92"/>
                    <measurement group_id="O8" value="40"/>
                    <measurement group_id="O9" value="78"/>
                    <measurement group_id="O10" value="50"/>
                    <measurement group_id="O11" value="504"/>
                    <measurement group_id="O12" value="306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="21"/>
                    <measurement group_id="O12" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body Temp. ( &gt;= 38° C )</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="33"/>
                    <measurement group_id="O6" value="20"/>
                    <measurement group_id="O7" value="13"/>
                    <measurement group_id="O8" value="10"/>
                    <measurement group_id="O9" value="26"/>
                    <measurement group_id="O10" value="14"/>
                    <measurement group_id="O11" value="164"/>
                    <measurement group_id="O12" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Eating Habits - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="18"/>
                    <measurement group_id="O5" value="94"/>
                    <measurement group_id="O6" value="39"/>
                    <measurement group_id="O7" value="25"/>
                    <measurement group_id="O8" value="11"/>
                    <measurement group_id="O9" value="23"/>
                    <measurement group_id="O10" value="9"/>
                    <measurement group_id="O11" value="126"/>
                    <measurement group_id="O12" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Eating Habits - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="5"/>
                    <measurement group_id="O12" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="41"/>
                    <measurement group_id="O6" value="26"/>
                    <measurement group_id="O7" value="17"/>
                    <measurement group_id="O8" value="8"/>
                    <measurement group_id="O9" value="12"/>
                    <measurement group_id="O10" value="11"/>
                    <measurement group_id="O11" value="97"/>
                    <measurement group_id="O12" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="2"/>
                    <measurement group_id="O12" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="73"/>
                    <measurement group_id="O3" value="131"/>
                    <measurement group_id="O4" value="70"/>
                    <measurement group_id="O5" value="285"/>
                    <measurement group_id="O6" value="157"/>
                    <measurement group_id="O7" value="57"/>
                    <measurement group_id="O8" value="29"/>
                    <measurement group_id="O9" value="62"/>
                    <measurement group_id="O10" value="28"/>
                    <measurement group_id="O11" value="311"/>
                    <measurement group_id="O12" value="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="5"/>
                    <measurement group_id="O12" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Persistent Crying - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="54"/>
                    <measurement group_id="O4" value="24"/>
                    <measurement group_id="O5" value="135"/>
                    <measurement group_id="O6" value="74"/>
                    <measurement group_id="O7" value="28"/>
                    <measurement group_id="O8" value="15"/>
                    <measurement group_id="O9" value="27"/>
                    <measurement group_id="O10" value="12"/>
                    <measurement group_id="O11" value="181"/>
                    <measurement group_id="O12" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Persistent Crying - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="11"/>
                    <measurement group_id="O12" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="14"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="6"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="62"/>
                    <measurement group_id="O12" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="29"/>
                    <measurement group_id="O12" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="78"/>
                    <measurement group_id="O4" value="39"/>
                    <measurement group_id="O5" value="179"/>
                    <measurement group_id="O6" value="91"/>
                    <measurement group_id="O7" value="38"/>
                    <measurement group_id="O8" value="15"/>
                    <measurement group_id="O9" value="45"/>
                    <measurement group_id="O10" value="17"/>
                    <measurement group_id="O11" value="317"/>
                    <measurement group_id="O12" value="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="6"/>
                    <measurement group_id="O12" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="31"/>
                    <measurement group_id="O6" value="20"/>
                    <measurement group_id="O7" value="16"/>
                    <measurement group_id="O8" value="9"/>
                    <measurement group_id="O9" value="11"/>
                    <measurement group_id="O10" value="12"/>
                    <measurement group_id="O11" value="104"/>
                    <measurement group_id="O12" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Analgesic / Antipyretic medication used</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="82"/>
                    <measurement group_id="O3" value="157"/>
                    <measurement group_id="O4" value="96"/>
                    <measurement group_id="O5" value="349"/>
                    <measurement group_id="O6" value="178"/>
                    <measurement group_id="O7" value="93"/>
                    <measurement group_id="O8" value="38"/>
                    <measurement group_id="O9" value="90"/>
                    <measurement group_id="O10" value="51"/>
                    <measurement group_id="O11" value="592"/>
                    <measurement group_id="O12" value="342"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Solicited Local and Systemic Reactions After Vaccination at 12 Months of Age</title>
        <description>Solicited local and systemic reactions after receiving MenACWY-CRM vaccination at 12 months of age were compared in subjects receiving Infant Vaccines only and subjects receiving MenACWY-CRM concomitantly with Infant Vaccines.</description>
        <time_frame>7 days after vaccination</time_frame>
        <population>The population used in analysis was the safety set: The total number of subjects analyzed was less than the safety set due to subject withdrawals.</population>
        <group_list>
          <group group_id="O1">
            <title>US1A (MenACWY-CRM + Infant Vaccines)</title>
            <description>US infants received MenACWY at 2, 4 and 6 months of age along with routine infant vaccines, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccine. These infants received a fourth dose of MenACWY concomitantly with pneumococcal, HAV, and MMR-V vaccines at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>US1B (MenACWY-CRM + Infant Vaccines)</title>
            <description>US infants received MenACWY at 2, 4 and 6 months of age along with routine infant vaccines, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines. These infants received pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months; and a fourth dose of MenACWY at 13 months of age.</description>
          </group>
          <group group_id="O3">
            <title>US1A + US3 (MenACWY-CRM + Infant Vaccines)</title>
            <description>Groups MenACWY-CRM + infant vaccines (US1A and US3) Pooled. In both groups US infants received MenACWY at 2, 4 and 6 months of age along with routine infant vaccines, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccine. These infants received a fourth dose of MenACWY concomitantly with pneumococcal, HAV, and MMR-V vaccines at 12 months of age.</description>
          </group>
          <group group_id="O4">
            <title>US2 + US4A (Infant Vaccines Only)</title>
            <description>Groups Infant Vaccines only (US2 and US4A) pooled.
In both groups US infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. These infants received one dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months; and a second dose of MenACWY at 15 months of age.</description>
          </group>
          <group group_id="O5">
            <title>US3 (MenACWY-CRM + Infant Vaccines)</title>
            <description>US infants received MenACWY at 2, 4 and 6 months of age along with routine infant vaccines, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccine. These infants received fourth dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months of age.</description>
          </group>
          <group group_id="O6">
            <title>US4B + US4C (Infant Vaccines Only)</title>
            <description>Groups Infant Vaccines only (US4B and US4C) pooled.
Infant Vaccines only (US4B): US infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. These subjects received concomitant pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months; and either received one dose of MenACWY at 13 and and a second dose of MenACWY at 15 months of age (US4B); or one dose at 18 months of age (US4C).</description>
          </group>
          <group group_id="O7">
            <title>LA1A (MenACWY-CRM + Infant Vaccines)</title>
            <description>LA infants received MenACWY at 2 and 6 months of age; and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. These subjects received a third dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months of age.</description>
          </group>
          <group group_id="O8">
            <title>LA1B (MenACWY-CRM + Infant Vaccines)</title>
            <description>LA infants received MenACWY at 2 and 6 months of age and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. These subjects received pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months and a third dose of MenACWY at 13 months of age.</description>
          </group>
          <group group_id="O9">
            <title>LA2 + LA4 + LA6A (Infant Vaccines Only)</title>
            <description>Groups Infant Vaccines only (LA2, LA4 and LA6A) pooled. In all groups LA infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. These infants received one dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months; and a second dose of MenACWY at 15 months of age.</description>
          </group>
          <group group_id="O10">
            <title>LA5 (MenACWY-CRM + Infant Vaccines)</title>
            <description>LA infants received MenACWY at 2, 4 and 6 months of age; and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines. At 12 months of age, these subjects received the fourth dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V.</description>
          </group>
          <group group_id="O11">
            <title>LA6B + LA6C (Infant Vaccines Only)</title>
            <description>Groups Infant Vaccines only LA6B and LA6C pooled.
Infant Vaccines only (LA6B): LA infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, rotavirus, and pneumococcal conjugate vaccines, at 2, 4 and 6 months of age. These infants received concomitant pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months; and either one dose of MenACWY at 13 and a second dose of MenACWY at 15 months of age (LA6B) or one dose of MenACWY at 18 months of age (LA6C).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Solicited Local and Systemic Reactions After Vaccination at 12 Months of Age</title>
          <description>Solicited local and systemic reactions after receiving MenACWY-CRM vaccination at 12 months of age were compared in subjects receiving Infant Vaccines only and subjects receiving MenACWY-CRM concomitantly with Infant Vaccines.</description>
          <population>The population used in analysis was the safety set: The total number of subjects analyzed was less than the safety set due to subject withdrawals.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="124"/>
                <count group_id="O3" value="704"/>
                <count group_id="O4" value="137"/>
                <count group_id="O5" value="582"/>
                <count group_id="O6" value="261"/>
                <count group_id="O7" value="145"/>
                <count group_id="O8" value="143"/>
                <count group_id="O9" value="564"/>
                <count group_id="O10" value="1275"/>
                <count group_id="O11" value="349"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Erythema (mm) - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="81"/>
                    <measurement group_id="O4" value="18"/>
                    <measurement group_id="O5" value="70"/>
                    <measurement group_id="O6" value="49"/>
                    <measurement group_id="O7" value="36"/>
                    <measurement group_id="O8" value="33"/>
                    <measurement group_id="O9" value="166"/>
                    <measurement group_id="O10" value="309"/>
                    <measurement group_id="O11" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema (mm) - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration (mm) - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="44"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="34"/>
                    <measurement group_id="O6" value="39"/>
                    <measurement group_id="O7" value="32"/>
                    <measurement group_id="O8" value="28"/>
                    <measurement group_id="O9" value="72"/>
                    <measurement group_id="O10" value="84"/>
                    <measurement group_id="O11" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration (mm) - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="177"/>
                    <measurement group_id="O4" value="38"/>
                    <measurement group_id="O5" value="149"/>
                    <measurement group_id="O6" value="75"/>
                    <measurement group_id="O7" value="35"/>
                    <measurement group_id="O8" value="32"/>
                    <measurement group_id="O9" value="184"/>
                    <measurement group_id="O10" value="392"/>
                    <measurement group_id="O11" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="8"/>
                    <measurement group_id="O11" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body Temp. ( &gt;= 38° C )</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="49"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="35"/>
                    <measurement group_id="O6" value="20"/>
                    <measurement group_id="O7" value="16"/>
                    <measurement group_id="O8" value="12"/>
                    <measurement group_id="O9" value="84"/>
                    <measurement group_id="O10" value="188"/>
                    <measurement group_id="O11" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Eating Habits - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="101"/>
                    <measurement group_id="O4" value="20"/>
                    <measurement group_id="O5" value="80"/>
                    <measurement group_id="O6" value="29"/>
                    <measurement group_id="O7" value="10"/>
                    <measurement group_id="O8" value="11"/>
                    <measurement group_id="O9" value="56"/>
                    <measurement group_id="O10" value="138"/>
                    <measurement group_id="O11" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Eating Habits - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="4"/>
                    <measurement group_id="O10" value="5"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="61"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="56"/>
                    <measurement group_id="O6" value="14"/>
                    <measurement group_id="O7" value="9"/>
                    <measurement group_id="O8" value="10"/>
                    <measurement group_id="O9" value="51"/>
                    <measurement group_id="O10" value="123"/>
                    <measurement group_id="O11" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="5"/>
                    <measurement group_id="O10" value="7"/>
                    <measurement group_id="O11" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="53"/>
                    <measurement group_id="O3" value="271"/>
                    <measurement group_id="O4" value="62"/>
                    <measurement group_id="O5" value="218"/>
                    <measurement group_id="O6" value="103"/>
                    <measurement group_id="O7" value="29"/>
                    <measurement group_id="O8" value="23"/>
                    <measurement group_id="O9" value="130"/>
                    <measurement group_id="O10" value="289"/>
                    <measurement group_id="O11" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="5"/>
                    <measurement group_id="O10" value="3"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Persistent Crying - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="120"/>
                    <measurement group_id="O4" value="24"/>
                    <measurement group_id="O5" value="99"/>
                    <measurement group_id="O6" value="55"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="12"/>
                    <measurement group_id="O9" value="52"/>
                    <measurement group_id="O10" value="134"/>
                    <measurement group_id="O11" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Persistent Crying - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="23"/>
                    <measurement group_id="O6" value="12"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="20"/>
                    <measurement group_id="O10" value="65"/>
                    <measurement group_id="O11" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="8"/>
                    <measurement group_id="O10" value="36"/>
                    <measurement group_id="O11" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="149"/>
                    <measurement group_id="O4" value="22"/>
                    <measurement group_id="O5" value="111"/>
                    <measurement group_id="O6" value="50"/>
                    <measurement group_id="O7" value="18"/>
                    <measurement group_id="O8" value="15"/>
                    <measurement group_id="O9" value="81"/>
                    <measurement group_id="O10" value="211"/>
                    <measurement group_id="O11" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="3"/>
                    <measurement group_id="O11" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="21"/>
                    <measurement group_id="O6" value="11"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="5"/>
                    <measurement group_id="O9" value="35"/>
                    <measurement group_id="O10" value="82"/>
                    <measurement group_id="O11" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="4"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Analgesic / Antipyretic medication used</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="56"/>
                    <measurement group_id="O3" value="320"/>
                    <measurement group_id="O4" value="78"/>
                    <measurement group_id="O5" value="260"/>
                    <measurement group_id="O6" value="120"/>
                    <measurement group_id="O7" value="48"/>
                    <measurement group_id="O8" value="43"/>
                    <measurement group_id="O9" value="204"/>
                    <measurement group_id="O10" value="406"/>
                    <measurement group_id="O11" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Solicited Local and Systemic Reactions Post First Vaccination – Toddler Series</title>
        <description>Solicited local and systemic reactions post first vaccination of toddler series were compared in subjects receiving Infant Vaccines only and subjects receiving MenACWY-CRM concomitantly with Infant Vaccines.</description>
        <time_frame>7 days post vaccination</time_frame>
        <population>The population used in analysis was the safety set: The total number of subjects analyzed was less than the safety set due to subject withdrawals.</population>
        <group_list>
          <group group_id="O1">
            <title>US1B (MenACWY-CRM + Infant Vaccines)</title>
            <description>US infants received MenACWY at 2, 4 and 6 months of age along with routine infant vaccines, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines. These infants received pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months; and a fourth dose of MenACWY at 13 months of age.</description>
          </group>
          <group group_id="O2">
            <title>US1A + US3 (MenACWY-CRM + Infant Vaccines)</title>
            <description>Groups MenACWY-CRM + infant vaccines (US1A and US3) Pooled.In both groups US infants received MenACWY at 2, 4 and 6 months of age along with routine infant vaccines, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccine. These infants received a fourth dose of MenACWY concomitantly with pneumococcal, HAV, and MMR-V vaccines at 12 months of age.</description>
          </group>
          <group group_id="O3">
            <title>US2 + US4A (Infant Vaccines Only)</title>
            <description>Groups Infant Vaccines only (US2 and US4A) pooled. In both groups US infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. These infants received one dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months; and a second dose of MenACWY at 15 months of age.</description>
          </group>
          <group group_id="O4">
            <title>US4B (Infant Vaccines Only)</title>
            <description>US infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. These subjects received concomitant pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months; and one dose of MenACWY at 13 and one dose at 15 months of age.</description>
          </group>
          <group group_id="O5">
            <title>US4C (Infant Vaccines Only)</title>
            <description>US infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines, at 2, 4 and 6 months of age. These subjects received concomitant pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months and one dose of MenACWY at 18 months of age.</description>
          </group>
          <group group_id="O6">
            <title>LA1A (MenACWY-CRM + Infant Vaccines)</title>
            <description>LA infants received MenACWY at 2 and 6 months of age; and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. These subjects received a third dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months of age.</description>
          </group>
          <group group_id="O7">
            <title>LA1B (MenACWY-CRM + Infant Vaccines)</title>
            <description>LA infants received MenACWY at 2 and 6 months of age and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. These subjects received pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months and a third dose of MenACWY at 13 months of age.</description>
          </group>
          <group group_id="O8">
            <title>LA2 + LA4 + LA6A (Infant Vaccines Only)</title>
            <description>Groups Infant Vaccines only (LA2, LA4 and LA6A) pooled. In all groups LA infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. These infants received one dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months; and a second dose of MenACWY at 15 months of age.</description>
          </group>
          <group group_id="O9">
            <title>LA3A (MenACWY-CRM + Infant Vaccines)</title>
            <description>LA infants received MenACWY at 2, 4 and 6 months of age; and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, pneumococcal conjugate vaccine, and rotavirus vaccine. Around 12 months of age, these infants were recommended to receive pneumococcal conjugate vaccine, HAV, and MMR-V. At 16 months of age, these subjects received the fourth dose of MenACWY along with concomitant DTaP and Hib.</description>
          </group>
          <group group_id="O10">
            <title>LA3B (MenACWY-CRM + Infant Vaccines)</title>
            <description>LA infants received MenACWY at 2, 4 and 6 months of age; and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, pneumococcal conjugate vaccine, and rotavirus vaccine. Around 12 months of age, received pneumococcal conjugate vaccine, HAV, and MMR-V. At 16 months of age, these subjects received DTaP and Hib. At 17 months of age, these subjects received the fourth dose of MenACWY.</description>
          </group>
          <group group_id="O11">
            <title>LA5 (MenACWY-CRM + Infant Vaccines)</title>
            <description>LA infants received MenACWY at 2, 4 and 6 months of age; and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines. At 12 months of age, these subjects received the fourth dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V.</description>
          </group>
          <group group_id="O12">
            <title>LA6B (Infant Vaccines Only)</title>
            <description>LA infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, rotavirus, and pneumococcal conjugate vaccines, at 2, 4 and 6 months of age. These infants received concomitant pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months; and one dose of MenACWY at 13 and one dose at 15 months of age.</description>
          </group>
          <group group_id="O13">
            <title>LA6C (Infant Vaccines Only)</title>
            <description>LA infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, rotavirus, and pneumococcal conjugate vaccines, at 2, 4 and 6 months of age. These infants received concomitant pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months; and one dose of MenACWY at 18 months of age</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Solicited Local and Systemic Reactions Post First Vaccination – Toddler Series</title>
          <description>Solicited local and systemic reactions post first vaccination of toddler series were compared in subjects receiving Infant Vaccines only and subjects receiving MenACWY-CRM concomitantly with Infant Vaccines.</description>
          <population>The population used in analysis was the safety set: The total number of subjects analyzed was less than the safety set due to subject withdrawals.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="704"/>
                <count group_id="O3" value="136"/>
                <count group_id="O4" value="59"/>
                <count group_id="O5" value="179"/>
                <count group_id="O6" value="145"/>
                <count group_id="O7" value="143"/>
                <count group_id="O8" value="564"/>
                <count group_id="O9" value="142"/>
                <count group_id="O10" value="137"/>
                <count group_id="O11" value="1275"/>
                <count group_id="O12" value="160"/>
                <count group_id="O13" value="175"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Erythema (mm) - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="81"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="28"/>
                    <measurement group_id="O6" value="36"/>
                    <measurement group_id="O7" value="17"/>
                    <measurement group_id="O8" value="166"/>
                    <measurement group_id="O9" value="36"/>
                    <measurement group_id="O10" value="19"/>
                    <measurement group_id="O11" value="309"/>
                    <measurement group_id="O12" value="24"/>
                    <measurement group_id="O13" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema (mm) - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration (mm) - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="14"/>
                    <measurement group_id="O6" value="32"/>
                    <measurement group_id="O7" value="9"/>
                    <measurement group_id="O8" value="72"/>
                    <measurement group_id="O9" value="33"/>
                    <measurement group_id="O10" value="16"/>
                    <measurement group_id="O11" value="84"/>
                    <measurement group_id="O12" value="5"/>
                    <measurement group_id="O13" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration (mm) - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="177"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="38"/>
                    <measurement group_id="O6" value="35"/>
                    <measurement group_id="O7" value="21"/>
                    <measurement group_id="O8" value="184"/>
                    <measurement group_id="O9" value="36"/>
                    <measurement group_id="O10" value="18"/>
                    <measurement group_id="O11" value="392"/>
                    <measurement group_id="O12" value="34"/>
                    <measurement group_id="O13" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="8"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body Temp. ( &gt;= 38° C )</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="16"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="84"/>
                    <measurement group_id="O9" value="4"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="188"/>
                    <measurement group_id="O12" value="7"/>
                    <measurement group_id="O13" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Eating Habits - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="101"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="14"/>
                    <measurement group_id="O6" value="10"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="56"/>
                    <measurement group_id="O9" value="6"/>
                    <measurement group_id="O10" value="6"/>
                    <measurement group_id="O11" value="138"/>
                    <measurement group_id="O12" value="9"/>
                    <measurement group_id="O13" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Eating Habits - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="5"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="61"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="13"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="51"/>
                    <measurement group_id="O9" value="8"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="123"/>
                    <measurement group_id="O12" value="6"/>
                    <measurement group_id="O13" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="5"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="7"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="271"/>
                    <measurement group_id="O3" value="62"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="52"/>
                    <measurement group_id="O6" value="29"/>
                    <measurement group_id="O7" value="10"/>
                    <measurement group_id="O8" value="130"/>
                    <measurement group_id="O9" value="13"/>
                    <measurement group_id="O10" value="9"/>
                    <measurement group_id="O11" value="289"/>
                    <measurement group_id="O12" value="25"/>
                    <measurement group_id="O13" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="5"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="3"/>
                    <measurement group_id="O12" value="1"/>
                    <measurement group_id="O13" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Persistent Crying - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="120"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="17"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="52"/>
                    <measurement group_id="O9" value="4"/>
                    <measurement group_id="O10" value="5"/>
                    <measurement group_id="O11" value="134"/>
                    <measurement group_id="O12" value="9"/>
                    <measurement group_id="O13" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Persistent Crying - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="2"/>
                    <measurement group_id="O12" value="1"/>
                    <measurement group_id="O13" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="20"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="65"/>
                    <measurement group_id="O12" value="2"/>
                    <measurement group_id="O13" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="8"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="36"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="149"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="21"/>
                    <measurement group_id="O6" value="18"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="81"/>
                    <measurement group_id="O9" value="6"/>
                    <measurement group_id="O10" value="7"/>
                    <measurement group_id="O11" value="211"/>
                    <measurement group_id="O12" value="14"/>
                    <measurement group_id="O13" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="3"/>
                    <measurement group_id="O12" value="1"/>
                    <measurement group_id="O13" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="35"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="3"/>
                    <measurement group_id="O11" value="82"/>
                    <measurement group_id="O12" value="4"/>
                    <measurement group_id="O13" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="4"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Analgesic / Antipyretic medication used</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="320"/>
                    <measurement group_id="O3" value="77"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="45"/>
                    <measurement group_id="O6" value="48"/>
                    <measurement group_id="O7" value="15"/>
                    <measurement group_id="O8" value="204"/>
                    <measurement group_id="O9" value="20"/>
                    <measurement group_id="O10" value="8"/>
                    <measurement group_id="O11" value="406"/>
                    <measurement group_id="O12" value="14"/>
                    <measurement group_id="O13" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Solicited Local and Systemic Reactions Post Second Vaccination – Toddler Series</title>
        <description>Solicited local and systemic reactions post second vaccination of toddler series at 15 months of age.</description>
        <time_frame>7 days post vaccination</time_frame>
        <population>The population used in analysis was the safety set: The total number of subjects analyzed was less than the safety set due to subject withdrawals. Only subjects who received the second dose at 15 months were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>US2 + US4A (Infant Vaccines Only)</title>
            <description>Groups Infant Vaccines only (US2 and US4A) pooled. In both groups US infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. These infants received one dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months; and a second dose of MenACWY at 15 months of age.</description>
          </group>
          <group group_id="O2">
            <title>US4B (Infant Vaccines Only)</title>
            <description>US infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. These subjects received concomitant pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months; and one dose of MenACWY at 13 and one dose at 15 months of age.</description>
          </group>
          <group group_id="O3">
            <title>LA2 + LA4 + LA6A (Infant Vaccines Only)</title>
            <description>Groups Infant Vaccines only (LA2, LA4 and LA6A) pooled. In all groups LA infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. These infants received one dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months; and a second dose of MenACWY at 15 months of age.</description>
          </group>
          <group group_id="O4">
            <title>LA6B (Infant Vaccines Only)</title>
            <description>LA infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, rotavirus, and pneumococcal conjugate vaccines, at 2, 4 and 6 months of age. These infants received concomitant pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months; and one dose of MenACWY at 13 and one dose at 15 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Solicited Local and Systemic Reactions Post Second Vaccination – Toddler Series</title>
          <description>Solicited local and systemic reactions post second vaccination of toddler series at 15 months of age.</description>
          <population>The population used in analysis was the safety set: The total number of subjects analyzed was less than the safety set due to subject withdrawals. Only subjects who received the second dose at 15 months were included in this analysis.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="539"/>
                <count group_id="O4" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Erythema (mm) - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="143"/>
                    <measurement group_id="O4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema (mm) - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration (mm) - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="51"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration (mm) - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="128"/>
                    <measurement group_id="O4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body Temp. ( &gt;= 38° C )</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Eating Habits - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Eating Habits - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="28"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="71"/>
                    <measurement group_id="O4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Persistent Crying - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="37"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Persistent Crying - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="36"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Analgesic / Antipyretic medication used</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="85"/>
                    <measurement group_id="O4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Solicited Local and Systemic Reactions Post First Vaccination – Infant Series</title>
        <description>Solicited local and systemic reactions reported post first vaccination was compared in subjects receiving MenACWY versus Hib Vaccines.</description>
        <time_frame>7 days post-vaccination</time_frame>
        <population>The population used in analysis was the safety set: The total number of subjects analyzed was less than the safety set due to subject withdrawals.</population>
        <group_list>
          <group group_id="O1">
            <title>US1 + US3 (Men ACWY-CRM + Infant Vaccines)</title>
            <description>Groups MenACWY-CRM + Infant Vaccines (US1 +US3) pooled.
US infants received MenACWY at 2, 4 and 6 months of age along with routine infant vaccines, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccine. These infants either received a fourth dose of MenACWY concomitantly with pneumococcal, HAV, and MMR-V vaccines at 12 months of age (US1A and US3) or received pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months and a fourth dose of MenACWY at 13 months of age( US1B).</description>
          </group>
          <group group_id="O2">
            <title>US2 + US4 (Infant Vaccines Only)</title>
            <description>Groups Infant Vaccines only (US2+US4) pooled
US infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. These infants received:
either one dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months; and a second dose of MenACWY at 15 months of age (US2 and US4A); or received concomitant pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months and one dose of MenACWY at 13 and one dose at 15 months of age (US4B); or one dose of MenACWY at 18 months of age (US4C).</description>
          </group>
          <group group_id="O3">
            <title>LA3 + LA5 (Men ACWY-CRM + Infant Vaccines)</title>
            <description>Groups Men ACWY-CRM + Infant Vaccines (LA3 and LA5) pooled.
LA infants received MenACWY at 2, 4 and 6 months of age; and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines. At 12 months of age these infants were:
Recommended to receive pneumococcal conjugate vaccine, HAV, and MMR-V. At 16 months of age, these subjects received the fourth dose of MenACWY along with concomitant DTaP and Hib (LA3A)
Received pneumococcal conjugate vaccine, HAV, and MMR-V. At 16 months of age, these subjects received DTaP and Hib. At 17 months of age, these subjects received the fourth dose of MenACWY (LA3B).
Received the fourth dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V (LA5).</description>
          </group>
          <group group_id="O4">
            <title>LA4 + LA6 (Infant Vaccines Only)</title>
            <description>Groups Infant Vaccines only (LA4 and LA6) pooled.
LA infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, rotavirus, and pneumococcal conjugate vaccines, at 2, 4 and 6 months of age. These infants received either:
One dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months and a second dose of MenACWY along with DTaP and Hib vaccines at 15 months of age (LA4).
Concomitant pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months; and either one dose each of MenACWY at 12 and 15 months of age (LA6A); or one dose each of MenACWY at 13 and 15 months of age (LA6B) or one dose of MenACWY at 18 months of age (LA6C).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Solicited Local and Systemic Reactions Post First Vaccination – Infant Series</title>
          <description>Solicited local and systemic reactions reported post first vaccination was compared in subjects receiving MenACWY versus Hib Vaccines.</description>
          <population>The population used in analysis was the safety set: The total number of subjects analyzed was less than the safety set due to subject withdrawals.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="989"/>
                <count group_id="O2" value="503"/>
                <count group_id="O3" value="1724"/>
                <count group_id="O4" value="859"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Erythema (mm) - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="77"/>
                    <measurement group_id="O3" value="628"/>
                    <measurement group_id="O4" value="338"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema (mm) - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration (mm) - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="69"/>
                    <measurement group_id="O3" value="321"/>
                    <measurement group_id="O4" value="179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration (mm) - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="464"/>
                    <measurement group_id="O2" value="230"/>
                    <measurement group_id="O3" value="1086"/>
                    <measurement group_id="O4" value="596"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="114"/>
                    <measurement group_id="O4" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body Temp. ( &gt;= 38° C )</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="229"/>
                    <measurement group_id="O4" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Eating Habits - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="259"/>
                    <measurement group_id="O2" value="130"/>
                    <measurement group_id="O3" value="294"/>
                    <measurement group_id="O4" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Eating Habits - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154"/>
                    <measurement group_id="O2" value="63"/>
                    <measurement group_id="O3" value="266"/>
                    <measurement group_id="O4" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="608"/>
                    <measurement group_id="O2" value="307"/>
                    <measurement group_id="O3" value="607"/>
                    <measurement group_id="O4" value="299"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Persistent Crying - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="369"/>
                    <measurement group_id="O2" value="174"/>
                    <measurement group_id="O3" value="566"/>
                    <measurement group_id="O4" value="301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Persistent Crying - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="40"/>
                    <measurement group_id="O4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="110"/>
                    <measurement group_id="O4" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="58"/>
                    <measurement group_id="O4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="541"/>
                    <measurement group_id="O2" value="249"/>
                    <measurement group_id="O3" value="820"/>
                    <measurement group_id="O4" value="433"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="244"/>
                    <measurement group_id="O4" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Analgesic / Antipyretic medication used</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="672"/>
                    <measurement group_id="O2" value="333"/>
                    <measurement group_id="O3" value="1155"/>
                    <measurement group_id="O4" value="590"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Solicited Local and Systemic Reactions Post Second Vaccination – Infant Series</title>
        <description>Solicited local and systemic reactions reported post second vaccination was compared in subjects receiving MenACWY versus Hib Vaccines.</description>
        <time_frame>7 days post-vaccination</time_frame>
        <population>The population used in analysis was the safety set: The total number of subjects analyzed was less than the safety set due to subject withdrawals. Only subjects who received the second dose of the infant series vaccination were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>US1+US3 (Men ACWY-CRM + Infant Vaccines)</title>
            <description>Groups MenACWY-CRM + Infant Vaccines (US1 +US3) pooled. US infants received MenACWY at 2, 4 and 6 months of age along with routine infant vaccines, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccine. These infants either received a fourth dose of MenACWY concomitantly with pneumococcal, HAV, and MMR-V vaccines at 12 months of age (US1A and US3) or received pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months and a fourth dose of MenACWY at 13 months of age( US1B).</description>
          </group>
          <group group_id="O2">
            <title>US2+US4 (Infant Vaccines Only)</title>
            <description>Groups Infant Vaccines only (US2+US4) pooled US infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. These infants received either one dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months; and a second dose of MenACWY at 15 months of age (US2 and US4A) or received concomitant pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months and one dose of MenACWY at 13 and a second dose of MenACWY at 15 months of age (US4B) or one dose of MenACWY at 18 months of age (US4C).</description>
          </group>
          <group group_id="O3">
            <title>LA3+LA5 (Men ACWY-CRM + Infant Vaccines)</title>
            <description>LA infants received MenACWY at 2, 4 and 6 months of age; and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines. At 12 months of age these infants were:
Recommended to receive pneumococcal conjugate vaccine, HAV, and MMR-V. At 16 months of age, these subjects received the fourth dose of MenACWY along with concomitant DTaP and Hib (LA3A)
Received pneumococcal conjugate vaccine, HAV, and MMR-V. At 16 months of age, these subjects received DTaP and Hib. At 17 months of age, these subjects received the fourth dose of MenACWY (LA3B).
Received the fourth dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V (LA5).</description>
          </group>
          <group group_id="O4">
            <title>LA4+LA6 (Infant Vaccines Only)</title>
            <description>Groups Infant Vaccines only (LA4 and LA6) pooled.
LA infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, rotavirus, and pneumococcal conjugate vaccines, at 2, 4 and 6 months of age. These infants received either:
One dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months and a second dose of MenACWY along with DTaP and Hib vaccines at 15 months of age (LA4).
Concomitant pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months; and either one dose each of MenACWY at 12 and 15 months of age (LA6A); or one dose each of MenACWY at 13 and 15 months of age (LA6B) or one dose of MenACWY at 18 months of age (LA6C).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Solicited Local and Systemic Reactions Post Second Vaccination – Infant Series</title>
          <description>Solicited local and systemic reactions reported post second vaccination was compared in subjects receiving MenACWY versus Hib Vaccines.</description>
          <population>The population used in analysis was the safety set: The total number of subjects analyzed was less than the safety set due to subject withdrawals. Only subjects who received the second dose of the infant series vaccination were included in the analysis.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="936"/>
                <count group_id="O2" value="476"/>
                <count group_id="O3" value="1672"/>
                <count group_id="O4" value="824"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Erythema (mm) - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108"/>
                    <measurement group_id="O2" value="95"/>
                    <measurement group_id="O3" value="675"/>
                    <measurement group_id="O4" value="356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema (mm) - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration (mm) - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="75"/>
                    <measurement group_id="O3" value="267"/>
                    <measurement group_id="O4" value="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration (mm) - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="348"/>
                    <measurement group_id="O2" value="193"/>
                    <measurement group_id="O3" value="841"/>
                    <measurement group_id="O4" value="460"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="62"/>
                    <measurement group_id="O4" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body Temp. ( &gt;= 38° C )</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="246"/>
                    <measurement group_id="O4" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Eating Habits - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168"/>
                    <measurement group_id="O2" value="84"/>
                    <measurement group_id="O3" value="188"/>
                    <measurement group_id="O4" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Eating Habits - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="177"/>
                    <measurement group_id="O4" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="505"/>
                    <measurement group_id="O2" value="265"/>
                    <measurement group_id="O3" value="496"/>
                    <measurement group_id="O4" value="250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Persistent Crying - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="261"/>
                    <measurement group_id="O2" value="141"/>
                    <measurement group_id="O3" value="336"/>
                    <measurement group_id="O4" value="209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Persistent Crying - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="110"/>
                    <measurement group_id="O4" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="57"/>
                    <measurement group_id="O4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="363"/>
                    <measurement group_id="O2" value="178"/>
                    <measurement group_id="O3" value="547"/>
                    <measurement group_id="O4" value="263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="156"/>
                    <measurement group_id="O4" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Analgesic / Antipyretic medication used</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="570"/>
                    <measurement group_id="O2" value="297"/>
                    <measurement group_id="O3" value="988"/>
                    <measurement group_id="O4" value="491"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Solicited Local and Systemic Reactions Post Third Vaccination – Infant Series</title>
        <description>Solicited local and systemic reactions reported post third vaccination was compared in subjects receiving MenACWY versus Hib Vaccines.</description>
        <time_frame>7 days post-vaccination</time_frame>
        <population>The population used in analysis was the safety set: The total number of subjects analyzed was less than the safety set due to subject withdrawals. Only subjects who received the third dose in the infant series were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>US1+US3 (Men ACWY-CRM + Infant Vaccines)</title>
            <description>Groups MenACWY-CRM + Infant Vaccines (US1 +US3) pooled. US infants received MenACWY at 2, 4 and 6 months of age along with routine infant vaccines, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccine. These infants either received a fourth dose of MenACWY concomitantly with pneumococcal, HAV, and MMR-V vaccines at 12 months of age (US1A and US3) or received pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months and a fourth dose of MenACWY at 13 months of age( US1B).</description>
          </group>
          <group group_id="O2">
            <title>US2+US4 (Infant Vaccines Only)</title>
            <description>Groups Infant Vaccines only (US2+US4) pooled US infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. These infants received either one dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months; and a second dose of MenACWY at 15 months of age (US2 and US4A) or received concomitant pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months and one dose of MenACWY at 13 and and a second dose of MenACWY at 15 months of age (US4B) or one dose of MenACWY at 18 months of age (US4C).</description>
          </group>
          <group group_id="O3">
            <title>LA3+LA5 (Men ACWY-CRM + Infant Vaccines)</title>
            <description>Groups Men ACWY-CRM + Infant Vaccines (LA3 and LA5) pooled
LA infants received MenACWY at 2, 4 and 6 months of age; and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines. At 12 months of age these infants were:
Recommended to receive pneumococcal conjugate vaccine, HAV, and MMR-V. At 16 months of age, these subjects received the fourth dose of MenACWY along with concomitant DTaP and Hib (LA3A)
Received pneumococcal conjugate vaccine, HAV, and MMR-V. At 16 months of age, these subjects received DTaP and Hib. At 17 months of age, these subjects received the fourth dose of MenACWY (LA3B).
Received the fourth dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V (LA5).</description>
          </group>
          <group group_id="O4">
            <title>LA4+LA6 (Infant Vaccines Only)</title>
            <description>Groups Infant Vaccines only (LA4 and LA6) pooled.
LA infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, rotavirus, and pneumococcal conjugate vaccines, at 2, 4 and 6 months of age. These infants received either:
One dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months and a second dose of MenACWY along with DTaP and Hib vaccines at 15 months of age (LA4).
Concomitant pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months; and either one dose each of MenACWY at 12 and 15 months of age (LA6A); or one dose each of MenACWY at 13 and 15 months of age (LA6B) or one dose of MenACWY at 18 months of age (LA6C).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Solicited Local and Systemic Reactions Post Third Vaccination – Infant Series</title>
          <description>Solicited local and systemic reactions reported post third vaccination was compared in subjects receiving MenACWY versus Hib Vaccines.</description>
          <population>The population used in analysis was the safety set: The total number of subjects analyzed was less than the safety set due to subject withdrawals. Only subjects who received the third dose in the infant series were included in this analysis.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="910"/>
                <count group_id="O2" value="454"/>
                <count group_id="O3" value="1646"/>
                <count group_id="O4" value="826"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Erythema (mm) - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126"/>
                    <measurement group_id="O2" value="95"/>
                    <measurement group_id="O3" value="549"/>
                    <measurement group_id="O4" value="311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema (mm) - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration (mm) - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="82"/>
                    <measurement group_id="O3" value="189"/>
                    <measurement group_id="O4" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration (mm) - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="271"/>
                    <measurement group_id="O2" value="137"/>
                    <measurement group_id="O3" value="582"/>
                    <measurement group_id="O4" value="356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body Temp. ( &gt;= 38° C )</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="190"/>
                    <measurement group_id="O4" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Eating Habits - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135"/>
                    <measurement group_id="O2" value="57"/>
                    <measurement group_id="O3" value="149"/>
                    <measurement group_id="O4" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Eating Habits - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="109"/>
                    <measurement group_id="O4" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="416"/>
                    <measurement group_id="O2" value="227"/>
                    <measurement group_id="O3" value="373"/>
                    <measurement group_id="O4" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Persistent Crying - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="189"/>
                    <measurement group_id="O2" value="98"/>
                    <measurement group_id="O3" value="208"/>
                    <measurement group_id="O4" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Persistent Crying - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="68"/>
                    <measurement group_id="O4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="257"/>
                    <measurement group_id="O2" value="130"/>
                    <measurement group_id="O3" value="362"/>
                    <measurement group_id="O4" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="115"/>
                    <measurement group_id="O4" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Analgesic / Antipyretic medication used</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="506"/>
                    <measurement group_id="O2" value="274"/>
                    <measurement group_id="O3" value="682"/>
                    <measurement group_id="O4" value="393"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean hSBA Titers Post-infant Series - US Subjects</title>
        <description>Geometric Mean hSBA Titers directed against N. meningitidis serogroups A, C, W and Y was measured after three doses at 2, 4, and 6 months of age.</description>
        <time_frame>7 months of age (one month post-infant series)</time_frame>
        <population>The analysis was done on per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>US1 (MenACWY-CRM + Infant Vaccines)</title>
            <description>US infants received one dose of MenACWY at 2, 4 and 6 months of age and received,as part of routine infant vaccination schedule, DTaP-IPV-HBV, Hib, pneumococcal conjugate vaccine, and rotavirus vaccine. Group US1 was randomized into subgroups US1A and US1B.</description>
          </group>
          <group group_id="O2">
            <title>US2 (Infant Vaccines Only)</title>
            <description>received as part of routine infant vaccination schedule DTaP-IPV-HBV,Hib, pneumococcal conjugate vaccine, and rotavirus vaccine at 2, 4 and 6 months of age. At 12 months of age, these subjects received a dose of MenACWY along with concomitant pneumococcal conjugate vaccine, HAV, and MMR-V. At 15 months of age, these subjects received a second dose of MenACWY.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean hSBA Titers Post-infant Series - US Subjects</title>
          <description>Geometric Mean hSBA Titers directed against N. meningitidis serogroups A, C, W and Y was measured after three doses at 2, 4, and 6 months of age.</description>
          <population>The analysis was done on per protocol population</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A (Pre-vaccination GMT; N= 177, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.11" lower_limit="2" upper_limit="2.23"/>
                    <measurement group_id="O2" value="2.1" lower_limit="1.92" upper_limit="2.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A (Post-vaccination GMT; N= 212, 80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="11" upper_limit="16"/>
                    <measurement group_id="O2" value="2.03" lower_limit="1.53" upper_limit="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C (Pre-vaccination GMT; N= 168, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.48" lower_limit="2.23" upper_limit="2.75"/>
                    <measurement group_id="O2" value="2.17" lower_limit="1.83" upper_limit="2.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C (Post-vaccination GMT; N= 204, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108" lower_limit="92" upper_limit="127"/>
                    <measurement group_id="O2" value="2.12" lower_limit="1.64" upper_limit="2.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W (Pre-vaccination GMT; N= 165, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.07" lower_limit="2.7" upper_limit="3.5"/>
                    <measurement group_id="O2" value="2.71" lower_limit="2.2" upper_limit="3.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W (Post-vaccination GMT; N=197, 90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="86" upper_limit="116"/>
                    <measurement group_id="O2" value="2.08" lower_limit="1.67" upper_limit="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Y (Pre-vaccination GMT; N=150, 62 )</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.53" lower_limit="2.31" upper_limit="2.77"/>
                    <measurement group_id="O2" value="2.13" lower_limit="1.85" upper_limit="2.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Y (Post-vaccination GMT; N=182, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73" lower_limit="62" upper_limit="86"/>
                    <measurement group_id="O2" value="2.03" lower_limit="1.6" upper_limit="2.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean hSBA Titers Post-infant Series - LA Subjects</title>
        <description>Geometric Mean hSBA Titers directed against N. meningitidis serogroups A, C, W and Y was measured after two doses of MenACWY at 2 and 6 months (LA1) versus three doses at 2, 4, and 6 (LA3) months of age.</description>
        <time_frame>7 months of age (one month post-infant series)</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>LA1 (MenACWY-CRM + Infant Vaccines)</title>
            <description>LA infants received MenACWY at 2 and 6 months of age and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. Group LA1 was randomized into LA1A and LA 1B subgroups.</description>
          </group>
          <group group_id="O2">
            <title>LA3 (MenACWY-CRM + Infant Vaccines)</title>
            <description>LA infants received MenACWY at 2, 4 and 6 months of age; and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, pneumococcal conjugate vaccine, and rotavirus vaccine. Group LA3 was further randomized into LA3A and LA3B subgroups.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean hSBA Titers Post-infant Series - LA Subjects</title>
          <description>Geometric Mean hSBA Titers directed against N. meningitidis serogroups A, C, W and Y was measured after two doses of MenACWY at 2 and 6 months (LA1) versus three doses at 2, 4, and 6 (LA3) months of age.</description>
          <population>Per protocol population</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="277"/>
                <count group_id="O2" value="272"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A (Pre-vaccination GMT; N= 272, 271)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.09" lower_limit="2.03" upper_limit="2.16"/>
                    <measurement group_id="O2" value="2.03" lower_limit="1.97" upper_limit="2.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A (Post-vaccination GMT; N= 277, 268)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31" lower_limit="26" upper_limit="38"/>
                    <measurement group_id="O2" value="43" lower_limit="36" upper_limit="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C (Pre-vaccination GMT; N= 273,272)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.32" lower_limit="2.18" upper_limit="2.47"/>
                    <measurement group_id="O2" value="2.34" lower_limit="2.19" upper_limit="2.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C (Post-vaccination GMT; N= 277, 272)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155" lower_limit="131" upper_limit="183"/>
                    <measurement group_id="O2" value="150" lower_limit="127" upper_limit="177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W (Pre-vaccination GMT; N= 263, 261)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" lower_limit="2.64" upper_limit="3.18"/>
                    <measurement group_id="O2" value="2.54" lower_limit="2.31" upper_limit="2.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W (Post-vaccination GMT; N=271,264)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="259" lower_limit="227" upper_limit="296"/>
                    <measurement group_id="O2" value="182" lower_limit="159" upper_limit="208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Y (Pre-vaccination GMT; N=258, 260)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.35" lower_limit="2.22" upper_limit="2.49"/>
                    <measurement group_id="O2" value="2.26" lower_limit="2.14" upper_limit="2.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Y (Post-vaccination GMT; N=272,263)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159" lower_limit="136" upper_limit="185"/>
                    <measurement group_id="O2" value="125" lower_limit="107" upper_limit="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serogroup A (Post-vaccination GMT; group ratio LA1:LA3)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>LA1 was noninferior to LA3, if the lower limit of the two-sided 95% CI for the ratio of GMTs between the 2 dose and the 3 dose schedule (GMTLA1/GMTLA3) must be &gt; 0.5.</non_inferiority_desc>
            <param_type>Ratio of GMT</param_type>
            <param_value>0.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>0.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serogroup C (Post-vaccination GMT; group ratio LA1:LA3)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>LA1 was noninferior to LA3, if the lower limit of the two-sided 95% CI for the ratio of GMTs between the 2 dose and the 3 dose schedule (GMTLA1/GMTLA3) must be &gt; 0.5.</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serogroup W (Post-vaccination GMT; group ratio LA1:LA3)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>LA1 was noninferior to LA3, if the lower limit of the two-sided 95% CI for the ratio of GMTs between the 2 dose and the 3 dose schedule (GMTLA1/GMTLA3) must be &gt; 0.5.</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>1.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.18</ci_lower_limit>
            <ci_upper_limit>1.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serogroup Y (Post-vaccination GMT; group ratio LA1:LA3)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>LA1 was noninferior to LA3, if the lower limit of the two-sided 95% CI for the ratio of GMTs between the 2 dose and the 3 dose schedule (GMTLA1/GMTLA3) must be &gt; 0.5.</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>1.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.02</ci_lower_limit>
            <ci_upper_limit>1.58</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With hSBA Titer &gt;=1:8 - US Subjects</title>
        <description>Immunogenicity as measured by percentage of subjects with hSBA titer &gt;=1:8 directed against N. meningitidis serogroups A, C, W and Y; after three doses of MenACWY at 2, 4, and 6 months of age.</description>
        <time_frame>7 months of age (one month post-infant series)</time_frame>
        <population>Per Protocol Population</population>
        <group_list>
          <group group_id="O1">
            <title>US1 (MenACWY-CRM + Infant Vaccines)</title>
            <description>US infants received one dose of MenACWY at 2, 4 and 6 months of age; and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines. Group US1 was randomized into US1A and US1B subgroups.</description>
          </group>
          <group group_id="O2">
            <title>US2 (Infant Vaccines Only)</title>
            <description>received as part of routine infant vaccination schedule DTaP-IPV-HBV,Hib, pneumococcal conjugate vaccine, and rotavirus vaccine at 2, 4 and 6 months of age. At 12 months of age, these subjects received a dose of MenACWY along with concomitant pneumococcal conjugate vaccine, HAV, and MMR-V. At 15 months of age, these subjects received a second dose of MenACWY.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With hSBA Titer &gt;=1:8 - US Subjects</title>
          <description>Immunogenicity as measured by percentage of subjects with hSBA titer &gt;=1:8 directed against N. meningitidis serogroups A, C, W and Y; after three doses of MenACWY at 2, 4, and 6 months of age.</description>
          <population>Per Protocol Population</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A (Pre-vaccination GMT; N= 177, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0" upper_limit="5"/>
                    <measurement group_id="O2" value="3" lower_limit="0" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A (Post-vaccination GMT; N= 212, 80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67" lower_limit="61" upper_limit="74"/>
                    <measurement group_id="O2" value="1" lower_limit="0.032" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C (Pre-vaccination GMT; N= 168, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="3" upper_limit="11"/>
                    <measurement group_id="O2" value="5" lower_limit="1" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C (Post-vaccination GMT; N= 204, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="93" upper_limit="99"/>
                    <measurement group_id="O2" value="1" lower_limit="0.03" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W (Pre-vaccination GMT; N= 165, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" lower_limit="12" upper_limit="24"/>
                    <measurement group_id="O2" value="11" lower_limit="4" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W (Post-vaccination GMT; N=197, 90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="93" upper_limit="99"/>
                    <measurement group_id="O2" value="2" lower_limit="0" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Y (Pre-vaccination GMT; N=150, 62 )</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="2" upper_limit="10"/>
                    <measurement group_id="O2" value="3" lower_limit="0" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Y (Post-vaccination GMT; N=182, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="92" upper_limit="98"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With hSBA Titer &gt;=1:4 - US Subjects</title>
        <description>Immunogenicity as measured by percentage of subjects with hSBA titer &gt;=1:4 directed against N. meningitidis serogroups A, C, W and Y; after three doses of MenACWY at 2, 4, and 6 months of age.</description>
        <time_frame>7 months of age (one month post-infant series)</time_frame>
        <population>Per Protocol Population</population>
        <group_list>
          <group group_id="O1">
            <title>US1 (MenACWY-CRM + Infant Vaccines)</title>
            <description>US infants received one dose of MenACWY at 2, 4 and 6 months of age; and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines. Group US1 was randomized into US1A and US1B subgroups.</description>
          </group>
          <group group_id="O2">
            <title>US2 (Infant Vaccines Only)</title>
            <description>received as part of routine infant vaccination schedule DTaP-IPV-HBV,Hib, pneumococcal conjugate vaccine, and rotavirus vaccine at 2, 4 and 6 months of age. At 12 months of age, these subjects received a dose of MenACWY along with concomitant pneumococcal conjugate vaccine, HAV, and MMR-V. At 15 months of age, these subjects received a second dose of MenACWY.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With hSBA Titer &gt;=1:4 - US Subjects</title>
          <description>Immunogenicity as measured by percentage of subjects with hSBA titer &gt;=1:4 directed against N. meningitidis serogroups A, C, W and Y; after three doses of MenACWY at 2, 4, and 6 months of age.</description>
          <population>Per Protocol Population</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A (Pre-vaccination GMT; N= 177, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="1" upper_limit="6"/>
                    <measurement group_id="O2" value="3" lower_limit="0" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A (Post-vaccination GMT; N= 212, 80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71" lower_limit="65" upper_limit="77"/>
                    <measurement group_id="O2" value="1" lower_limit="0.03" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C (Pre-vaccination GMT; N= 168, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="6" upper_limit="16"/>
                    <measurement group_id="O2" value="5" lower_limit="1" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C (Post-vaccination GMT; N= 204, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O2" value="2" lower_limit="0" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W (Pre-vaccination GMT; N= 165, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22" lower_limit="16" upper_limit="30"/>
                    <measurement group_id="O2" value="15" lower_limit="8" upper_limit="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W (Post-vaccination GMT; N=197, 90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O2" value="2" lower_limit="0" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Y (Pre-vaccination GMT; N=150, 62 )</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" lower_limit="11" upper_limit="24"/>
                    <measurement group_id="O2" value="5" lower_limit="1" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Y (Post-vaccination GMT; N=182, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O2" value="1" lower_limit="0.032" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With hSBA Titer &gt;=1:8 - LA Subjects</title>
        <description>Immunogenicity as measured by percentage of subjects with hSBA titer &gt;=1:8 directed against N. meningitidis serogroups A, C, W and Y; after two doses of MenACWY at 2 and 6 months (LA1) versus three doses at 2, 4, and 6 months of age (LA3) .</description>
        <time_frame>7 months of age (one month post-infant series)</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>LA1 (MenACWY-CRM + Infant Vaccines)</title>
            <description>LA infants received MenACWY at 2 and 6 months of age and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. Group LA1 was randomized into LA1A and LA 1B subgroups.</description>
          </group>
          <group group_id="O2">
            <title>LA3 (MenACWY-CRM + Infant Vaccines)</title>
            <description>LA infants received MenACWY at 2, 4 and 6 months of age; and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, pneumococcal conjugate vaccine, and rotavirus vaccine. Group LA3 was further randomized into LA3A and LA3B subgroups.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With hSBA Titer &gt;=1:8 - LA Subjects</title>
          <description>Immunogenicity as measured by percentage of subjects with hSBA titer &gt;=1:8 directed against N. meningitidis serogroups A, C, W and Y; after two doses of MenACWY at 2 and 6 months (LA1) versus three doses at 2, 4, and 6 months of age (LA3) .</description>
          <population>Per protocol population</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="277"/>
                <count group_id="O2" value="272"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A (Pre-vaccination hSBA titer ≥1:8; N= 272, 271)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A (Post-vaccination hSBA titer ≥1:8; N= 277, 268)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74" lower_limit="69" upper_limit="79"/>
                    <measurement group_id="O2" value="89" lower_limit="85" upper_limit="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C (Pre-vaccination hSBA titer ≥1:8; N= 273,272)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="2" upper_limit="7"/>
                    <measurement group_id="O2" value="4" lower_limit="2" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C (Post-vaccination hSBA titer ≥1:8; N= 277, 272)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" lower_limit="90" upper_limit="96"/>
                    <measurement group_id="O2" value="97" lower_limit="94" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W (Pre-vaccination hSBA titer ≥1:8; N= 263, 261)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="12" upper_limit="21"/>
                    <measurement group_id="O2" value="10" lower_limit="7" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W (Post-vaccination hSBA titer ≥1:8; N=271,264)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O2" value="98" lower_limit="96" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Y (Pre-vaccination hSBA titer ≥1:8; N=258, 260)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="3" upper_limit="9"/>
                    <measurement group_id="O2" value="3" lower_limit="2" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Y (Post-vaccination hSBA titer ≥1:8; N=272,263)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="94" upper_limit="99"/>
                    <measurement group_id="O2" value="98" lower_limit="96" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serogroup A (post-vaccination percentage of subjects with hSBA titer &gt;=8, group difference (PLA1 - PLA3))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>LA1 was noninferior to LA3, if the lower limit of the two-sided 95% CI for the difference in percentage of subjects with hSBA ≥ 1:8 and ≥1:4 between the 2 dose and the 3 dose schedule (PLA1 – PLA3) must be greater than -10%.</non_inferiority_desc>
            <param_type>Percentage (hSBA titers &gt;=8) difference</param_type>
            <param_value>-15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.2</ci_lower_limit>
            <ci_upper_limit>-8.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serogroup C (post-vaccination percentage of subjects with hSBA titer &gt;=8, group difference (PLA1 - PLA3))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>LA1 was noninferior to LA3, if the lower limit of the two-sided 95% CI for the difference in percentage of subjects with hSBA ≥ 1:8 and ≥1:4 between the 2 dose and the 3 dose schedule (PLA1 – PLA3) must be greater than -10%.</non_inferiority_desc>
            <param_type>Percentage (hSBA titers &gt;=8) difference</param_type>
            <param_value>-3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7</ci_lower_limit>
            <ci_upper_limit>0.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serogroup W (post-vaccination percentage of subjects with hSBA titer &gt;=8, group difference (PLA1 - PLA3))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>LA1 was noninferior to LA3, if the lower limit of the two-sided 95% CI for the difference in percentage of subjects with hSBA ≥ 1:8 and ≥1:4 between the 2 dose and the 3 dose schedule (PLA1 – PLA3) must be greater than -10%.</non_inferiority_desc>
            <param_type>Percentage (hSBA titers &gt;=8) difference</param_type>
            <param_value>1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.3</ci_lower_limit>
            <ci_upper_limit>3.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serogroup Y (post-vaccination percentage of subjects with hSBA titer &gt;=8, group difference (PLA1 - PLA3))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>LA1 was noninferior to LA3, if the lower limit of the two-sided 95% CI for the difference in percentage of subjects with hSBA ≥ 1:8 and ≥1:4 between the 2 dose and the 3 dose schedule (PLA1 – PLA3) must be greater than -10%.</non_inferiority_desc>
            <param_type>Percentage (hSBA titers &gt;=8) difference</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4</ci_lower_limit>
            <ci_upper_limit>1.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With hSBA Titer &gt;=1:4 - LA Subjects</title>
        <description>Immunogenicity as measured by percentage of subjects with hSBA titer &gt;=1:4 directed against N. meningitidis serogroups A, C, W and Y; after two doses of MenACWY at 2 and 6 months (LA1) versus three doses at 2, 4, and 6 months of age (LA3) .</description>
        <time_frame>7 months of age (one month post-infant series)</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>LA1 (MenACWY-CRM + Infant Vaccines)</title>
            <description>LA infants received MenACWY at 2 and 6 months of age and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. Group LA1 was randomized into LA1A and LA 1B subgroups.</description>
          </group>
          <group group_id="O2">
            <title>LA3 (MenACWY-CRM + Infant Vaccines)</title>
            <description>LA infants received MenACWY at 2, 4 and 6 months of age; and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, pneumococcal conjugate vaccine, and rotavirus vaccine. Group LA3 was further randomized into LA3A and LA3B subgroups.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With hSBA Titer &gt;=1:4 - LA Subjects</title>
          <description>Immunogenicity as measured by percentage of subjects with hSBA titer &gt;=1:4 directed against N. meningitidis serogroups A, C, W and Y; after two doses of MenACWY at 2 and 6 months (LA1) versus three doses at 2, 4, and 6 months of age (LA3) .</description>
          <population>Per protocol population</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="277"/>
                <count group_id="O2" value="272"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A (Pre-vaccination hSBA titer ≥1:4; N= 272, 271)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="1" upper_limit="5"/>
                    <measurement group_id="O2" value="1" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A (Post-vaccination hSBA titer ≥1:4; N= 277, 268)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78" lower_limit="73" upper_limit="83"/>
                    <measurement group_id="O2" value="91" lower_limit="87" upper_limit="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C (Pre-vaccination hSBA titer ≥1:4; N= 273,272)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="7" upper_limit="14"/>
                    <measurement group_id="O2" value="10" lower_limit="7" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C (Post-vaccination hSBA titer ≥1:4; N= 277, 272)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="93" upper_limit="98"/>
                    <measurement group_id="O2" value="98" lower_limit="96" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W (Pre-vaccination hSBA titer ≥1:4; N= 263, 261)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" lower_limit="13" upper_limit="23"/>
                    <measurement group_id="O2" value="13" lower_limit="9" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W (Post-vaccination hSBA titer ≥1:4; N=271,264)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="99" upper_limit="100"/>
                    <measurement group_id="O2" value="99" lower_limit="97" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Y (Pre-vaccination hSBA titer ≥1:4; N=258, 260)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="8" upper_limit="16"/>
                    <measurement group_id="O2" value="8" lower_limit="5" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Y (Post-vaccination hSBA titer ≥1:4; N=272,263)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="96" upper_limit="99"/>
                    <measurement group_id="O2" value="99" lower_limit="97" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Concentrations or Titers of DTaP, HBV, Hib, Pneumococcal and Polio Antigens at 1 Month After Infant Series Vaccination - US Subjects</title>
        <description>Immunogenicity as measured by antibody GMCs / GMTs directed against DTaP, HBV, Hib, pneumococcal and polio antigens.</description>
        <time_frame>7 months of age (one month post-infant series)</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>US1 (Men ACWY-CRM + Infant Vaccines)</title>
            <description>US infants received one dose of MenACWY at 2, 4 and 6 months of age; and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines. Group US1 was randomized into US1A and US1B subgroups.</description>
          </group>
          <group group_id="O2">
            <title>US2 (Infant Vaccines Only)</title>
            <description>US infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. These infants received one dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months; and a second dose of MenACWY at 15 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentrations or Titers of DTaP, HBV, Hib, Pneumococcal and Polio Antigens at 1 Month After Infant Series Vaccination - US Subjects</title>
          <description>Immunogenicity as measured by antibody GMCs / GMTs directed against DTaP, HBV, Hib, pneumococcal and polio antigens.</description>
          <population>Per Protocol</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="214"/>
                <count group_id="O2" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Diphtheria (214, 102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.52" lower_limit="2.28" upper_limit="2.78"/>
                    <measurement group_id="O2" value="2.88" lower_limit="2.5" upper_limit="3.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tetanus (214, 102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="2.28" upper_limit="2.74"/>
                    <measurement group_id="O2" value="2.31" lower_limit="2.01" upper_limit="2.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PT (174, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54" lower_limit="48" upper_limit="62"/>
                    <measurement group_id="O2" value="54" lower_limit="44" upper_limit="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FHA (174, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118" lower_limit="106" upper_limit="132"/>
                    <measurement group_id="O2" value="114" lower_limit="97" upper_limit="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertactin (174, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114" lower_limit="100" upper_limit="130"/>
                    <measurement group_id="O2" value="110" lower_limit="90" upper_limit="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Polio Type 1 (176, 98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="422" lower_limit="363" upper_limit="491"/>
                    <measurement group_id="O2" value="441" lower_limit="361" upper_limit="540"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Polio Type 2 (175, 98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="348" lower_limit="297" upper_limit="408"/>
                    <measurement group_id="O2" value="290" lower_limit="235" upper_limit="358"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Polio Type 3 (176, 98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="733" lower_limit="607" upper_limit="885"/>
                    <measurement group_id="O2" value="635" lower_limit="493" upper_limit="818"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatitis B (N=148, N=98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1863" lower_limit="1538" upper_limit="2257"/>
                    <measurement group_id="O2" value="2112" lower_limit="1668" upper_limit="2674"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hib (N=213, N=101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.64" lower_limit="3.9" upper_limit="5.53"/>
                    <measurement group_id="O2" value="3.56" lower_limit="2.77" upper_limit="4.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PnC 4 (N=181, N=102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.67" lower_limit="1.5" upper_limit="1.86"/>
                    <measurement group_id="O2" value="2" lower_limit="1.73" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PnC 6B (N=181, N=102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.94" lower_limit="1.61" upper_limit="2.34"/>
                    <measurement group_id="O2" value="2.55" lower_limit="1.99" upper_limit="3.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PnC 9V (N=181, N=102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.83" lower_limit="1.62" upper_limit="2.06"/>
                    <measurement group_id="O2" value="2.15" lower_limit="1.83" upper_limit="2.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PnC 14 (N=181, N=102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.97" lower_limit="6.18" upper_limit="7.86"/>
                    <measurement group_id="O2" value="6.79" lower_limit="5.78" upper_limit="7.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PnC 18C (N=181, N=102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.96" lower_limit="1.75" upper_limit="2.19"/>
                    <measurement group_id="O2" value="2.54" lower_limit="2.18" upper_limit="2.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PnC 19F (N=181, N=102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.24" lower_limit="2.02" upper_limit="2.48"/>
                    <measurement group_id="O2" value="2.73" lower_limit="2.39" upper_limit="3.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PnC 23F (N=181, N=102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.71" lower_limit="1.47" upper_limit="1.98"/>
                    <measurement group_id="O2" value="2.15" lower_limit="1.76" upper_limit="2.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Diphtheria (Post-vaccination GMT; group ratio US1:US2)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of US1 over US2, the lower limit of 95% CI for the ratio of pertussis GMCs (GMCUS1 /GMCUS2) must be greater than 0.67; the lower limit of 95% CI for the ratio of all other GMCs (GMCUS1 / GMCUS2) must be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Tetanus (Post-vaccination GMT; group ratio US1:US2)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of US1 over US2, the lower limit of 95% CI for the ratio of pertussis GMCs (GMCUS1 /GMCUS2) must be greater than 0.67; the lower limit of 95% CI for the ratio of all other GMCs (GMCUS1 / GMCUS2) must be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>1.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.92</ci_lower_limit>
            <ci_upper_limit>1.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PT (Post-vaccination GMT; group ratio US1:US2)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of US1 over US2, the lower limit of 95% CI for the ratio of pertussis GMCs (GMCUS1 /GMCUS2) must be greater than 0.67; the lower limit of 95% CI for the ratio of all other GMCs (GMCUS1 / GMCUS2) must be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>1.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>FHA (Post-vaccination GMT; group ratio US1:US2)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of US1 over US2, the lower limit of 95% CI for the ratio of pertussis GMCs (GMCUS1 /GMCUS2) must be greater than 0.67; the lower limit of 95% CI for the ratio of all other GMCs (GMCUS1 / GMCUS2) must be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pertactin (Post-vaccination GMT; group ratio US1:US2</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of US1 over US2, the lower limit of 95% CI for the ratio of pertussis GMCs (GMCUS1 /GMCUS2) must be greater than 0.67; the lower limit of 95% CI for the ratio of all other GMCs (GMCUS1 / GMCUS2) must be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>1.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Polio Type 1 (Post-vaccination GMT; group ratio US1:US2)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of US1 over US2, the lower limit of 95% CI for the ratio of pertussis GMCs (GMCUS1 /GMCUS2) must be greater than 0.67; the lower limit of 95% CI for the ratio of all other GMCs (GMCUS1 / GMCUS2) must be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Polio Type 2 (Post-vaccination GMT; group ratio US1:US2)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of US1 over US2, the lower limit of 95% CI for the ratio of pertussis GMCs (GMCUS1 /GMCUS2) must be greater than 0.67; the lower limit of 95% CI for the ratio of all other GMCs (GMCUS1 / GMCUS2) must be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.93</ci_lower_limit>
            <ci_upper_limit>1.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Polio Type 3 (Post-vaccination GMT; group ratio US1:US2)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of US1 over US2, the lower limit of 95% CI for the ratio of pertussis GMCs (GMCUS1 /GMCUS2) must be greater than 0.67; the lower limit of 95% CI for the ratio of all other GMCs (GMCUS1 / GMCUS2) must be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>1.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hepatitis B (Post-vaccination GMT; group ratio US1:US2)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of US1 over US2, the lower limit of 95% CI for the ratio of pertussis GMCs (GMCUS1 /GMCUS2) must be greater than 0.67; the lower limit of 95% CI for the ratio of all other GMCs (GMCUS1 / GMCUS2) must be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>1.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>HIb (Post-vaccination GMT; group ratio US1:US2)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of US1 over US2, the lower limit of 95% CI for the ratio of pertussis GMCs (GMCUS1 /GMCUS2) must be greater than 0.67; the lower limit of 95% CI for the ratio of all other GMCs (GMCUS1 / GMCUS2) must be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>1.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.77</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PnC 4 (Post-vaccination GMT; group ratio US1:US2)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of US1 over US2, the lower limit of 95% CI for the ratio of pertussis GMCs (GMCUS1 /GMCUS2) must be greater than 0.67; the lower limit of 95% CI for the ratio of all other GMCs (GMCUS1 / GMCUS2) must be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.7</ci_lower_limit>
            <ci_upper_limit>1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PnC 6B (Post-vaccination GMT; group ratio US1:US2)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of US1 over US2, the lower limit of 95% CI for the ratio of pertussis GMCs (GMCUS1 /GMCUS2) must be greater than 0.67; the lower limit of 95% CI for the ratio of all other GMCs (GMCUS1 / GMCUS2) must be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>0.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.56</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PnC 9V (Post-vaccination GMT; group ratio US1:US2)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of US1 over US2, the lower limit of 95% CI for the ratio of pertussis GMCs (GMCUS1 /GMCUS2) must be greater than 0.67; the lower limit of 95% CI for the ratio of all other GMCs (GMCUS1 / GMCUS2) must be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.7</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PnC 14 (Post-vaccination GMT; group ratio US1:US2)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of US1 over US2, the lower limit of 95% CI for the ratio of pertussis GMCs (GMCUS1 /GMCUS2) must be greater than 0.67; the lower limit of 95% CI for the ratio of all other GMCs (GMCUS1 / GMCUS2) must be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PnC 18C (Post-vaccination GMT; group ratio US1:US2)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of US1 over US2, the lower limit of 95% CI for the ratio of pertussis GMCs (GMCUS1 /GMCUS2) must be greater than 0.67; the lower limit of 95% CI for the ratio of all other GMCs (GMCUS1 / GMCUS2) must be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>0.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>0.93</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PnC 19F (Post-vaccination GMT; group ratio US1:US2)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of US1 over US2, the lower limit of 95% CI for the ratio of pertussis GMCs (GMCUS1 /GMCUS2) must be greater than 0.67; the lower limit of 95% CI for the ratio of all other GMCs (GMCUS1 / GMCUS2) must be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>0.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PnC 23F (Post-vaccination GMT; group ratio US1:US2)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of US1 over US2, the lower limit of 95% CI for the ratio of pertussis GMCs (GMCUS1 /GMCUS2) must be greater than 0.67; the lower limit of 95% CI for the ratio of all other GMCs (GMCUS1 / GMCUS2) must be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>0.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.62</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroresponse Rates to DTaP, HBV, Hib, Pneumococcal and Polio Antigens at 1 Month After Infant Series Vaccination - US Subjects</title>
        <description>Immunogenicity as measured by percentage of subjects with predefined seroprotective antibody titers against DTaP, HBV, Hib, pneumococcal and polio antigens.</description>
        <time_frame>7 months of age (one month post-infant series)</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>US1 (Men ACWY-CRM + Infant Vaccines)</title>
            <description>US infants received one dose of MenACWY at 2, 4 and 6 months of age; and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines. Group US1 was randomized into US1A and US1B subgroups.</description>
          </group>
          <group group_id="O2">
            <title>US2 (Infant Vaccines Only)</title>
            <description>US infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. These infants received one dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months; and a second dose of MenACWY at 15 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroresponse Rates to DTaP, HBV, Hib, Pneumococcal and Polio Antigens at 1 Month After Infant Series Vaccination - US Subjects</title>
          <description>Immunogenicity as measured by percentage of subjects with predefined seroprotective antibody titers against DTaP, HBV, Hib, pneumococcal and polio antigens.</description>
          <population>Per Protocol</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="214"/>
                <count group_id="O2" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Diphtheria (≥ 0.1 IU/mL) (214, 102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="96" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tetanus (≥ 0.1 IU/mL) (214, 102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="96" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PT(≥ 4-fold rise) (174, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87" lower_limit="81" upper_limit="92"/>
                    <measurement group_id="O2" value="86" lower_limit="76" upper_limit="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FHA (≥ 4-fold rise) (174, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85" lower_limit="79" upper_limit="90"/>
                    <measurement group_id="O2" value="80" lower_limit="69" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertactin (≥ 4-fold rise) (174, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76" lower_limit="69" upper_limit="83"/>
                    <measurement group_id="O2" value="78" lower_limit="68" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Polio Type 1 (≥1:8) (176, 98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="96" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Polio Type 2 (≥1:8) (176, 98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="96" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Polio Type 3 (≥1:8)(175, 98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="96" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatitis B (≥10 mIU/mL) (N=148, N=98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="96" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hib (≥ 0.15 μg/mL) (N=213, N=101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="96" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hib (≥1.0 μg/mL) (N=213, N=101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89" lower_limit="84" upper_limit="93"/>
                    <measurement group_id="O2" value="84" lower_limit="76" upper_limit="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PnC 4 (≥ 0.35 μg/mL) (N=181, N=102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="95" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="96" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PnC 6B (≥ 0.35 μg/mL) (N=181, N=102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88" lower_limit="83" upper_limit="93"/>
                    <measurement group_id="O2" value="96" lower_limit="90" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PnC 9V (≥ 0.35 μg/mL) (N=181, N=102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="94" upper_limit="99"/>
                    <measurement group_id="O2" value="98" lower_limit="93" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PnC 14 (≥ 0.35 μg/mL) (N=181, N=102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O2" value="99" lower_limit="95" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PnC 18C (≥ 0.35 μg/mL) (N=181, N=102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="94" upper_limit="99"/>
                    <measurement group_id="O2" value="100" lower_limit="96" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PnC 19F (≥ 0.35 μg/mL) (N=181, N=102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="96" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PnC 23F (≥ 0.35 μg/mL) (N=181, N=102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" lower_limit="87" upper_limit="95"/>
                    <measurement group_id="O2" value="94" lower_limit="88" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Diphtheria (Seroconversion percentage difference (PUS1 – PUS2))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of US1 over US2, the lower limit of 95% CI for the difference in seroresponse rates (PUS1 – PUS2) must be greater than -5% for polio and -10% for all others.</non_inferiority_desc>
            <param_type>Seroconversion Percentage difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3</ci_lower_limit>
            <ci_upper_limit>3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Tetanus (Seroconversion percentage difference (PUS1 – PUS2))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of US1 over US2, the lower limit of 95% CI for the difference in seroresponse rates (PUS1 – PUS2) must be greater than -5% for polio and -10% for all others.</non_inferiority_desc>
            <param_type>Seroconversion Percentage difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2</ci_lower_limit>
            <ci_upper_limit>4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PT (Seroconversion percentage difference (PUS1 – PUS2))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of US1 over US2, the lower limit of 95% CI for the difference in seroresponse rates (PUS1 – PUS2) must be greater than -5% for polio and -10% for all others.</non_inferiority_desc>
            <param_type>Seroconversion Percentage difference</param_type>
            <param_value>2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7</ci_lower_limit>
            <ci_upper_limit>12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>FHA(Seroconversion percentage difference (PUS1 – PUS2))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of US1 over US2, the lower limit of 95% CI for the difference in seroresponse rates (PUS1 – PUS2) must be greater than -5% for polio and -10% for all others.</non_inferiority_desc>
            <param_type>Seroconversion Percentage difference</param_type>
            <param_value>6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4</ci_lower_limit>
            <ci_upper_limit>17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pertactin (Seroconversion percentage difference (PUS1 – PUS2))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of US1 over US2, the lower limit of 95% CI for the difference in seroresponse rates (PUS1 – PUS2) must be greater than -5% for polio and -10% for all others.</non_inferiority_desc>
            <param_type>Seroconversion Percentage difference</param_type>
            <param_value>-2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12</ci_lower_limit>
            <ci_upper_limit>10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Polio Type 1 (Seroconversion percentage difference (PUS1 – PUS2))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of US1 over US2, the lower limit of 95% CI for the difference in seroresponse rates (PUS1 – PUS2) must be greater than -5% for polio and -10% for all others.</non_inferiority_desc>
            <param_type>Seroconversion Percentage difference</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3</ci_lower_limit>
            <ci_upper_limit>3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Polio Type 2 (Seroconversion percentage difference (PUS1 – PUS2))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of US1 over US2, the lower limit of 95% CI for the difference in seroresponse rates (PUS1 – PUS2) must be greater than -5% for polio and -10% for all others.</non_inferiority_desc>
            <param_type>Seroconversion Percentage difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2</ci_lower_limit>
            <ci_upper_limit>4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Polio Type 3 (Seroconversion percentage difference (PUS1 - PUS2))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of US1 over US2, the lower limit of 95% CI for the difference in seroresponse rates (PUS1 – PUS2) must be greater than -5% for polio and -10% for all others.</non_inferiority_desc>
            <param_type>Seroconversion Percentage difference</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3</ci_lower_limit>
            <ci_upper_limit>3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hepatitis B(Seroconversion percentage difference (PUS1 – PUS2))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of US1 over US2, the lower limit of 95% CI for the difference in seroresponse rates (PUS1 – PUS2) must be greater than -5% for polio and -10% for all others.</non_inferiority_desc>
            <param_type>Seroconversion Percentage difference</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4</ci_lower_limit>
            <ci_upper_limit>3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hib (≥ 0.15 μg/mL)(Seroconversion percentage difference (PUS1 – PUS2))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of US1 over US2, the lower limit of 95% CI for the difference in seroresponse rates (PUS1 – PUS2) must be greater than -5% for polio and -10% for all others.</non_inferiority_desc>
            <param_type>Seroconversion Percentage difference</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3</ci_lower_limit>
            <ci_upper_limit>3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hib (≥1.0 μg/mL)(Seroconversion percentage difference (PUS1 – PUS2))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of US1 over US2, the lower limit of 95% CI for the difference in seroresponse rates (PUS1 – PUS2) must be greater than -5% for polio and -10% for all others.</non_inferiority_desc>
            <param_type>Seroconversion Percentage difference</param_type>
            <param_value>5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3</ci_lower_limit>
            <ci_upper_limit>14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PnC 4(Seroconversion percentage difference (PUS1 – PUS2))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of US1 over US2, the lower limit of 95% CI for the difference in seroresponse rates (PUS1 – PUS2) must be greater than -5% for polio and -10% for all others.</non_inferiority_desc>
            <param_type>Seroconversion Percentage difference</param_type>
            <param_value>-2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5</ci_lower_limit>
            <ci_upper_limit>2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PnC 6B(Seroconversion percentage difference (PUS1 - PUS2))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of US1 over US2, the lower limit of 95% CI for the difference in seroresponse rates (PUS1 – PUS2) must be greater than -5% for polio and -10% for all others.</non_inferiority_desc>
            <param_type>(Seroconversion percentage difference (P</param_type>
            <param_value>-8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14</ci_lower_limit>
            <ci_upper_limit>-1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PnC 9V (Seroconversion percentage difference (PUS1 – PUS2))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of US1 over US2, the lower limit of 95% CI for the difference in seroresponse rates (PUS1 – PUS2) must be greater than -5% for polio and -10% for all others.</non_inferiority_desc>
            <param_type>Seroconversion Percentage difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4</ci_lower_limit>
            <ci_upper_limit>5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PnC 14 (Seroconversion percentage difference (PUS1 – PUS2))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of US1 over US2, the lower limit of 95% CI for the difference in seroresponse rates (PUS1 – PUS2) must be greater than -5% for polio and -10% for all others.</non_inferiority_desc>
            <param_type>Diphtheria (Seroconversion percentage di</param_type>
            <param_value>1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1</ci_lower_limit>
            <ci_upper_limit>5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PnC 18C (Seroconversion percentage difference (PUS1 – PUS2))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of US1 over US2, the lower limit of 95% CI for the difference in seroresponse rates (PUS1 – PUS2) must be greater than -5% for polio and -10% for all others.</non_inferiority_desc>
            <param_type>Seroconversion Percentage difference</param_type>
            <param_value>-3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6</ci_lower_limit>
            <ci_upper_limit>1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PnC 19F (Seroconversion percentage difference (PUS1 – PUS2))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of US1 over US2, the lower limit of 95% CI for the difference in seroresponse rates (PUS1 – PUS2) must be greater than -5% for polio and -10% for all others.</non_inferiority_desc>
            <param_type>(Seroconversion percentage difference (P</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4</ci_lower_limit>
            <ci_upper_limit>3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PnC 23F (Seroconversion percentage difference (PUS1 – PUS2))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of US1 over US2, the lower limit of 95% CI for the difference in seroresponse rates (PUS1 – PUS2) must be greater than -5% for polio and -10% for all others.</non_inferiority_desc>
            <param_type>Seroconversion Percentage difference</param_type>
            <param_value>-2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8</ci_lower_limit>
            <ci_upper_limit>5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Concentrations or Titers of DTaP, HBV, Hib, Pneumococcal and Polio Antigens at 1 Month After Infant Series Vaccination - LA Subjects</title>
        <description>Immunogenicity as measured by antibody GMCs / GMTs directed against DTaP, HBV, Hib, pneumococcal and polio antigens.</description>
        <time_frame>7 months of age (one month post-infant series)</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>LA1 (Men ACWY-CRM + Infant Vaccines)</title>
            <description>LA infants received MenACWY at 2 and 6 months of age and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. Group LA1 was randomized into LA1A and LA 1B subgroups.</description>
          </group>
          <group group_id="O2">
            <title>LA2 (Infant Vaccines Only)</title>
            <description>LA infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. These infants received one dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months; and a second dose of MenACWY at 15 months of age.</description>
          </group>
          <group group_id="O3">
            <title>LA3 (Men ACWY-CRM + Infant Vaccines)</title>
            <description>LA infants received MenACWY at 2, 4 and 6 months of age; and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, pneumococcal conjugate vaccine, and rotavirus vaccine. Group LA3 was further randomized into LA3A and LA3B subgroups.</description>
          </group>
          <group group_id="O4">
            <title>LA4 (Infant Vaccines Only)</title>
            <description>LA infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, pneumococcal conjugate vaccine, and rotavirus vaccine at 2, 4 and 6 months of age. These infants received one dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months and a second dose of MenACWY along with DTaP and Hib vaccines at 15 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentrations or Titers of DTaP, HBV, Hib, Pneumococcal and Polio Antigens at 1 Month After Infant Series Vaccination - LA Subjects</title>
          <description>Immunogenicity as measured by antibody GMCs / GMTs directed against DTaP, HBV, Hib, pneumococcal and polio antigens.</description>
          <population>Per Protocol</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
                <count group_id="O2" value="123"/>
                <count group_id="O3" value="283"/>
                <count group_id="O4" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Diphtheria (N=287, N=123, N=283, N=137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="1.62" upper_limit="1.99"/>
                    <measurement group_id="O2" value="1.54" lower_limit="1.32" upper_limit="1.81"/>
                    <measurement group_id="O3" value="1.45" lower_limit="1.31" upper_limit="1.61"/>
                    <measurement group_id="O4" value="1.77" lower_limit="1.52" upper_limit="2.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tetanus (N=287, N=123, N=283, N=137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.41" lower_limit="2.23" upper_limit="2.6"/>
                    <measurement group_id="O2" value="2.19" lower_limit="1.94" upper_limit="2.46"/>
                    <measurement group_id="O3" value="2.51" lower_limit="2.33" upper_limit="2.71"/>
                    <measurement group_id="O4" value="2.65" lower_limit="2.37" upper_limit="2.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PT (N=285, N=123, N=281, N=135)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47" lower_limit="43" upper_limit="52"/>
                    <measurement group_id="O2" value="45" lower_limit="39" upper_limit="53"/>
                    <measurement group_id="O3" value="45" lower_limit="41" upper_limit="50"/>
                    <measurement group_id="O4" value="49" lower_limit="42" upper_limit="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FHA (N=286, N=123, N=281, N=135)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102" lower_limit="93" upper_limit="112"/>
                    <measurement group_id="O2" value="97" lower_limit="85" upper_limit="112"/>
                    <measurement group_id="O3" value="99" lower_limit="91" upper_limit="109"/>
                    <measurement group_id="O4" value="112" lower_limit="99" upper_limit="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertactin (N=286, N=123, N=281, N=135)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123" lower_limit="110" upper_limit="137"/>
                    <measurement group_id="O2" value="124" lower_limit="105" upper_limit="146"/>
                    <measurement group_id="O3" value="119" lower_limit="106" upper_limit="133"/>
                    <measurement group_id="O4" value="149" lower_limit="127" upper_limit="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Polio Type 1 (N=265, N=112, N=252, N=120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="535" lower_limit="462" upper_limit="620"/>
                    <measurement group_id="O2" value="598" lower_limit="477" upper_limit="749"/>
                    <measurement group_id="O3" value="533" lower_limit="458" upper_limit="619"/>
                    <measurement group_id="O4" value="684" lower_limit="550" upper_limit="850"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Polio Type 2 (N=265, N=112, N=252, N=120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="353" lower_limit="302" upper_limit="411"/>
                    <measurement group_id="O2" value="366" lower_limit="289" upper_limit="463"/>
                    <measurement group_id="O3" value="318" lower_limit="271" upper_limit="372"/>
                    <measurement group_id="O4" value="385" lower_limit="306" upper_limit="483"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Polio Type 3 (N=265, N=112, N=252, N=120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="710" lower_limit="596" upper_limit="846"/>
                    <measurement group_id="O2" value="747" lower_limit="571" upper_limit="977"/>
                    <measurement group_id="O3" value="656" lower_limit="548" upper_limit="785"/>
                    <measurement group_id="O4" value="813" lower_limit="627" upper_limit="1054"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatitis B (N=243, N=104, N=237, N=118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2273" lower_limit="2001" upper_limit="2583"/>
                    <measurement group_id="O2" value="2045" lower_limit="1682" upper_limit="2485"/>
                    <measurement group_id="O3" value="1900" lower_limit="1670" upper_limit="2162"/>
                    <measurement group_id="O4" value="1993" lower_limit="1660" upper_limit="2394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hib (N=287, N=123, N=283, N=137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.64" lower_limit="6.63" upper_limit="8.8"/>
                    <measurement group_id="O2" value="6.01" lower_limit="4.84" upper_limit="7.47"/>
                    <measurement group_id="O3" value="7.19" lower_limit="6.23" upper_limit="8.29"/>
                    <measurement group_id="O4" value="6.74" lower_limit="5.49" upper_limit="8.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PnC 4 (N=268, N=116, N=256, N=126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.07" lower_limit="1.88" upper_limit="2.27"/>
                    <measurement group_id="O2" value="2.24" lower_limit="1.94" upper_limit="2.58"/>
                    <measurement group_id="O3" value="1.91" lower_limit="1.74" upper_limit="2.1"/>
                    <measurement group_id="O4" value="2.39" lower_limit="2.08" upper_limit="2.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PnC 6B (N=264, N=116, N=255, N=124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.15" lower_limit="1.85" upper_limit="2.49"/>
                    <measurement group_id="O2" value="2.21" lower_limit="1.76" upper_limit="2.77"/>
                    <measurement group_id="O3" value="2.09" lower_limit="1.8" upper_limit="2.44"/>
                    <measurement group_id="O4" value="2.4" lower_limit="1.93" upper_limit="2.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PnC 9V (N=268, N=116, N=256, N=126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.89" lower_limit="1.71" upper_limit="2.1"/>
                    <measurement group_id="O2" value="2.21" lower_limit="1.89" upper_limit="2.6"/>
                    <measurement group_id="O3" value="1.81" lower_limit="1.63" upper_limit="2.02"/>
                    <measurement group_id="O4" value="2.19" lower_limit="1.88" upper_limit="2.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PnC 14 (N=268, N=116, N=256, N=126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.29" lower_limit="6.42" upper_limit="8.29"/>
                    <measurement group_id="O2" value="8.06" lower_limit="6.63" upper_limit="9.78"/>
                    <measurement group_id="O3" value="7.69" lower_limit="6.75" upper_limit="8.77"/>
                    <measurement group_id="O4" value="9.18" lower_limit="7.62" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PnC 18C (N=268, N=116, N=256, N=126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.86" lower_limit="1.68" upper_limit="2.07"/>
                    <measurement group_id="O2" value="2.09" lower_limit="1.78" upper_limit="2.44"/>
                    <measurement group_id="O3" value="1.7" lower_limit="1.53" upper_limit="1.89"/>
                    <measurement group_id="O4" value="2.26" lower_limit="1.94" upper_limit="2.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PnC 19F (N=268, N=116, N=254, N=126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.34" lower_limit="2.1" upper_limit="2.6"/>
                    <measurement group_id="O2" value="2.6" lower_limit="2.2" upper_limit="3.06"/>
                    <measurement group_id="O3" value="2.3" lower_limit="2.06" upper_limit="2.57"/>
                    <measurement group_id="O4" value="2.53" lower_limit="2.16" upper_limit="2.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PnC 23F (N=267, N=115, N=256, N=125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.88" lower_limit="1.64" upper_limit="2.16"/>
                    <measurement group_id="O2" value="2.46" lower_limit="1.99" upper_limit="3.03"/>
                    <measurement group_id="O3" value="2.12" lower_limit="1.84" upper_limit="2.44"/>
                    <measurement group_id="O4" value="2.42" lower_limit="1.98" upper_limit="2.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Diphtheria (Post-vaccination GMC; group ratio LA1:LA2)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA1 to LA2, the lower limit of the 95% CI for the ratio of pertussis GMCs (GMCLA1 / GMCLA2) must be greater than 0.67; the lower limit of the 95% CI for the ratio of all other GMCs (GMCLA1 / GMCLA2) must be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMCs</param_type>
            <param_value>1.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Tetanus (Post-vaccination GMC; group ratio LA1:LA2)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA1 to LA2, the lower limit of the 95% CI for the ratio of pertussis GMCs (GMCLA1 / GMCLA2) must be greater than 0.67; the lower limit of the 95% CI for the ratio of all other GMCs (GMCLA1 / GMCLA2) must be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMCs</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>1.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PT (Post-vaccination GMC; group ratio LA1:LA2)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA1 to LA2, the lower limit of the 95% CI for the ratio of pertussis GMCs (GMCLA1 / GMCLA2) must be greater than 0.67; the lower limit of the 95% CI for the ratio of all other GMCs (GMCLA1 / GMCLA2) must be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMCs</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>FHA (Post-vaccination GMC; group ratio LA1:LA2)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA1 to LA2, the lower limit of the 95% CI for the ratio of pertussis GMCs (GMCLA1 / GMCLA2) must be greater than 0.67; the lower limit of the 95% CI for the ratio of all other GMCs (GMCLA1 / GMCLA2) must be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMCs</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pertactin (Post-vaccination GMC; group ratio LA1:LA2)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA1 to LA2, the lower limit of the 95% CI for the ratio of pertussis GMCs (GMCLA1 / GMCLA2) must be greater than 0.67; the lower limit of the 95% CI for the ratio of all other GMCs (GMCLA1 / GMCLA2) must be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMCs</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Polio Type 1 (Post-vaccination GMT; group ratio LA1:LA2)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA1 to LA2, the lower limit of the 95% CI for the ratio of pertussis GMCs (GMCLA1 / GMCLA2) must be greater than 0.67; the lower limit of the 95% CI for the ratio of all other GMCs (GMCLA1 / GMCLA2) must be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Polio Type 2 (Post-vaccination GMT; group ratio LA1:LA2)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA1 to LA2, the lower limit of the 95% CI for the ratio of pertussis GMCs (GMCLA1 / GMCLA2) must be greater than 0.67; the lower limit of the 95% CI for the ratio of all other GMCs (GMCLA1 / GMCLA2) must be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>1.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Polio Type 3 (Post-vaccination GMT; group ratio LA1:LA2)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA1 to LA2, the lower limit of the 95% CI for the ratio of pertussis GMCs (GMCLA1 / GMCLA2) must be greater than 0.67; the lower limit of the 95% CI for the ratio of all other GMCs (GMCLA1 / GMCLA2) must be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>1.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hepatitis B (Post-vaccination GMC; group ratio LA1:LA2)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA1 to LA2, the lower limit of the 95% CI for the ratio of pertussis GMCs (GMCLA1 / GMCLA2) must be greater than 0.67; the lower limit of the 95% CI for the ratio of all other GMCs (GMCLA1 / GMCLA2) must be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMCs</param_type>
            <param_value>1.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>HIb (Post-vaccination GMC; group ratio LA1:LA2)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA1 to LA2, the lower limit of the 95% CI for the ratio of pertussis GMCs (GMCLA1 / GMCLA2) must be greater than 0.67; the lower limit of the 95% CI for the ratio of all other GMCs (GMCLA1 / GMCLA2) must be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMCs</param_type>
            <param_value>1.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>1.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PnC 4 (Post-vaccination GMC; group ratio LA1:LA2)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA1 to LA2, the lower limit of the 95% CI for the ratio of pertussis GMCs (GMCLA1 / GMCLA2) must be greater than 0.67; the lower limit of the 95% CI for the ratio of all other GMCs (GMCLA1 / GMCLA2) must be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMCs</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PnC 6B (Post-vaccination GMC; group ratio LA1:LA2)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA1 to LA2, the lower limit of the 95% CI for the ratio of pertussis GMCs (GMCLA1 / GMCLA2) must be greater than 0.67; the lower limit of the 95% CI for the ratio of all other GMCs (GMCLA1 / GMCLA2) must be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMCs</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>1.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PnC 9V (Post-vaccination GMC; group ratio LA1:LA2)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA1 to LA2, the lower limit of the 95% CI for the ratio of pertussis GMCs (GMCLA1 / GMCLA2) must be greater than 0.67; the lower limit of the 95% CI for the ratio of all other GMCs (GMCLA1 / GMCLA2) must be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMCs</param_type>
            <param_value>0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PnC 14 (Post-vaccination GMC; group ratio LA1:LA2)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA1 to LA2, the lower limit of the 95% CI for the ratio of pertussis GMCs (GMCLA1 / GMCLA2) must be greater than 0.67; the lower limit of the 95% CI for the ratio of all other GMCs (GMCLA1 / GMCLA2) must be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMCs</param_type>
            <param_value>0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PnC 18C (Post-vaccination GMC; group ratio LA1:LA2)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA1 to LA2, the lower limit of the 95% CI for the ratio of pertussis GMCs (GMCLA1 / GMCLA2) must be greater than 0.67; the lower limit of the 95% CI for the ratio of all other GMCs (GMCLA1 / GMCLA2) must be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMCs</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PnC 19F (Post-vaccination GMC; group ratio LA1:LA2)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA1 to LA2, the lower limit of the 95% CI for the ratio of pertussis GMCs (GMCLA1 / GMCLA2) must be greater than 0.67; the lower limit of the 95% CI for the ratio of all other GMCs (GMCLA1 / GMCLA2) must be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMCs</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PnC 23F (Post-vaccination GMC; group ratio LA1:LA2)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA1 to LA2, the lower limit of the 95% CI for the ratio of pertussis GMCs (GMCLA1 / GMCLA2) must be greater than 0.67; the lower limit of the 95% CI for the ratio of all other GMCs (GMCLA1 / GMCLA2) must be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMCs</param_type>
            <param_value>0.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Diphtheria (Post-vaccination GMC; group ratio LA3:LA4)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA3 over LA4, the lower limit of two-sided 95% CI for the ratio of pertussis GMCs (GMCLA3 / GMCLA4) must be greater than 0.67; the lower limit of the two-sided 95% CI for the ratio of GMCs (GMCLA3 / GMCLA4) or GMTs (poliovirus antigens) for the other antigens must be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMCs</param_type>
            <param_value>0.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Tetanus (Post-vaccination GMC; group ratio LA3:LA4)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA3 over LA4, the lower limit of two-sided 95% CI for the ratio of pertussis GMCs (GMCLA3 / GMCLA4) must be greater than 0.67; the lower limit of the two-sided 95% CI for the ratio of GMCs (GMCLA3 / GMCLA4) or GMTs (poliovirus antigens) for the other antigens must be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMCs</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>PT (Post-vaccination GMC; group ratio LA3:LA4)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA3 over LA4, the lower limit of two-sided 95% CI for the ratio of pertussis GMCs (GMCLA3 / GMCLA4) must be greater than 0.67; the lower limit of the two-sided 95% CI for the ratio of GMCs (GMCLA3 / GMCLA4) or GMTs (poliovirus antigens) for the other antigens must be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMCs</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>FHA (Post-vaccination GMC; group ratio LA3:LA4)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA3 over LA4, the lower limit of two-sided 95% CI for the ratio of pertussis GMCs (GMCLA3 / GMCLA4) must be greater than 0.67; the lower limit of the two-sided 95% CI for the ratio of GMCs (GMCLA3 / GMCLA4) or GMTs (poliovirus antigens) for the other antigens must be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMCs</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Pertactin (Post-vaccination GMC; group ratio LA3:LA4</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA3 over LA4, the lower limit of two-sided 95% CI for the ratio of pertussis GMCs (GMCLA3 / GMCLA4) must be greater than 0.67; the lower limit of the two-sided 95% CI for the ratio of GMCs (GMCLA3 / GMCLA4) or GMTs (poliovirus antigens) for the other antigens must be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMCs</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Polio Type 1 (Post-vaccination GMT; group ratio LA3:LA4)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA3 over LA4, the lower limit of two-sided 95% CI for the ratio of pertussis GMCs (GMCLA3 / GMCLA4) must be greater than 0.67; the lower limit of the two-sided 95% CI for the ratio of GMCs (GMCLA3 / GMCLA4) or GMTs (poliovirus antigens) for the other antigens must be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>0.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Polio Type 2 (Post-vaccination GMT; group ratio LA3:LA4)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA3 over LA4, the lower limit of two-sided 95% CI for the ratio of pertussis GMCs (GMCLA3 / GMCLA4) must be greater than 0.67; the lower limit of the two-sided 95% CI for the ratio of GMCs (GMCLA3 / GMCLA4) or GMTs (poliovirus antigens) for the other antigens must be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Polio Type 3 (Post-vaccination GMT; group ratio LA3:LA4)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA3 over LA4, the lower limit of two-sided 95% CI for the ratio of pertussis GMCs (GMCLA3 / GMCLA4) must be greater than 0.67; the lower limit of the two-sided 95% CI for the ratio of GMCs (GMCLA3 / GMCLA4) or GMTs (poliovirus antigens) for the other antigens must be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>0.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Hepatitis B (Post-vaccination GMT; group ratio LA3:LA4)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA3 over LA4, the lower limit of two-sided 95% CI for the ratio of pertussis GMCs (GMCLA3 / GMCLA4) must be greater than 0.67; the lower limit of the two-sided 95% CI for the ratio of GMCs (GMCLA3 / GMCLA4) or GMTs (poliovirus antigens) for the other antigens must be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>HIb (Post-vaccination GMC; group ratio LA3:LA4)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA3 over LA4, the lower limit of two-sided 95% CI for the ratio of pertussis GMCs (GMCLA3 / GMCLA4) must be greater than 0.67; the lower limit of the two-sided 95% CI for the ratio of GMCs (GMCLA3 / GMCLA4) or GMTs (poliovirus antigens) for the other antigens must be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMCs</param_type>
            <param_value>1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>1.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>PnC 4 (Post-vaccination GMT; group ratio LA3:LA4)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA3 over LA4, the lower limit of two-sided 95% CI for the ratio of pertussis GMCs (GMCLA3 / GMCLA4) must be greater than 0.67; the lower limit of the two-sided 95% CI for the ratio of GMCs (GMCLA3 / GMCLA4) or GMTs (poliovirus antigens) for the other antigens must be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>0.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>PnC 6B (Post-vaccination GMC; group ratio LA3:LA4)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA3 over LA4, the lower limit of two-sided 95% CI for the ratio of pertussis GMCs (GMCLA3 / GMCLA4) must be greater than 0.67; the lower limit of the two-sided 95% CI for the ratio of GMCs (GMCLA3 / GMCLA4) or GMTs (poliovirus antigens) for the other antigens must be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMCs</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>PnC 9V (Post-vaccination GMC; group ratio LA3:LA4)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA3 over LA4, the lower limit of two-sided 95% CI for the ratio of pertussis GMCs (GMCLA3 / GMCLA4) must be greater than 0.67; the lower limit of the two-sided 95% CI for the ratio of GMCs (GMCLA3 / GMCLA4) or GMTs (poliovirus antigens) for the other antigens must be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMCs</param_type>
            <param_value>0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>PnC 14 (Post-vaccination GMC; group ratio LA3:LA4)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA3 over LA4, the lower limit of two-sided 95% CI for the ratio of pertussis GMCs (GMCLA3 / GMCLA4) must be greater than 0.67; the lower limit of the two-sided 95% CI for the ratio of GMCs (GMCLA3 / GMCLA4) or GMTs (poliovirus antigens) for the other antigens must be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMCs</param_type>
            <param_value>0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>PnC 18C (Post-vaccination GMC; group ratio LA3:LA4)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA3 over LA4, the lower limit of two-sided 95% CI for the ratio of pertussis GMCs (GMCLA3 / GMCLA4) must be greater than 0.67; the lower limit of the two-sided 95% CI for the ratio of GMCs (GMCLA3 / GMCLA4) or GMTs (poliovirus antigens) for the other antigens must be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMCs</param_type>
            <param_value>0.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.62</ci_lower_limit>
            <ci_upper_limit>0.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>PnC 19F (Post-vaccination GMC; group ratio LA3:LA4)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA3 over LA4, the lower limit of two-sided 95% CI for the ratio of pertussis GMCs (GMCLA3 / GMCLA4) must be greater than 0.67; the lower limit of the two-sided 95% CI for the ratio of GMCs (GMCLA3 / GMCLA4) or GMTs (poliovirus antigens) for the other antigens must be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMCs</param_type>
            <param_value>0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>PnC 23F (Post-vaccination GMC; group ratio LA3:LA4)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA3 over LA4, the lower limit of two-sided 95% CI for the ratio of pertussis GMCs (GMCLA3 / GMCLA4) must be greater than 0.67; the lower limit of the two-sided 95% CI for the ratio of GMCs (GMCLA3 / GMCLA4) or GMTs (poliovirus antigens) for the other antigens must be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMCs</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroresponse Rates to DTaP, HBV, Hib, Pneumococcal and Polio Antigens at 1 Month After Infant Series Vaccination - LA Subjects</title>
        <description>Immunogenicity as measured by percentage of subjects with predefined seroprotective antibody titers against DTaP, HBV, Hib, pneumococcal and polio antigens.</description>
        <time_frame>7 months of age (one month post-infant series)</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>LA1 (Men ACWY-CRM + Infant Vaccines)</title>
            <description>LA infants received MenACWY at 2 and 6 months of age and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. Group LA1 was randomized into LA1A and LA 1B subgroups.</description>
          </group>
          <group group_id="O2">
            <title>LA2 (Infant Vaccines Only)</title>
            <description>LA infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. These infants received one dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months; and a second dose of MenACWY at 15 months of age.</description>
          </group>
          <group group_id="O3">
            <title>LA3 (Men ACWY-CRM + Infant Vaccines)</title>
            <description>LA infants received MenACWY at 2, 4 and 6 months of age; and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, pneumococcal conjugate vaccine, and rotavirus vaccine. Group LA3 was further randomized into LA3A and LA3B subgroups.</description>
          </group>
          <group group_id="O4">
            <title>LA4 (Infant Vaccines Only)</title>
            <description>LA infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, pneumococcal conjugate vaccine, and rotavirus vaccine at 2, 4 and 6 months of age. These infants received one dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months and a second dose of MenACWY along with DTaP and Hib vaccines at 15 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroresponse Rates to DTaP, HBV, Hib, Pneumococcal and Polio Antigens at 1 Month After Infant Series Vaccination - LA Subjects</title>
          <description>Immunogenicity as measured by percentage of subjects with predefined seroprotective antibody titers against DTaP, HBV, Hib, pneumococcal and polio antigens.</description>
          <population>Per Protocol</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
                <count group_id="O2" value="123"/>
                <count group_id="O3" value="283"/>
                <count group_id="O4" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Diphtheria(≥ 0.1 IU/mL) (N=287,N=123,N=283,N=137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O2" value="98" lower_limit="94" upper_limit="100"/>
                    <measurement group_id="O3" value="99" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O4" value="99" lower_limit="95" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tetanus (≥ 0.1 IU/mL) (N=287,N=123,N=283,N=137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="99" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="97" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PT(≥ 4-fold rise) (N=285,N=123, N=281,N=135)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85" lower_limit="81" upper_limit="89"/>
                    <measurement group_id="O2" value="86" lower_limit="79" upper_limit="92"/>
                    <measurement group_id="O3" value="85" lower_limit="80" upper_limit="89"/>
                    <measurement group_id="O4" value="82" lower_limit="75" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FHA (≥ 4-fold rise) (N=286,N=123, N=281,N=135)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84" lower_limit="79" upper_limit="88"/>
                    <measurement group_id="O2" value="86" lower_limit="79" upper_limit="92"/>
                    <measurement group_id="O3" value="82" lower_limit="77" upper_limit="86"/>
                    <measurement group_id="O4" value="81" lower_limit="74" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertactin(≥ 4-fold rise)(N=286,N=123,N=281,N=135)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81" lower_limit="76" upper_limit="85"/>
                    <measurement group_id="O2" value="87" lower_limit="80" upper_limit="92"/>
                    <measurement group_id="O3" value="86" lower_limit="82" upper_limit="90"/>
                    <measurement group_id="O4" value="88" lower_limit="81" upper_limit="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Polio Type 1 (≥1:8) (N=265,N=112,N=252,N=120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="95" upper_limit="99"/>
                    <measurement group_id="O2" value="100" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O3" value="99" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O4" value="98" lower_limit="94" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Polio Type 2 (≥1:8) (N=265,N=112,N=252,N=120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="95" upper_limit="99"/>
                    <measurement group_id="O2" value="99" lower_limit="95" upper_limit="100"/>
                    <measurement group_id="O3" value="98" lower_limit="95" upper_limit="99"/>
                    <measurement group_id="O4" value="98" lower_limit="93" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Polio Type 3 (≥1:8) (N=265,N=112,N=252,N=120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="95" upper_limit="99"/>
                    <measurement group_id="O2" value="97" lower_limit="92" upper_limit="99"/>
                    <measurement group_id="O3" value="96" lower_limit="93" upper_limit="98"/>
                    <measurement group_id="O4" value="97" lower_limit="92" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatitis B(≥10 mIU/mL)(N=243,N=104,N=237,N=118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="97" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hib (≥0.15 μg/mL) (N=287,N=123,N=283,N=137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O2" value="98" lower_limit="94" upper_limit="100"/>
                    <measurement group_id="O3" value="97" lower_limit="94" upper_limit="99"/>
                    <measurement group_id="O4" value="99" lower_limit="96" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hib (≥1.0 μg/mL) (N=287,N=123,N=283,N=137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="92" upper_limit="97"/>
                    <measurement group_id="O2" value="93" lower_limit="88" upper_limit="97"/>
                    <measurement group_id="O3" value="93" lower_limit="90" upper_limit="96"/>
                    <measurement group_id="O4" value="96" lower_limit="91" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PnC 4 (≥ 0.35 μg/mL) (N=268,N=116,N=256,N=126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O2" value="99" lower_limit="95" upper_limit="100"/>
                    <measurement group_id="O3" value="97" lower_limit="94" upper_limit="99"/>
                    <measurement group_id="O4" value="98" lower_limit="94" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PnC 6B (≥ 0.35 μg/mL) (N=264,N=116,N=255,N=124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91" lower_limit="86" upper_limit="94"/>
                    <measurement group_id="O2" value="86" lower_limit="79" upper_limit="92"/>
                    <measurement group_id="O3" value="91" lower_limit="87" upper_limit="95"/>
                    <measurement group_id="O4" value="90" lower_limit="83" upper_limit="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PnC 9V (≥ 0.35 μg/mL) (N=268,N=116,N=256,N=126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="95" upper_limit="99"/>
                    <measurement group_id="O2" value="98" lower_limit="94" upper_limit="100"/>
                    <measurement group_id="O3" value="97" lower_limit="94" upper_limit="99"/>
                    <measurement group_id="O4" value="96" lower_limit="91" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PnC 14 (≥ 0.35 μg/mL) (N=268,N=116,N=256,N=126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O2" value="97" lower_limit="93" upper_limit="99"/>
                    <measurement group_id="O3" value="98" lower_limit="95" upper_limit="99"/>
                    <measurement group_id="O4" value="98" lower_limit="94" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PnC 18C(≥ 0.35 μg/mL) (N=268,N=116,N=256, N=126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="94" upper_limit="98"/>
                    <measurement group_id="O2" value="98" lower_limit="94" upper_limit="100"/>
                    <measurement group_id="O3" value="95" lower_limit="91" upper_limit="97"/>
                    <measurement group_id="O4" value="98" lower_limit="94" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PnC 19F (≥ 0.35 μg/mL)(N=268,N=116,N=254,N=126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="94" upper_limit="98"/>
                    <measurement group_id="O2" value="98" lower_limit="94" upper_limit="100"/>
                    <measurement group_id="O3" value="98" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O4" value="96" lower_limit="91" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PnC 23F (≥ 0.35 μg/mL)(N=267,N=115,N=256, N=125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93" lower_limit="89" upper_limit="96"/>
                    <measurement group_id="O2" value="97" lower_limit="91" upper_limit="99"/>
                    <measurement group_id="O3" value="95" lower_limit="91" upper_limit="97"/>
                    <measurement group_id="O4" value="94" lower_limit="88" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Diphtheria (Seroconversion percentage difference (PLA1 - PLA2))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA1 to LA2, the lower limit of the 95% CI for the difference in seroresponse rates (PLA1 – PLA2) must be greater than -5% for poliovirus and greater than -10% for all other antigens.</non_inferiority_desc>
            <param_type>Seroconversion Percentage difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.2</ci_lower_limit>
            <ci_upper_limit>4.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Tetanus (Seroconversion percentage difference (PLA1 - PLA2))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA1 to LA2, the lower limit of the 95% CI for the difference in seroresponse rates (PLA1 – PLA2) must be greater than -5% for poliovirus and greater than -10% for all other antigens.</non_inferiority_desc>
            <param_type>Seroconversion Percentage difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.9</ci_lower_limit>
            <ci_upper_limit>2.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PT (Seroconversion percentage difference (PLA1 - PLA2))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA1 to LA2, the lower limit of the 95% CI for the difference in seroresponse rates (PLA1 – PLA2) must be greater than -5% for poliovirus and greater than -10% for all other antigens.</non_inferiority_desc>
            <param_type>Seroconversion Percentage difference</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.7</ci_lower_limit>
            <ci_upper_limit>7.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>FHA(Seroconversion percentage difference (PLA1 - PLA2))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA1 to LA2, the lower limit of the 95% CI for the difference in seroresponse rates (PLA1 – PLA2) must be greater than -5% for poliovirus and greater than -10% for all other antigens.</non_inferiority_desc>
            <param_type>Seroconversion Percentage difference</param_type>
            <param_value>-2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.2</ci_lower_limit>
            <ci_upper_limit>5.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pertactin (Seroconversion percentage difference (PLA1 - PLA2))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA1 to LA2, the lower limit of the 95% CI for the difference in seroresponse rates (PLA1 – PLA2) must be greater than -5% for poliovirus and greater than -10% for all other antigens.</non_inferiority_desc>
            <param_type>Seroconversion Percentage difference</param_type>
            <param_value>-6</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-12.9</ci_lower_limit>
            <ci_upper_limit>2.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Polio Type 1 (Seroconversion percentage difference (PLA1 - PLA2))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA1 to LA2, the lower limit of the 95% CI for the difference in seroresponse rates (PLA1 – PLA2) must be greater than -5% for poliovirus and greater than -10% for all other antigens.</non_inferiority_desc>
            <param_type>Seroconversion Percentage difference</param_type>
            <param_value>-2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.8</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Polio Type 2 (Seroconversion percentage difference (PLA1 - PLA2))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA1 to LA2, the lower limit of the 95% CI for the difference in seroresponse rates (PLA1 – PLA2) must be greater than -5% for poliovirus and greater than -10% for all other antigens.</non_inferiority_desc>
            <param_type>Seroconversion Percentage difference</param_type>
            <param_value>-2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.6</ci_lower_limit>
            <ci_upper_limit>2.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Polio Type 3 (Seroconversion percentage difference (PLA1 - PLA2))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA1 to LA2, the lower limit of the 95% CI for the difference in seroresponse rates (PLA1 – PLA2) must be greater than -5% for poliovirus and greater than -10% for all other antigens.</non_inferiority_desc>
            <param_type>Seroconversion Percentage difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.2</ci_lower_limit>
            <ci_upper_limit>5.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hepatitis B (Seroconversion percentage difference (PLA1 - PLA2))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA1 to LA2, the lower limit of the 95% CI for the difference in seroresponse rates (PLA1 – PLA2) must be greater than -5% for poliovirus and greater than -10% for all other antigens.</non_inferiority_desc>
            <param_type>Seroconversion Percentage difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.5</ci_lower_limit>
            <ci_upper_limit>3.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hib (≥ 0.15 μg/mL)(Seroconversion percentage difference (PLA1 - PLA2))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA1 to LA2, the lower limit of the 95% CI for the difference in seroresponse rates (PLA1 – PLA2) must be greater than -5% for poliovirus and greater than -10% for all other antigens.</non_inferiority_desc>
            <param_type>Seroconversion Percentage difference</param_type>
            <param_value>1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hib (≥1.0 μg/mL)(Seroconversion percentage difference (PLA1 - PLA2))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA1 to LA2, the lower limit of the 95% CI for the difference in seroresponse rates (PLA1 – PLA2) must be greater than -5% for poliovirus and greater than -10% for all other antigens.</non_inferiority_desc>
            <param_type>Seroconversion Percentage difference</param_type>
            <param_value>2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.8</ci_lower_limit>
            <ci_upper_limit>7.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PnC 4(Seroconversion percentage difference (PLA1 - PLA2))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA1 to LA2, the lower limit of the 95% CI for the difference in seroresponse rates (PLA1 – PLA2) must be greater than -5% for poliovirus and greater than -10% for all other antigens.</non_inferiority_desc>
            <param_type>Seroconversion Percentage difference</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3</ci_lower_limit>
            <ci_upper_limit>3.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PnC 6B(Seroconversion percentage difference (PLA1 - PLA2))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA1 to LA2, the lower limit of the 95% CI for the difference in seroresponse rates (PLA1 – PLA2) must be greater than -5% for poliovirus and greater than -10% for all other antigens.</non_inferiority_desc>
            <param_type>Seroconversion Percentage difference</param_type>
            <param_value>4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.2</ci_lower_limit>
            <ci_upper_limit>12.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PnC 9V (Seroconversion percentage difference (PLA1 - PLA2))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA1 to LA2, the lower limit of the 95% CI for the difference in seroresponse rates (PLA1 – PLA2) must be greater than -5% for poliovirus and greater than -10% for all other antigens.</non_inferiority_desc>
            <param_type>Seroconversion Percentage difference</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.9</ci_lower_limit>
            <ci_upper_limit>3.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PnC 14 (Seroconversion percentage difference (PLA1 - PLA2))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA1 to LA2, the lower limit of the 95% CI for the difference in seroresponse rates (PLA1 – PLA2) must be greater than -5% for poliovirus and greater than -10% for all other antigens.</non_inferiority_desc>
            <param_type>Seroconversion Percentage difference</param_type>
            <param_value>1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>6.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PnC 18C (Seroconversion percentage difference (PLA1 - PLA2))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA1 to LA2, the lower limit of the 95% CI for the difference in seroresponse rates (PLA1 – PLA2) must be greater than -5% for poliovirus and greater than -10% for all other antigens.</non_inferiority_desc>
            <param_type>Seroconversion Percentage difference</param_type>
            <param_value>-2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.8</ci_lower_limit>
            <ci_upper_limit>2.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PnC 19F (Seroconversion percentage difference (PLA1 - PLA2))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA1 to LA2, the lower limit of the 95% CI for the difference in seroresponse rates (PLA1 – PLA2) must be greater than -5% for poliovirus and greater than -10% for all other antigens.</non_inferiority_desc>
            <param_type>Seroconversion Percentage difference</param_type>
            <param_value>-2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.8</ci_lower_limit>
            <ci_upper_limit>2.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PnC 23F (Seroconversion percentage difference (PLA1 - PLA2))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA1 to LA2, the lower limit of the 95% CI for the difference in seroresponse rates (PLA1 – PLA2) must be greater than -5% for poliovirus and greater than -10% for all other antigens.</non_inferiority_desc>
            <param_type>Seroconversion Percentage difference</param_type>
            <param_value>-4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8</ci_lower_limit>
            <ci_upper_limit>1.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Diphtheria (Seroconversion percentage difference (PLA3 - PLA4))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA3 over LA4, the lower limit of the two-sided 95% CI for the difference in seroresponse rates (PLA3 – PLA4) must be greater than 5% for poliovirus and greater than -10% for all other antigens.</non_inferiority_desc>
            <param_type>Seroconversion Percentage difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.3</ci_lower_limit>
            <ci_upper_limit>3.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Tetanus (Seroconversion percentage difference (PLA3 - PLA4))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA3 over LA4, the lower limit of the two-sided 95% CI for the difference in seroresponse rates (PLA3 – PLA4) must be greater than 5% for poliovirus and greater than -10% for all other antigens.</non_inferiority_desc>
            <param_type>Seroconversion Percentage difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.3</ci_lower_limit>
            <ci_upper_limit>2.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>PT (Seroconversion percentage difference (PLA3 - PLA4))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA3 over LA4, the lower limit of the two-sided 95% CI for the difference in seroresponse rates (PLA3 – PLA4) must be greater than 5% for poliovirus and greater than -10% for all other antigens.</non_inferiority_desc>
            <param_type>Seroconversion Percentage difference</param_type>
            <param_value>2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.8</ci_lower_limit>
            <ci_upper_limit>10.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>FHA(Seroconversion percentage difference (PLA3 - PLA4))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA3 over LA4, the lower limit of the two-sided 95% CI for the difference in seroresponse rates (PLA3 – PLA4) must be greater than 5% for poliovirus and greater than -10% for all other antigens.</non_inferiority_desc>
            <param_type>Seroconversion Percentage difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.1</ci_lower_limit>
            <ci_upper_limit>8.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Pertactin (Seroconversion percentage difference (PLA3 - PLA4))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA3 over LA4, the lower limit of the two-sided 95% CI for the difference in seroresponse rates (PLA3 – PLA4) must be greater than 5% for poliovirus and greater than -10% for all other antigens.</non_inferiority_desc>
            <param_type>Seroconversion Percentage difference</param_type>
            <param_value>-2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8</ci_lower_limit>
            <ci_upper_limit>5.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Polio Type 1 (Seroconversion percentage difference (PLA3 - PLA4))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA3 over LA4, the lower limit of the two-sided 95% CI for the difference in seroresponse rates (PLA3 – PLA4) must be greater than 5% for poliovirus and greater than -10% for all other antigens.</non_inferiority_desc>
            <param_type>Seroconversion Percentage difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2</ci_lower_limit>
            <ci_upper_limit>4.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Polio Type 2 (Seroconversion percentage difference (PLA3 - PLA4))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA3 over LA4, the lower limit of the two-sided 95% CI for the difference in seroresponse rates (PLA3 – PLA4) must be greater than 5% for poliovirus and greater than -10% for all other antigens.</non_inferiority_desc>
            <param_type>Seroconversion Percentage difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3</ci_lower_limit>
            <ci_upper_limit>4.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Polio Type 3 (Seroconversion percentage difference (PLA3 - PLA4))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA3 over LA4, the lower limit of the two-sided 95% CI for the difference in seroresponse rates (PLA3 – PLA4) must be greater than 5% for poliovirus and greater than -10% for all other antigens.</non_inferiority_desc>
            <param_type>Seroconversion Percentage difference</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.4</ci_lower_limit>
            <ci_upper_limit>4.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Hepatitis B (Seroconversion percentage difference (PLA3 - PLA4))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA3 over LA4, the lower limit of the two-sided 95% CI for the difference in seroresponse rates (PLA3 – PLA4) must be greater than 5% for poliovirus and greater than -10% for all other antigens.</non_inferiority_desc>
            <param_type>Seroconversion Percentage difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.3</ci_lower_limit>
            <ci_upper_limit>2.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Hib (≥ 0.15 μg/mL)(Seroconversion percentage difference (PLA3 - PLA4))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA3 over LA4, the lower limit of the two-sided 95% CI for the difference in seroresponse rates (PLA3 – PLA4) must be greater than 5% for poliovirus and greater than -10% for all other antigens.</non_inferiority_desc>
            <param_type>Seroconversion Percentage difference</param_type>
            <param_value>-2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.3</ci_lower_limit>
            <ci_upper_limit>1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Hib (≥1.0 μg/mL)(Seroconversion percentage difference (PLA3 - PLA4))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA3 over LA4, the lower limit of the two-sided 95% CI for the difference in seroresponse rates (PLA3 – PLA4) must be greater than 5% for poliovirus and greater than -10% for all other antigens.</non_inferiority_desc>
            <param_type>Seroconversion Percentage difference</param_type>
            <param_value>-2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-6.6</ci_lower_limit>
            <ci_upper_limit>3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>PnC 4 (Seroconversion percentage difference (PLA3 - PLA4))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA3 over LA4, the lower limit of the two-sided 95% CI for the difference in seroresponse rates (PLA3 – PLA4) must be greater than 5% for poliovirus and greater than -10% for all other antigens.</non_inferiority_desc>
            <param_type>Seroconversion Percentage difference</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.2</ci_lower_limit>
            <ci_upper_limit>3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>PnC 6B (Seroconversion percentage difference (PLA3 - PLA4))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA3 over LA4, the lower limit of the two-sided 95% CI for the difference in seroresponse rates (PLA3 – PLA4) must be greater than 5% for poliovirus and greater than -10% for all other antigens.</non_inferiority_desc>
            <param_type>Seroconversion Percentage difference</param_type>
            <param_value>2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4</ci_lower_limit>
            <ci_upper_limit>9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>PnC 9V (Seroconversion percentage difference (PLA3 - PLA4))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA3 over LA4, the lower limit of the two-sided 95% CI for the difference in seroresponse rates (PLA3 – PLA4) must be greater than 5% for poliovirus and greater than -10% for all other antigens.</non_inferiority_desc>
            <param_type>Seroconversion Percentage difference</param_type>
            <param_value>1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.8</ci_lower_limit>
            <ci_upper_limit>6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>PnC 14 (Seroconversion percentage difference (PLA3 - PLA4))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA3 over LA4, the lower limit of the two-sided 95% CI for the difference in seroresponse rates (PLA3 – PLA4) must be greater than 5% for poliovirus and greater than -10% for all other antigens.</non_inferiority_desc>
            <param_type>Seroconversion Percentage difference</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.7</ci_lower_limit>
            <ci_upper_limit>3.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>PnC 18C (Seroconversion percentage difference (PLA3 - PLA4))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA3 over LA4, the lower limit of the two-sided 95% CI for the difference in seroresponse rates (PLA3 – PLA4) must be greater than 5% for poliovirus and greater than -10% for all other antigens.</non_inferiority_desc>
            <param_type>Seroconversion Percentage difference</param_type>
            <param_value>-3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.2</ci_lower_limit>
            <ci_upper_limit>0.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>PnC 19F (Seroconversion percentage difference (PLA3 - PLA4))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA3 over LA4, the lower limit of the two-sided 95% CI for the difference in seroresponse rates (PLA3 – PLA4) must be greater than 5% for poliovirus and greater than -10% for all other antigens.</non_inferiority_desc>
            <param_type>Seroconversion Percentage difference</param_type>
            <param_value>2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.8</ci_lower_limit>
            <ci_upper_limit>7.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>PnC 23F (Seroconversion percentage difference (PLA3 - PLA4))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA3 over LA4, the lower limit of the two-sided 95% CI for the difference in seroresponse rates (PLA3 – PLA4) must be greater than 5% for poliovirus and greater than -10% for all other antigens.</non_inferiority_desc>
            <param_type>Seroconversion Percentage difference</param_type>
            <param_value>1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.7</ci_lower_limit>
            <ci_upper_limit>7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Persistence Antibodies hSBA ≥1:4 at 12 Months of Age- US Subject</title>
        <description>Persistence of Antibodies as measured by the percentage of subjects with serum bactericidal activity using human complement (hSBA) ≥ 1:4, directed against N.meningitidis serogroups A, C, W and Y.</description>
        <time_frame>12 Months of Age (one month pre-toddler vaccination)</time_frame>
        <population>The analysis was done on per protocol population
Per protocol was defined as subjects who:
received all the relevant doses of vaccine correctly
provided evaluable serum samples at the relevant time points
had no major protocol deviation as defined prior to database lock</population>
        <group_list>
          <group group_id="O1">
            <title>US1A (MenACWY- CRM + Infant Vaccines)</title>
            <description>US infants received one dose of MenACWY at 2, 4 and 6 months of age and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, pneumococcal conjugate vaccine, and rotavirus vaccine.At 12 months of age received fourth dose of MenACWY along with concomitant pneumococcal,HAV, and MMR-V vaccines.</description>
          </group>
          <group group_id="O2">
            <title>US2 (Infant Vaccine Only)</title>
            <description>received as part of routine infant vaccination schedule DTaP-IPV-HBV,Hib, pneumococcal conjugate vaccine, and rotavirus vaccine at 2, 4 and 6 months of age. At 12 months of age, these subjects received a dose of MenACWY along with concomitant pneumococcal conjugate vaccine, HAV, and MMR-V. At 15 months of age, these subjects received a second dose of MenACWY.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Persistence Antibodies hSBA ≥1:4 at 12 Months of Age- US Subject</title>
          <description>Persistence of Antibodies as measured by the percentage of subjects with serum bactericidal activity using human complement (hSBA) ≥ 1:4, directed against N.meningitidis serogroups A, C, W and Y.</description>
          <population>The analysis was done on per protocol population
Per protocol was defined as subjects who:
received all the relevant doses of vaccine correctly
provided evaluable serum samples at the relevant time points
had no major protocol deviation as defined prior to database lock</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A (84, 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="6" upper_limit="21"/>
                    <measurement group_id="O2" value="3" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C (86, 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53" lower_limit="42" upper_limit="64"/>
                    <measurement group_id="O2" value="8" lower_limit="3" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W (85, 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80" lower_limit="70" upper_limit="88"/>
                    <measurement group_id="O2" value="4" lower_limit="1" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Y (84, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74" lower_limit="63" upper_limit="83"/>
                    <measurement group_id="O2" value="1" lower_limit="0" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Persistence Antibodies hSBA ≥1:8 at 12 Months of Age- US Subject</title>
        <description>Persistence of Antibodies as measured by the percentage of subjects with serum bactericidal activity using human complement (hSBA) ≥ 1:8, directed against N.meningitidis serogroups A, C, W and Y.</description>
        <time_frame>12 Months of Age (one month pre-toddler vaccination)</time_frame>
        <population>The analysis was done on per protocol population
Per protocol was defined as subjects who:
received all the relevant doses of vaccine correctly
provided evaluable serum samples at the relevant time points
had no major protocol deviation as defined prior to database lock</population>
        <group_list>
          <group group_id="O1">
            <title>US1A (MenACWY- CRM + Infant Vaccines)</title>
            <description>US infants received one dose of MenACWY at 2, 4 and 6 months of age and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, pneumococcal conjugate vaccine, and rotavirus vaccine.At 12 months of age received fourth dose of MenACWY along with concomitant pneumococcal,HAV, and MMR-V vaccines.</description>
          </group>
          <group group_id="O2">
            <title>US2 (Infant Vaccine Only)</title>
            <description>received as part of routine infant vaccination schedule DTaP-IPV-HBV,Hib, pneumococcal conjugate vaccine, and rotavirus vaccine at 2, 4 and 6 months of age. At 12 months of age, these subjects received a dose of MenACWY along with concomitant pneumococcal conjugate vaccine, HAV, and MMR-V. At 15 months of age, these subjects received a second dose of MenACWY.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Persistence Antibodies hSBA ≥1:8 at 12 Months of Age- US Subject</title>
          <description>Persistence of Antibodies as measured by the percentage of subjects with serum bactericidal activity using human complement (hSBA) ≥ 1:8, directed against N.meningitidis serogroups A, C, W and Y.</description>
          <population>The analysis was done on per protocol population
Per protocol was defined as subjects who:
received all the relevant doses of vaccine correctly
provided evaluable serum samples at the relevant time points
had no major protocol deviation as defined prior to database lock</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A (84, 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="4" upper_limit="18"/>
                    <measurement group_id="O2" value="1" lower_limit="0.034" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C (86, 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" lower_limit="39" upper_limit="61"/>
                    <measurement group_id="O2" value="7" lower_limit="2" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W (85, 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71" lower_limit="60" upper_limit="80"/>
                    <measurement group_id="O2" value="4" lower_limit="1" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Y (84, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61" lower_limit="49" upper_limit="71"/>
                    <measurement group_id="O2" value="1" lower_limit="0.037" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Persistence Antibodies Geometric Mean Titers – US Subject</title>
        <description>Geometric Mean hSBA Titers directed against N. meningitides serogroups A, C, W and Y was measured at 12 Months of Age.</description>
        <time_frame>12 Months of Age (one month pre-toddler vaccination)</time_frame>
        <population>The analysis was done on per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>US1A (MenACWY- CRM + Infant Vaccines )</title>
            <description>US infants received one dose of MenACWY at 2, 4 and 6 months of age and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, pneumococcal conjugate vaccine, and rotavirus vaccine.At 12 months of age received fourth dose of MenACWY along with concomitant pneumococcal,HAV, and MMR-V vaccines.</description>
          </group>
          <group group_id="O2">
            <title>US2 (Infant Vaccine Only)</title>
            <description>received as part of routine infant vaccination schedule DTaP-IPV-HBV,Hib, pneumococcal conjugate vaccine, and rotavirus vaccine at 2, 4 and 6 months of age. At 12 months of age, these subjects received a dose of MenACWY along with concomitant pneumococcal conjugate vaccine, HAV, and MMR-V. At 15 months of age, these subjects received a second dose of MenACWY.</description>
          </group>
        </group_list>
        <measure>
          <title>Persistence Antibodies Geometric Mean Titers – US Subject</title>
          <description>Geometric Mean hSBA Titers directed against N. meningitides serogroups A, C, W and Y was measured at 12 Months of Age.</description>
          <population>The analysis was done on per protocol population</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A (84, 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.51" lower_limit="2.14" upper_limit="2.96"/>
                    <measurement group_id="O2" value="2.14" lower_limit="1.8" upper_limit="2.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C (86, 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.72" lower_limit="5.9" upper_limit="10"/>
                    <measurement group_id="O2" value="2.26" lower_limit="1.69" upper_limit="3.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W (85, 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="11" upper_limit="18"/>
                    <measurement group_id="O2" value="2.21" lower_limit="1.69" upper_limit="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Y (84, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="8.76" upper_limit="15"/>
                    <measurement group_id="O2" value="2.14" lower_limit="1.6" upper_limit="2.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Persistence Antibodies hSBA ≥1:4 at 12 or 16 Months of Age- LA Subject</title>
        <description>Persistence of Antibodies as measured by the percentage of subjects with serum bactericidal activity using human complement (hSBA) ≥ 1:4, directed against N.meningitidis serogroups A, C, W and Y.</description>
        <time_frame>12 or 16 Months of Age (one month pre-toddler vaccination)</time_frame>
        <population>The analysis was done on per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>LA1 (Men ACWY-CRM + Infant Vaccines) (12m)</title>
            <description>LA infants received MenACWY at 2 and 6 months of age and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. Group LA1 was randomized into LA1A and LA 1B subgroups.</description>
          </group>
          <group group_id="O2">
            <title>LA2 (Infant Vaccines Only) (12m)</title>
            <description>LA infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. These infants received one dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months; and a second dose of MenACWY at 15 months of age.</description>
          </group>
          <group group_id="O3">
            <title>LA3 (Men ACWY-CRM + Infant Vaccines) (16m)</title>
            <description>LA infants received MenACWY at 2, 4 and 6 months of age; and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, pneumococcal conjugate vaccine, and rotavirus vaccine. Group LA3 was further randomized into LA3A and LA3B subgroups.</description>
          </group>
          <group group_id="O4">
            <title>LA4 (Infant Vaccines Only) (12m)</title>
            <description>LA infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, pneumococcal conjugate vaccine, and rotavirus vaccine at 2, 4 and 6 months of age. These infants received one dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months and a second dose of MenACWY along with DTaP and Hib vaccines at 15 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Persistence Antibodies hSBA ≥1:4 at 12 or 16 Months of Age- LA Subject</title>
          <description>Persistence of Antibodies as measured by the percentage of subjects with serum bactericidal activity using human complement (hSBA) ≥ 1:4, directed against N.meningitidis serogroups A, C, W and Y.</description>
          <population>The analysis was done on per protocol population</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="206"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="229"/>
                <count group_id="O4" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A (205, 78, 229, 101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29" lower_limit="23" upper_limit="36"/>
                    <measurement group_id="O2" value="1" lower_limit="0.032" upper_limit="7"/>
                    <measurement group_id="O3" value="18" lower_limit="14" upper_limit="24"/>
                    <measurement group_id="O4" value="1" lower_limit="0.025" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C (206, 78, 229, 102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62" lower_limit="55" upper_limit="68"/>
                    <measurement group_id="O2" value="4" lower_limit="1" upper_limit="11"/>
                    <measurement group_id="O3" value="32" lower_limit="26" upper_limit="38"/>
                    <measurement group_id="O4" value="2" lower_limit="0" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W (198, 70, 218, 98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="92" upper_limit="98"/>
                    <measurement group_id="O2" value="4" lower_limit="1" upper_limit="12"/>
                    <measurement group_id="O3" value="72" lower_limit="66" upper_limit="78"/>
                    <measurement group_id="O4" value="5" lower_limit="2" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Y (195, 71, 212, 95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82" lower_limit="76" upper_limit="87"/>
                    <measurement group_id="O2" value="3" lower_limit="0" upper_limit="10"/>
                    <measurement group_id="O3" value="65" lower_limit="58" upper_limit="71"/>
                    <measurement group_id="O4" value="2" lower_limit="0" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Persistence Antibodies hSBA ≥1:8 at 12 or 16 Months of Age- LA Subject</title>
        <description>Persistence of Antibodies as measured by the percentage of subjects with serum bactericidal activity using human complement (hSBA) ≥ 1:8, directed against N.meningitidis serogroups A, C, W and Y.</description>
        <time_frame>12 or 16 Months of Age (one month pre-toddler vaccination)</time_frame>
        <population>The analysis was done on per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>LA1 (Men ACWY-CRM + Infant Vaccines) (12m)</title>
            <description>LA infants received MenACWY at 2 and 6 months of age and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. Group LA1 was randomized into LA1A and LA 1B subgroups.</description>
          </group>
          <group group_id="O2">
            <title>LA2 (Infant Vaccines Only) (12m)</title>
            <description>LA infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. These infants received one dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months; and a second dose of MenACWY at 15 months of age.</description>
          </group>
          <group group_id="O3">
            <title>LA3 (Men ACWY-CRM + Infant Vaccines) (16m)</title>
            <description>LA infants received MenACWY at 2, 4 and 6 months of age; and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, pneumococcal conjugate vaccine, and rotavirus vaccine. Group LA3 was further randomized into LA3A and LA3B subgroups.</description>
          </group>
          <group group_id="O4">
            <title>LA4 (Infant Vaccines Only) (12m)</title>
            <description>LA infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, pneumococcal conjugate vaccine, and rotavirus vaccine at 2, 4 and 6 months of age. These infants received one dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months and a second dose of MenACWY along with DTaP and Hib vaccines at 15 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Persistence Antibodies hSBA ≥1:8 at 12 or 16 Months of Age- LA Subject</title>
          <description>Persistence of Antibodies as measured by the percentage of subjects with serum bactericidal activity using human complement (hSBA) ≥ 1:8, directed against N.meningitidis serogroups A, C, W and Y.</description>
          <population>The analysis was done on per protocol population</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="206"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="229"/>
                <count group_id="O4" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A (205, 78, 229, 101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" lower_limit="20" upper_limit="32"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="5"/>
                    <measurement group_id="O3" value="15" lower_limit="11" upper_limit="20"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C (206, 78, 229, 102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57" lower_limit="50" upper_limit="64"/>
                    <measurement group_id="O2" value="4" lower_limit="1" upper_limit="11"/>
                    <measurement group_id="O3" value="26" lower_limit="20" upper_limit="32"/>
                    <measurement group_id="O4" value="1" lower_limit="0.025" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W (198, 70, 218, 98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85" lower_limit="79" upper_limit="90"/>
                    <measurement group_id="O2" value="4" lower_limit="1" upper_limit="12"/>
                    <measurement group_id="O3" value="63" lower_limit="56" upper_limit="69"/>
                    <measurement group_id="O4" value="5" lower_limit="2" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Y (195, 71, 212, 95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72" lower_limit="65" upper_limit="78"/>
                    <measurement group_id="O2" value="3" lower_limit="0" upper_limit="10"/>
                    <measurement group_id="O3" value="52" lower_limit="45" upper_limit="59"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Persistence Antibodies Geometric Mean Titers - LA Subjects</title>
        <description>Geometric Mean hSBA Titers directed against N. meningitidis serogroups A, C, W and Y was measured at 12 or 16 Months of Age.</description>
        <time_frame>12 or 16 Months of Age (one month pre-toddler vaccination)</time_frame>
        <population>The analysis was done on per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>LA1 (Men ACWY-CRM + Infant Vaccines) (12m)</title>
            <description>LA infants received MenACWY at 2 and 6 months of age and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. Group LA1 was randomized into LA1A and LA 1B subgroups.</description>
          </group>
          <group group_id="O2">
            <title>LA2 (Infant Vaccines Only) (12m)</title>
            <description>LA infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. These infants received one dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months; and a second dose of MenACWY at 15 months of age.</description>
          </group>
          <group group_id="O3">
            <title>LA3 (Men ACWY-CRM + Infant Vaccines) (16m)</title>
            <description>LA infants received MenACWY at 2, 4 and 6 months of age; and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, pneumococcal conjugate vaccine, and rotavirus vaccine. Group LA3 was further randomized into LA3A and LA3B subgroups.</description>
          </group>
          <group group_id="O4">
            <title>LA4 (Infant Vaccines Only) (12m)</title>
            <description>LA infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, pneumococcal conjugate vaccine, and rotavirus vaccine at 2, 4 and 6 months of age. These infants received one dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months and a second dose of MenACWY along with DTaP and Hib vaccines at 15 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Persistence Antibodies Geometric Mean Titers - LA Subjects</title>
          <description>Geometric Mean hSBA Titers directed against N. meningitidis serogroups A, C, W and Y was measured at 12 or 16 Months of Age.</description>
          <population>The analysis was done on per protocol population</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="206"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="229"/>
                <count group_id="O4" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A (205, 78, 229, 101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.26" lower_limit="3.55" upper_limit="5.11"/>
                    <measurement group_id="O2" value="2.02" lower_limit="1.7" upper_limit="2.4"/>
                    <measurement group_id="O3" value="2.96" lower_limit="2.63" upper_limit="3.33"/>
                    <measurement group_id="O4" value="2.02" lower_limit="1.74" upper_limit="2.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C (206, 78, 229, 102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="9.33" upper_limit="15"/>
                    <measurement group_id="O2" value="2.18" lower_limit="1.73" upper_limit="2.74"/>
                    <measurement group_id="O3" value="4.14" lower_limit="3.54" upper_limit="4.84"/>
                    <measurement group_id="O4" value="2.05" lower_limit="1.68" upper_limit="2.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W (198, 70, 218, 98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31" lower_limit="26" upper_limit="37"/>
                    <measurement group_id="O2" value="2.34" lower_limit="1.79" upper_limit="3.05"/>
                    <measurement group_id="O3" value="14" lower_limit="12" upper_limit="18"/>
                    <measurement group_id="O4" value="2.33" lower_limit="1.86" upper_limit="2.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Y (195, 71, 212, 95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" lower_limit="15" upper_limit="22"/>
                    <measurement group_id="O2" value="2.2" lower_limit="1.7" upper_limit="2.84"/>
                    <measurement group_id="O3" value="9.45" lower_limit="7.81" upper_limit="11"/>
                    <measurement group_id="O4" value="2.04" lower_limit="1.64" upper_limit="2.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects (95% CI) With hSBA ≥ 1:4 at 1 Month After Toddler MenACWY Vaccination - US Subjects</title>
        <description>Immunogenicity as measured by the percentage of subjects with serum bactericidal activity using human complement (hSBA) ≥ 1:4 , directed against N.meningitidis serogroups A, C, W and Y.</description>
        <time_frame>13 months of age (one month post-toddler vaccination)</time_frame>
        <population>The analysis was done on per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>US1A (MenACWY- CRM + Infant Vaccines )</title>
            <description>US infants received one dose of MenACWY at 2, 4 and 6 months of age and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, pneumococcal conjugate vaccine, and rotavirus vaccine.At 12 months of age received fourth dose of MenACWY along with concomitant pneumococcal,HAV, and MMR-V vaccines.</description>
          </group>
          <group group_id="O2">
            <title>US2 (Infant Vaccine Only)</title>
            <description>received as part of routine infant vaccination schedule DTaP-IPV-HBV,Hib, pneumococcal conjugate vaccine, and rotavirus vaccine at 2, 4 and 6 months of age. At 12 months of age, these subjects received a dose of MenACWY along with concomitant pneumococcal conjugate vaccine, HAV, and MMR-V. At 15 months of age, these subjects received a second dose of MenACWY.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects (95% CI) With hSBA ≥ 1:4 at 1 Month After Toddler MenACWY Vaccination - US Subjects</title>
          <description>Immunogenicity as measured by the percentage of subjects with serum bactericidal activity using human complement (hSBA) ≥ 1:4 , directed against N.meningitidis serogroups A, C, W and Y.</description>
          <population>The analysis was done on per protocol population</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A Pre-vaccination (84, 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="6" upper_limit="21"/>
                    <measurement group_id="O2" value="3" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A Post-vaccination (84, 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" lower_limit="87" upper_limit="98"/>
                    <measurement group_id="O2" value="78" lower_limit="67" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C Pre-vaccination (86, 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53" lower_limit="42" upper_limit="64"/>
                    <measurement group_id="O2" value="8" lower_limit="3" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C Post-vaccination (86, 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="94" upper_limit="100"/>
                    <measurement group_id="O2" value="95" lower_limit="87" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W Pre-vaccination (85, 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80" lower_limit="70" upper_limit="88"/>
                    <measurement group_id="O2" value="4" lower_limit="1" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W Post-vaccination (85, 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="6" upper_limit="100"/>
                    <measurement group_id="O2" value="73" lower_limit="61" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Y Pre-vaccination (84, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74" lower_limit="63" upper_limit="83"/>
                    <measurement group_id="O2" value="1" lower_limit="0.037" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Y Post-vaccination (84, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O2" value="62" lower_limit="49" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects (95% CI) With hSBA ≥ 1:8 at 1 Month After Toddler MenACWY Vaccination - US Subjects</title>
        <description>Immunogenicity as measured by the percentage of subjects with serum bactericidal activity using human complement (hSBA) ≥ 1:8 , directed against N.meningitidis serogroups A, C, W and Y.</description>
        <time_frame>13 months of age (one month post-toddler vaccination)</time_frame>
        <population>The analysis was done on per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>US1A (MenACWY- CRM + Infant Vaccines )</title>
            <description>US infants received one dose of MenACWY at 2, 4 and 6 months of age and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, pneumococcal conjugate vaccine, and rotavirus vaccine.At 12 months of age received fourth dose of MenACWY along with concomitant pneumococcal,HAV, and MMR-V vaccines.</description>
          </group>
          <group group_id="O2">
            <title>US2 (Infant Vaccine Only)</title>
            <description>received as part of routine infant vaccination schedule DTaP-IPV-HBV,Hib, pneumococcal conjugate vaccine, and rotavirus vaccine at 2, 4 and 6 months of age. At 12 months of age, these subjects received a dose of MenACWY along with concomitant pneumococcal conjugate vaccine, HAV, and MMR-V. At 15 months of age, these subjects received a second dose of MenACWY.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects (95% CI) With hSBA ≥ 1:8 at 1 Month After Toddler MenACWY Vaccination - US Subjects</title>
          <description>Immunogenicity as measured by the percentage of subjects with serum bactericidal activity using human complement (hSBA) ≥ 1:8 , directed against N.meningitidis serogroups A, C, W and Y.</description>
          <population>The analysis was done on per protocol population</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A Pre-vaccination (84, 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="4" upper_limit="18"/>
                    <measurement group_id="O2" value="1" lower_limit="0.034" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A Post-vaccination (84, 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" lower_limit="87" upper_limit="98"/>
                    <measurement group_id="O2" value="72" lower_limit="60" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C Pre-vaccination (86, 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" lower_limit="39" upper_limit="61"/>
                    <measurement group_id="O2" value="7" lower_limit="2" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C Post-vaccination (86, 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="92" upper_limit="100"/>
                    <measurement group_id="O2" value="90" lower_limit="81" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W Pre-vaccination (85, 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71" lower_limit="60" upper_limit="80"/>
                    <measurement group_id="O2" value="4" lower_limit="1" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W Post-vaccination (85, 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O2" value="58" lower_limit="45" upper_limit="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Y Pre-vaccination (84, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61" lower_limit="49" upper_limit="71"/>
                    <measurement group_id="O2" value="1" lower_limit="0.037" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Y Post-vaccination (84, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O2" value="56" lower_limit="43" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects (95% CI) With hSBA ≥ 1:16 at 1 Month After Toddler MenACWY Vaccination - US Subjects</title>
        <description>Immunogenicity as measured by the percentage of subjects with serum bactericidal activity using human complement (hSBA) ≥ 1:16 , directed against N.meningitidis serogroups A, C, W and Y.</description>
        <time_frame>13 months of age (one month post-toddler vaccination)</time_frame>
        <population>The analysis was done on per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>US1A (MenACWY- CRM + Infant Vaccines )</title>
            <description>US infants received one dose of MenACWY at 2, 4 and 6 months of age and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, pneumococcal conjugate vaccine, and rotavirus vaccine.At 12 months of age received fourth dose of MenACWY along with concomitant pneumococcal,HAV, and MMR-V vaccines.</description>
          </group>
          <group group_id="O2">
            <title>US2 (Infant Vaccine Only)</title>
            <description>received as part of routine infant vaccination schedule DTaP-IPV-HBV,Hib, pneumococcal conjugate vaccine, and rotavirus vaccine at 2, 4 and 6 months of age. At 12 months of age, these subjects received a dose of MenACWY along with concomitant pneumococcal conjugate vaccine, HAV, and MMR-V. At 15 months of age, these subjects received a second dose of MenACWY.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects (95% CI) With hSBA ≥ 1:16 at 1 Month After Toddler MenACWY Vaccination - US Subjects</title>
          <description>Immunogenicity as measured by the percentage of subjects with serum bactericidal activity using human complement (hSBA) ≥ 1:16 , directed against N.meningitidis serogroups A, C, W and Y.</description>
          <population>The analysis was done on per protocol population</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A Pre-vaccination (84, 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="1" upper_limit="12"/>
                    <measurement group_id="O2" value="1" lower_limit="0.034" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A Post-vaccination (84, 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" lower_limit="82" upper_limit="96"/>
                    <measurement group_id="O2" value="55" lower_limit="43" upper_limit="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C Pre-vaccination (86, 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" lower_limit="25" upper_limit="46"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C Post-vaccination (86, 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="89" upper_limit="99"/>
                    <measurement group_id="O2" value="78" lower_limit="67" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W Pre-vaccination (85, 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48" lower_limit="37" upper_limit="59"/>
                    <measurement group_id="O2" value="3" lower_limit="0" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W Post-vaccination (85, 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O2" value="38" lower_limit="27" upper_limit="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Y Pre-vaccination (84, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45" lower_limit="34" upper_limit="56"/>
                    <measurement group_id="O2" value="1" lower_limit="0.037" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Y Post-vaccination (84, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O2" value="41" lower_limit="29" upper_limit="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean hSBA Titers at 1 Month After Toddler MenACWY Vaccination - US Subjects</title>
        <description>Immunogenicity as measured by Geometric Mean hSBA Titers directed against N. meningitidis serogroups A, C, W and Y; comparison of four doses of MenACWY-CRM at 2, 4, and 6 and 12 months of age versus a single dose at 12 months of age.</description>
        <time_frame>13 months of age (one month post-toddler vaccination)</time_frame>
        <population>The analysis was done on per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>US1A (MenACWY- CRM + Infant Vaccines )</title>
            <description>US infants received one dose of MenACWY at 2, 4 and 6 months of age and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, pneumococcal conjugate vaccine, and rotavirus vaccine.At 12 months of age received fourth dose of MenACWY along with concomitant pneumococcal,HAV, and MMR-V vaccines.</description>
          </group>
          <group group_id="O2">
            <title>US2 (Infant Vaccine Only)</title>
            <description>received as part of routine infant vaccination schedule DTaP-IPV-HBV,Hib, pneumococcal conjugate vaccine, and rotavirus vaccine at 2, 4 and 6 months of age. At 12 months of age, these subjects received a dose of MenACWY along with concomitant pneumococcal conjugate vaccine, HAV, and MMR-V. At 15 months of age, these subjects received a second dose of MenACWY.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean hSBA Titers at 1 Month After Toddler MenACWY Vaccination - US Subjects</title>
          <description>Immunogenicity as measured by Geometric Mean hSBA Titers directed against N. meningitidis serogroups A, C, W and Y; comparison of four doses of MenACWY-CRM at 2, 4, and 6 and 12 months of age versus a single dose at 12 months of age.</description>
          <population>The analysis was done on per protocol population</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A Pre-vaccination (84, 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.51" lower_limit="2.14" upper_limit="2.96"/>
                    <measurement group_id="O2" value="2.14" lower_limit="1.8" upper_limit="2.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A Post-vaccination (84, 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77" lower_limit="55" upper_limit="109"/>
                    <measurement group_id="O2" value="17" lower_limit="12" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C Pre-vaccination (86, 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.72" lower_limit="5.9" upper_limit="10"/>
                    <measurement group_id="O2" value="2.26" lower_limit="1.69" upper_limit="3.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C Post-vaccination (86, 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="227" lower_limit="155" upper_limit="332"/>
                    <measurement group_id="O2" value="35" lower_limit="23" upper_limit="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W Pre-vaccination (85, 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="11" upper_limit="18"/>
                    <measurement group_id="O2" value="2.21" lower_limit="1.69" upper_limit="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W Post-vaccination (85, 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="416" lower_limit="288" upper_limit="602"/>
                    <measurement group_id="O2" value="11" lower_limit="7.59" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Y Pre-vaccination (84, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="8.76" upper_limit="15"/>
                    <measurement group_id="O2" value="2.14" lower_limit="1.6" upper_limit="2.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Y Post-vaccination (84, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="395" lower_limit="269" upper_limit="580"/>
                    <measurement group_id="O2" value="10" lower_limit="6.72" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects (95% CI) With hSBA ≥1:4 at 1 Month After Toddler MenACWY Vaccination - LA Subjects</title>
        <description>Immunogenicity as measured by the percentage of subjects with serum bactericidal activity using human complement (hSBA) ≥ 1:4, directed against N. meningitidis serogroups A, C, W and Y.</description>
        <time_frame>13 or 17 Months of Age (one month post-toddler vaccination)</time_frame>
        <population>The analysis was done on per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>LA1A (Men ACWY-CRM + Infant Vaccines)</title>
            <description>LA infants received MenACWY at 2 and 6 months of age; and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. These subjects received a third dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>LA3A (Men ACWY-CRM + Infant Vaccines)</title>
            <description>LA infants received MenACWY at 2, 4 and 6 months of age; and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, pneumococcal conjugate vaccine, and rotavirus vaccine. Around 12 months of age, these infants were recommended to receive pneumococcal conjugate vaccine, HAV, and MMR-V. At 16 months of age, these subjects received the fourth dose of MenACWY along with concomitant DTaP and Hib.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects (95% CI) With hSBA ≥1:4 at 1 Month After Toddler MenACWY Vaccination - LA Subjects</title>
          <description>Immunogenicity as measured by the percentage of subjects with serum bactericidal activity using human complement (hSBA) ≥ 1:4, directed against N. meningitidis serogroups A, C, W and Y.</description>
          <population>The analysis was done on per protocol population</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A Pre-vaccination (103, 120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28" lower_limit="20" upper_limit="38"/>
                    <measurement group_id="O2" value="18" lower_limit="12" upper_limit="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A Post-vaccination (103,120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" lower_limit="88" upper_limit="98"/>
                    <measurement group_id="O2" value="95" lower_limit="89" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C Pre-vaccination (102,122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61" lower_limit="51" upper_limit="70"/>
                    <measurement group_id="O2" value="30" lower_limit="22" upper_limit="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C Post-vaccination (102,122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="93" upper_limit="100"/>
                    <measurement group_id="O2" value="98" lower_limit="94" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W Pre-vaccination (98,112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="91" upper_limit="99"/>
                    <measurement group_id="O2" value="71" lower_limit="61" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W Post-vaccination (98,112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="97" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Y Pre-vaccination (98,109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78" lower_limit="68" upper_limit="85"/>
                    <measurement group_id="O2" value="61" lower_limit="52" upper_limit="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Y Post-vaccination (98,109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="94" upper_limit="100"/>
                    <measurement group_id="O2" value="99" lower_limit="95" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects (95% CI) With hSBA ≥1:8 at 1 Month After Toddler MenACWY Vaccination - LA Subjects</title>
        <description>Immunogenicity as measured by the percentage of subjects with serum bactericidal activity using human complement (hSBA) ≥ 1:8, directed against N. meningitidis serogroups A, C, W and Y.</description>
        <time_frame>13 or 17 Months of Age (one month post-toddler vaccination)</time_frame>
        <population>The analysis was done on per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>LA1A (Men ACWY-CRM + Infant Vaccines)</title>
            <description>LA infants received MenACWY at 2 and 6 months of age; and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. These subjects received a third dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>LA3A (Men ACWY-CRM + Infant Vaccines)</title>
            <description>LA infants received MenACWY at 2, 4 and 6 months of age; and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, pneumococcal conjugate vaccine, and rotavirus vaccine. Around 12 months of age, these infants were recommended to receive pneumococcal conjugate vaccine, HAV, and MMR-V. At 16 months of age, these subjects received the fourth dose of MenACWY along with concomitant DTaP and Hib.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects (95% CI) With hSBA ≥1:8 at 1 Month After Toddler MenACWY Vaccination - LA Subjects</title>
          <description>Immunogenicity as measured by the percentage of subjects with serum bactericidal activity using human complement (hSBA) ≥ 1:8, directed against N. meningitidis serogroups A, C, W and Y.</description>
          <population>The analysis was done on per protocol population</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A Pre-vaccination (103, 120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" lower_limit="16" upper_limit="33"/>
                    <measurement group_id="O2" value="13" lower_limit="8" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A Post-vaccination (103,120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" lower_limit="88" upper_limit="98"/>
                    <measurement group_id="O2" value="95" lower_limit="89" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C Pre-vaccination (102,122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57" lower_limit="47" upper_limit="67"/>
                    <measurement group_id="O2" value="22" lower_limit="15" upper_limit="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C Post-vaccination (102,122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="92" upper_limit="99"/>
                    <measurement group_id="O2" value="98" lower_limit="94" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W Pre-vaccination (98,112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84" lower_limit="75" upper_limit="90"/>
                    <measurement group_id="O2" value="62" lower_limit="52" upper_limit="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W Post-vaccination (98,112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="94" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="97" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Y Pre-vaccination (98,109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67" lower_limit="57" upper_limit="76"/>
                    <measurement group_id="O2" value="47" lower_limit="37" upper_limit="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Y Post-vaccination (98,109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="94" upper_limit="100"/>
                    <measurement group_id="O2" value="99" lower_limit="95" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With hSBA ≥ 1:16 at 1 Month After Toddler MenACWY Vaccination - LA Subjects</title>
        <description>Immunogenicity as measured by the percentage of subjects with serum bactericidal activity using human complement (hSBA) ≥ 1:16, directed against N. meningitidis serogroups A, C, W and Y.</description>
        <time_frame>13 or 17 Months of Age (one month post-toddler vaccination)</time_frame>
        <population>The analysis was done on per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>LA1A (Men ACWY-CRM + Infant Vaccines)</title>
            <description>LA infants received MenACWY at 2 and 6 months of age; and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. These subjects received a third dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>LA3A (Men ACWY-CRM + Infant Vaccines)</title>
            <description>LA infants received MenACWY at 2, 4 and 6 months of age; and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, pneumococcal conjugate vaccine, and rotavirus vaccine. Around 12 months of age, these infants were recommended to receive pneumococcal conjugate vaccine, HAV, and MMR-V. At 16 months of age, these subjects received the fourth dose of MenACWY along with concomitant DTaP and Hib.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With hSBA ≥ 1:16 at 1 Month After Toddler MenACWY Vaccination - LA Subjects</title>
          <description>Immunogenicity as measured by the percentage of subjects with serum bactericidal activity using human complement (hSBA) ≥ 1:16, directed against N. meningitidis serogroups A, C, W and Y.</description>
          <population>The analysis was done on per protocol population</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A Pre-vaccination (103, 120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="9" upper_limit="24"/>
                    <measurement group_id="O2" value="9" lower_limit="5" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A Post-vaccination (103, 120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93" lower_limit="86" upper_limit="97"/>
                    <measurement group_id="O2" value="94" lower_limit="88" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C Pre-vaccination (102, 122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47" lower_limit="37" upper_limit="57"/>
                    <measurement group_id="O2" value="18" lower_limit="12" upper_limit="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C Post-vaccination (102, 122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="89" upper_limit="98"/>
                    <measurement group_id="O2" value="96" lower_limit="91" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W Pre-vaccination (98,112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64" lower_limit="54" upper_limit="74"/>
                    <measurement group_id="O2" value="50" lower_limit="40" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W Post-vaccination (98, 112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="94" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="97" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Y Pre-vaccination (98,109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53" lower_limit="43" upper_limit="63"/>
                    <measurement group_id="O2" value="32" lower_limit="23" upper_limit="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Y Post-vaccination (98, 109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="94" upper_limit="100"/>
                    <measurement group_id="O2" value="98" lower_limit="94" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean hSBA Titers at 1 Month After Toddler MenACWY Vaccination - LA Subjects</title>
        <description>Immunogenicity as measured by Serum bactericidal activity using human complement (hSBA) GMTs, directed against N. meningitidis serogroups A, C, W and Y.</description>
        <time_frame>13 or 17 Months of Age (one month post-toddler vaccination)</time_frame>
        <population>The analysis was done on per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>LA1A (Men ACWY-CRM + Infant Vaccines)</title>
            <description>LA infants received MenACWY at 2 and 6 months of age; and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. These subjects received a third dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>LA3A (Men ACWY-CRM + Infant Vaccines)</title>
            <description>LA infants received MenACWY at 2, 4 and 6 months of age; and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, pneumococcal conjugate vaccine, and rotavirus vaccine. Around 12 months of age, these infants were recommended to receive pneumococcal conjugate vaccine, HAV, and MMR-V. At 16 months of age, these subjects received the fourth dose of MenACWY along with concomitant DTaP and Hib.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean hSBA Titers at 1 Month After Toddler MenACWY Vaccination - LA Subjects</title>
          <description>Immunogenicity as measured by Serum bactericidal activity using human complement (hSBA) GMTs, directed against N. meningitidis serogroups A, C, W and Y.</description>
          <population>The analysis was done on per protocol population</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A Pre-vaccination (103, 120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.83" lower_limit="3.3" upper_limit="4.45"/>
                    <measurement group_id="O2" value="2.95" lower_limit="2.57" upper_limit="3.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A Post-vaccination (103, 120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112" lower_limit="85" upper_limit="148"/>
                    <measurement group_id="O2" value="146" lower_limit="113" upper_limit="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C Pre-vaccination (102, 122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="8.91" upper_limit="13"/>
                    <measurement group_id="O2" value="3.83" lower_limit="3.2" upper_limit="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C Post-vaccination (102, 122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="279" lower_limit="218" upper_limit="358"/>
                    <measurement group_id="O2" value="283" lower_limit="225" upper_limit="355"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W Pre-vaccination (98, 112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28" lower_limit="22" upper_limit="34"/>
                    <measurement group_id="O2" value="13" lower_limit="11" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W Post-vaccination (98, 112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="762" lower_limit="604" upper_limit="960"/>
                    <measurement group_id="O2" value="727" lower_limit="586" upper_limit="903"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Y Pre-vaccination (98, 109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="13" upper_limit="20"/>
                    <measurement group_id="O2" value="8.1" lower_limit="6.58" upper_limit="9.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Y Post-vaccination (98, 109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="550" lower_limit="426" upper_limit="710"/>
                    <measurement group_id="O2" value="590" lower_limit="463" upper_limit="751"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Concentrations of Pneumococcal Antibodies at 1 Month After Toddler Vaccination - US Subjects</title>
        <description>Immunogenicity as measured by antibody GMTs, directed against pneumococcal antigens PnC 4, PnC 6B, PnC 9V, PnC 14, PnC 18C, PnC 19F and PnC 23F.</description>
        <time_frame>13 months of age (one month post-toddler vaccination)</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>US1A (MenACWY-CRM + Infant Vaccines)</title>
            <description>US infants received MenACWY at 2, 4 and 6 months of age along with routine infant vaccines, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccine. These infants received a fourth dose of MenACWY concomitantly with pneumococcal, HAV, and MMR-V vaccines at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>US1B (MenACWY-CRM + Infant Vaccines)</title>
            <description>US infants received MenACWY at 2, 4 and 6 months of age along with routine infant vaccines, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines. These infants received pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months; and a fourth dose of MenACWY at 13 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentrations of Pneumococcal Antibodies at 1 Month After Toddler Vaccination - US Subjects</title>
          <description>Immunogenicity as measured by antibody GMTs, directed against pneumococcal antigens PnC 4, PnC 6B, PnC 9V, PnC 14, PnC 18C, PnC 19F and PnC 23F.</description>
          <population>Per Protocol</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PnC 4 (N=86, N=99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" lower_limit="2.33" upper_limit="3.61"/>
                    <measurement group_id="O2" value="3.24" lower_limit="2.64" upper_limit="3.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PnC 6B (N=86, N=99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.82" lower_limit="5.67" upper_limit="8.21"/>
                    <measurement group_id="O2" value="8.58" lower_limit="7.22" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PnC 9V (N=86, N=99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" lower_limit="2.26" upper_limit="3.47"/>
                    <measurement group_id="O2" value="3.13" lower_limit="2.56" upper_limit="3.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PnC 14 (N=86, N=99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="9.74" upper_limit="14"/>
                    <measurement group_id="O2" value="15" lower_limit="12" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PnC 18C (N=87, N=98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.76" lower_limit="2.26" upper_limit="3.38"/>
                    <measurement group_id="O2" value="2.71" lower_limit="2.24" upper_limit="3.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PnC 19F(N=86, N=99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.63" lower_limit="3" upper_limit="4.39"/>
                    <measurement group_id="O2" value="3.48" lower_limit="2.92" upper_limit="4.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PnC 23F (N=87, N=99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.31" lower_limit="4.2" upper_limit="6.71"/>
                    <measurement group_id="O2" value="5.63" lower_limit="4.52" upper_limit="7.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PnC 4 (Post-vaccination GMC; group ratio US1A:US1B)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of US1A over US1B, the lower limit of 95% CI for the ratio of pneumococcal GMCs (GMCUS1A / GMCUS1B) had to be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMCs</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>1.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PnC 6B (Post-vaccination GMC; group ratio US1A:US1B)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of US1A over US1B, the lower limit of 95% CI for the ratio of pneumococcal GMCs (GMCUS1A / GMCUS1B) had to be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMCs</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.62</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PnC 9V (Post-vaccination GMC; group ratio US1A:US1B)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of US1A over US1B, the lower limit of 95% CI for the ratio of pneumococcal GMCs (GMCUS1A / GMCUS1B) had to be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMCs</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>1.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PnC 14 (Post-vaccination GMC; group ratio US1A:US1B)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of US1A over US1B, the lower limit of 95% CI for the ratio of pneumococcal GMCs (GMCUS1A / GMCUS1B) had to be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMCs</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PnC 18C (Post-vaccination GMC; group ratio US1A:US1B)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of US1A over US1B, the lower limit of 95% CI for the ratio of pneumococcal GMCs (GMCUS1A / GMCUS1B) had to be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMCs</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>1.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PnC 19F (Post-vaccination GMC; group ratio US1A:US1B)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of US1A over US1B, the lower limit of 95% CI for the ratio of pneumococcal GMCs (GMCUS1A / GMCUS1B) had to be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMCs</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PnC 23F (Post-vaccination GMC; group ratio US1A:US1B)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of US1A over US1B, the lower limit of 95% CI for the ratio of pneumococcal GMCs (GMCUS1A / GMCUS1B) had to be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMCs</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>1.29</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Pneumococcal Antibody GMCs ≥1.0 μg/mL at 1 Month After Toddler Vaccination - US Subjects</title>
        <description>Immunogenicity as measured by Percentage of Subjects with Pneumococcal Antibody GMCs ≥1.0 μg/mL directed against pneumococcal antigens PnC 4, PnC 6B, PnC 9V, PnC 14, PnC 18C, PnC 19F and PnC 23F.</description>
        <time_frame>13 months of age (one month post-toddler vaccination)</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>US1A (MenACWY-CRM + Infant Vaccines)</title>
            <description>US infants received MenACWY at 2, 4 and 6 months of age along with routine infant vaccines, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccine. These infants received a fourth dose of MenACWY concomitantly with pneumococcal, HAV, and MMR-V vaccines at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>US1B (MenACWY-CRM + Infant Vaccines)</title>
            <description>US infants received MenACWY at 2, 4 and 6 months of age along with routine infant vaccines, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines. These infants received pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months; and a fourth dose of MenACWY at 13 months of age.</description>
          </group>
          <group group_id="O3">
            <title>US2 (Infant Vaccines Only)</title>
            <description>US infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. These infants received one dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months; and a second dose of MenACWY at 15 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Pneumococcal Antibody GMCs ≥1.0 μg/mL at 1 Month After Toddler Vaccination - US Subjects</title>
          <description>Immunogenicity as measured by Percentage of Subjects with Pneumococcal Antibody GMCs ≥1.0 μg/mL directed against pneumococcal antigens PnC 4, PnC 6B, PnC 9V, PnC 14, PnC 18C, PnC 19F and PnC 23F.</description>
          <population>Per Protocol</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PnC 4 (N=86, N=99, N=81)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91" lower_limit="82" upper_limit="96"/>
                    <measurement group_id="O2" value="90" lower_limit="82" upper_limit="95"/>
                    <measurement group_id="O3" value="84" lower_limit="74" upper_limit="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PnC 6B (N=86, N=99, N=80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O2" value="96" lower_limit="90" upper_limit="99"/>
                    <measurement group_id="O3" value="99" lower_limit="93" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PnC 9V (N=86, N=99, N=80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87" lower_limit="78" upper_limit="93"/>
                    <measurement group_id="O2" value="91" lower_limit="83" upper_limit="96"/>
                    <measurement group_id="O3" value="86" lower_limit="77" upper_limit="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PnC 14 (N=86, N=99, N=81)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="94" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="96" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PnC 18C (N=87, N=98, N=81)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86" lower_limit="77" upper_limit="93"/>
                    <measurement group_id="O2" value="92" lower_limit="85" upper_limit="96"/>
                    <measurement group_id="O3" value="94" lower_limit="86" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PnC 19F(N=86, N=99, N=80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="90" upper_limit="99"/>
                    <measurement group_id="O2" value="93" lower_limit="86" upper_limit="97"/>
                    <measurement group_id="O3" value="99" lower_limit="93" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PnC 23F (N=87, N=99, N=80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93" lower_limit="86" upper_limit="97"/>
                    <measurement group_id="O2" value="95" lower_limit="89" upper_limit="98"/>
                    <measurement group_id="O3" value="99" lower_limit="93" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PnC 4 (percentage difference (US1A - US1B))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of US1A over US1B, the lower limit of 95% CI for the difference in rates (PUS1A – PUS1B) had to be greater than -10%.</non_inferiority_desc>
            <param_type>Percentage difference</param_type>
            <param_value>1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8</ci_lower_limit>
            <ci_upper_limit>10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PnC 6B (percentage difference (US1A - US1B))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of US1A over US1B, the lower limit of 95% CI for the difference in rates (PUS1A – PUS1B) had to be greater than -10%.</non_inferiority_desc>
            <param_type>Percentage difference</param_type>
            <param_value>4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PnC 9V (percentage difference (US1A - US1B))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of US1A over US1B, the lower limit of 95% CI for the difference in rates (PUS1A – PUS1B) had to be greater than -10%.</non_inferiority_desc>
            <param_type>Percentage difference</param_type>
            <param_value>-4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13</ci_lower_limit>
            <ci_upper_limit>5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PnC 14 (percentage difference (US1A - US1B))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of US1A over US1B, the lower limit of 95% CI for the difference in rates (PUS1A – PUS1B) had to be greater than -10%.</non_inferiority_desc>
            <param_type>Percentage difference</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6</ci_lower_limit>
            <ci_upper_limit>3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PnC 18C (percentage difference (US1A:US1B))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of US1A over US1B, the lower limit of 95% CI for the difference in rates (PUS1A – PUS1B) had to be greater than -10%.</non_inferiority_desc>
            <param_type>Percentage difference</param_type>
            <param_value>-6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15</ci_lower_limit>
            <ci_upper_limit>3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PnC 19F (percentage difference (US1A:US1B))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of US1A over US1B, the lower limit of 95% CI for the difference in rates (PUS1A – PUS1B) had to be greater than -10%.</non_inferiority_desc>
            <param_type>Percentage difference</param_type>
            <param_value>4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4</ci_lower_limit>
            <ci_upper_limit>11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PnC 239F (percentage difference (US1A:US1B))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of US1A over US1B, the lower limit of 95% CI for the difference in rates (PUS1A – PUS1B) had to be greater than -10%.</non_inferiority_desc>
            <param_type>Percentage difference</param_type>
            <param_value>-2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10</ci_lower_limit>
            <ci_upper_limit>5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Concentrations of Pneumococcal Antibodies at 1 Month After Toddler Vaccination – LA Subjects</title>
        <description>Immunogenicity as measured by antibody GMTs, directed against pneumococcal antigens PnC 4, PnC 6B, PnC 9V, PnC 14, PnC 18C, PnC 19F and PnC 23F.</description>
        <time_frame>13 months of age (one month post-toddler vaccination)</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>LA1A (Men ACWY-CRM + Infant Vaccines)</title>
            <description>LA infants received MenACWY at 2 and 6 months of age; and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. These subjects received a third dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>LA1B (Men ACWY-CRM + Infant Vaccines)</title>
            <description>LA infants received MenACWY at 2 and 6 months of age and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. These subjects received pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months and a third dose of MenACWY at 13 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentrations of Pneumococcal Antibodies at 1 Month After Toddler Vaccination – LA Subjects</title>
          <description>Immunogenicity as measured by antibody GMTs, directed against pneumococcal antigens PnC 4, PnC 6B, PnC 9V, PnC 14, PnC 18C, PnC 19F and PnC 23F.</description>
          <population>Per Protocol</population>
          <units>Concentrations (μg/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PnC 4 (N=97, N=97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.16" lower_limit="2.63" upper_limit="3.8"/>
                    <measurement group_id="O2" value="4.02" lower_limit="3.34" upper_limit="4.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PnC 6B (N=96, N=97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.52" lower_limit="3.42" upper_limit="5.97"/>
                    <measurement group_id="O2" value="5.61" lower_limit="4.25" upper_limit="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PnC 9V (N=97, N=97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.79" lower_limit="2.34" upper_limit="3.31"/>
                    <measurement group_id="O2" value="3.77" lower_limit="3.17" upper_limit="4.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PnC 14(N=97, N=97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.91" lower_limit="7.52" upper_limit="11"/>
                    <measurement group_id="O2" value="14" lower_limit="12" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PnC 18C (N=97, N=97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.15" lower_limit="1.79" upper_limit="2.58"/>
                    <measurement group_id="O2" value="2.77" lower_limit="2.31" upper_limit="3.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PnC 19F (N=97, N=97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.26" lower_limit="2.62" upper_limit="4.05"/>
                    <measurement group_id="O2" value="4.26" lower_limit="3.43" upper_limit="5.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PnC 23F (N=97, N=97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.38" lower_limit="3.51" upper_limit="5.48"/>
                    <measurement group_id="O2" value="5.92" lower_limit="4.74" upper_limit="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PnC 4 (Post-vaccination GMC; group ratio LA1A:LA1B)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA1A over LA1B, the lower limit of the two-sided 95% CI for the ratio of pneumococcal GMCs (GMCLA1A / GMCLA1B) had to be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMCs</param_type>
            <param_value>0.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PnC 6B (Post-vaccination GMC; group ratio LA1A:LA1B)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA1A over LA1B, the lower limit of the two-sided 95% CI for the ratio of pneumococcal GMCs (GMCLA1A / GMCLA1B) had to be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMCs</param_type>
            <param_value>0.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.54</ci_lower_limit>
            <ci_upper_limit>1.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PnC 9V (Post-vaccination GMC; group ratio LA1A:LA1B)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA1A over LA1B, the lower limit of the two-sided 95% CI for the ratio of pneumococcal GMCs (GMCLA1A / GMCLA1B) had to be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMCs</param_type>
            <param_value>0.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>0.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PnC 14 (Post-vaccination GMC; group ratio LA1A:LA1B)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA1A over LA1B, the lower limit of the two-sided 95% CI for the ratio of pneumococcal GMCs (GMCLA1A / GMCLA1B) had to be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMCs</param_type>
            <param_value>0.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.51</ci_lower_limit>
            <ci_upper_limit>0.82</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PnC 18C (Post-vaccination GMC; group ratio LA1A:LA1B)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA1A over LA1B, the lower limit of the two-sided 95% CI for the ratio of pneumococcal GMCs (GMCLA1A / GMCLA1B) had to be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMCs</param_type>
            <param_value>0.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PnC 19F (Post-vaccination GMC; group ratio LA1A:LA1B)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA1A over LA1B, the lower limit of the two-sided 95% CI for the ratio of pneumococcal GMCs (GMCLA1A / GMCLA1B) had to be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMCs</param_type>
            <param_value>0.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.56</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PnC 23F (Post-vaccination GMC; group ratio LA1A:LA1B)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA1A over LA1B, the lower limit of the two-sided 95% CI for the ratio of pneumococcal GMCs (GMCLA1A / GMCLA1B) had to be greater than 0.50.</non_inferiority_desc>
            <param_type>Ratio of GMCs</param_type>
            <param_value>0.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.54</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Pneumococcal Antibody Concentration ≥1.0 μg/mL at 1 Month After Toddler Vaccination - LA Subjects</title>
        <description>Immunogenicity as measured by Percentage of Subjects with Pneumococcal Antibody GMCs ≥1.0 μg/mL directed against pneumococcal antigens PnC 4, PnC 6B, PnC 9V, PnC 14, PnC 18C, PnC 19F and PnC 23F</description>
        <time_frame>13 months of age (one month post-toddler vaccination)</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>LA1A (Men ACWY-CRM + Infant Vaccines)</title>
            <description>LA infants received MenACWY at 2 and 6 months of age; and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. These subjects received a third dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>LA1B (Men ACWY-CRM + Infant Vaccines)</title>
            <description>LA infants received MenACWY at 2 and 6 months of age and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. These subjects received pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months and a third dose of MenACWY at 13 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Pneumococcal Antibody Concentration ≥1.0 μg/mL at 1 Month After Toddler Vaccination - LA Subjects</title>
          <description>Immunogenicity as measured by Percentage of Subjects with Pneumococcal Antibody GMCs ≥1.0 μg/mL directed against pneumococcal antigens PnC 4, PnC 6B, PnC 9V, PnC 14, PnC 18C, PnC 19F and PnC 23F</description>
          <population>Per Protocol</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PnC 4 (N=97, N=97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93" lower_limit="86" upper_limit="97"/>
                    <measurement group_id="O2" value="95" lower_limit="88" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PnC 6B (N=96, N=97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86" lower_limit="78" upper_limit="93"/>
                    <measurement group_id="O2" value="89" lower_limit="81" upper_limit="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PnC 9V (N=97, N=97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" lower_limit="84" upper_limit="96"/>
                    <measurement group_id="O2" value="95" lower_limit="88" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PnC 14 (N=97, N=97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="94" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="96" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PnC 18C (N=97, N=97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80" lower_limit="71" upper_limit="88"/>
                    <measurement group_id="O2" value="95" lower_limit="88" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PnC 19F (N=97, N=97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" lower_limit="82" upper_limit="95"/>
                    <measurement group_id="O2" value="93" lower_limit="86" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PnC 23F (N=97, N=97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="88" upper_limit="98"/>
                    <measurement group_id="O2" value="95" lower_limit="88" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PnC 4 (percentage difference (LA1A - LA1B))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA1A over LA1B, the lower limit of the two-sided 95% CI for the difference in rates (PLA1A – PLA1B) had to be greater than -10%.</non_inferiority_desc>
            <param_type>Percentage difference</param_type>
            <param_value>-2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.6</ci_lower_limit>
            <ci_upper_limit>5.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PnC 6B (percentage difference (LA1A - LA1B))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA1A over LA1B, the lower limit of the two-sided 95% CI for the difference in rates (PLA1A – PLA1B) had to be greater than -10%.</non_inferiority_desc>
            <param_type>Percentage difference</param_type>
            <param_value>-2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.9</ci_lower_limit>
            <ci_upper_limit>7.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PnC 9V (percentage difference (LA1A - LA1B))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA1A over LA1B, the lower limit of the two-sided 95% CI for the difference in rates (PLA1A – PLA1B) had to be greater than -10%.</non_inferiority_desc>
            <param_type>Percentage difference</param_type>
            <param_value>-3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.9</ci_lower_limit>
            <ci_upper_limit>4.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PnC 14 (percentage difference (LA1A - LA1B))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA1A over LA1B, the lower limit of the two-sided 95% CI for the difference in rates (PLA1A – PLA1B) had to be greater than -10%.</non_inferiority_desc>
            <param_type>Percentage difference</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.6</ci_lower_limit>
            <ci_upper_limit>2.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PnC 18C (percentage difference (LA1A - LA1B))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA1A over LA1B, the lower limit of the two-sided 95% CI for the difference in rates (PLA1A – PLA1B) had to be greater than -10%.</non_inferiority_desc>
            <param_type>Percentage difference</param_type>
            <param_value>-14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.1</ci_lower_limit>
            <ci_upper_limit>-5.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PnC 19F (percentage difference (LA1A - LA1B))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA1A over LA1B, the lower limit of the two-sided 95% CI for the difference in rates (PLA1A – PLA1B) had to be greater than -10%.</non_inferiority_desc>
            <param_type>Percentage difference</param_type>
            <param_value>-3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.6</ci_lower_limit>
            <ci_upper_limit>5.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PnC 23F (percentage difference (LA1A - LA1B))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA1A over LA1B, the lower limit of the two-sided 95% CI for the difference in rates (PLA1A – PLA1B) had to be greater than -10%.</non_inferiority_desc>
            <param_type>Percentage difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7</ci_lower_limit>
            <ci_upper_limit>7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Concentrations or Titers of DTaP and Hib Antigens at 1 Month After Toddler Vaccination - LA Subjects</title>
        <description>Immunogenicity as measured by antibody GMCs/GMTs, directed against DTaP and Hib Antigens</description>
        <time_frame>17 months of age (one month post-toddler vaccination)</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>LA3A (Men ACWY-CRM + Infant Vaccines)</title>
            <description>LA infants received MenACWY at 2, 4 and 6 months of age; and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, pneumococcal conjugate vaccine, and rotavirus vaccine. Around 12 months of age, these infants were recommended to receive pneumococcal conjugate vaccine, HAV, and MMR-V. At 16 months of age, these subjects received the fourth dose of MenACWY along with concomitant DTaP and Hib.</description>
          </group>
          <group group_id="O2">
            <title>LA3B (Men ACWY-CRM + Infant Vaccines)</title>
            <description>LA infants received MenACWY at 2, 4 and 6 months of age; and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, pneumococcal conjugate vaccine, and rotavirus vaccine. Around 12 months of age, received pneumococcal conjugate vaccine, HAV, and MMR-V. At 16 months of age, these subjects received DTaP and Hib. At 17 months of age, these subjects received the fourth dose of MenACWY.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentrations or Titers of DTaP and Hib Antigens at 1 Month After Toddler Vaccination - LA Subjects</title>
          <description>Immunogenicity as measured by antibody GMCs/GMTs, directed against DTaP and Hib Antigens</description>
          <population>Per Protocol</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Diphtheria (N=118, N=101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" lower_limit="4.74" upper_limit="6.15"/>
                    <measurement group_id="O2" value="5.16" lower_limit="4.48" upper_limit="5.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tetanus (N=118, N=101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.17" lower_limit="5.29" upper_limit="7.2"/>
                    <measurement group_id="O2" value="6.58" lower_limit="5.57" upper_limit="7.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PT (N=113, N=99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68" lower_limit="58" upper_limit="80"/>
                    <measurement group_id="O2" value="62" lower_limit="52" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FHA (N=113, N=99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245" lower_limit="208" upper_limit="288"/>
                    <measurement group_id="O2" value="215" lower_limit="181" upper_limit="256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertactin (N=113, N=99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="238" lower_limit="198" upper_limit="286"/>
                    <measurement group_id="O2" value="197" lower_limit="161" upper_limit="240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hib (N=117, N=101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" lower_limit="28" upper_limit="43"/>
                    <measurement group_id="O2" value="41" lower_limit="32" upper_limit="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Diphtheria (Post-vaccination GMC; group ratio LA3A:LA3B)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA3A over LA3B, the lower limit of the two-sided 95% CI for the ratio of GMCs (GMCLA3A/GMCLA3B) had to be greater than 0.67 for PT, FHA and pertactin and greater than 0.50 for Hib, diphtheria and tetanus.</non_inferiority_desc>
            <param_type>Ratio of GMCs</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Tetanus (Post-vaccination GMC; group ratio LA3A:LA3B)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA3A over LA3B, the lower limit of the two-sided 95% CI for the ratio of GMCs (GMCLA3A / GMCLA3B) had to be greater than 0.67 for PT, FHA and pertactin and greater than 0.50 for Hib, diphtheria and tetanus.</non_inferiority_desc>
            <param_type>Ratio of GMCs</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PT (Post-vaccination GMC; group ratio LA3A:LA3B)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA3A over LA3B, the lower limit of the two-sided 95% CI for the ratio of GMCs (GMCLA3A / GMCLA3B) had to be greater than 0.67 for PT, FHA and pertactin and greater than 0.50 for Hib, diphtheria and tetanus.</non_inferiority_desc>
            <param_type>Ratio of GMCs</param_type>
            <param_value>1.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>FHA (Post-vaccination GMC; group ratio LA3A:LA3B)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA3A over LA3B, the lower limit of the two-sided 95% CI for the ratio of GMCs (GMCLA3A / GMCLA3B) had to be greater than 0.67 for PT, FHA and pertactin and greater than 0.50 for Hib, diphtheria and tetanus.</non_inferiority_desc>
            <param_type>Ratio of GMCs</param_type>
            <param_value>1.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9</ci_lower_limit>
            <ci_upper_limit>1.44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pertactin (Post-vaccination GMC; group ratio LA3A:LA3B</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA3A over LA3B, the lower limit of the two-sided 95% CI for the ratio of GMCs (GMCLA3A / GMCLA3B) had to be greater than 0.67 for PT, FHA and pertactin and greater than 0.50 for Hib, diphtheria and tetanus.</non_inferiority_desc>
            <param_type>Ratio of GMCs</param_type>
            <param_value>1.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.92</ci_lower_limit>
            <ci_upper_limit>1.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hib (Post-vaccination GMC; group ratio LA3A:LA3B)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA3A over LA3B, the lower limit of the two-sided 95% CI for the ratio of GMCs (GMCLA3A / GMCLA3B) had to be greater than 0.67 for PT, FHA and pertactin and greater than 0.50 for Hib, diphtheria and tetanus.</non_inferiority_desc>
            <param_type>Ratio of GMCs</param_type>
            <param_value>0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroresponse Rates to DTaP and Hib Antigens at 1 Month After Toddler Vaccination - LA Subjects</title>
        <description>Immunogenicity as measured by Percentage of Subjects with predefined seroprotective antibody titers against DTaP and Hib Antigens</description>
        <time_frame>17 months of age (one month post-toddler vaccination)</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>LA3A (Men ACWY-CRM + Infant Vaccines)</title>
            <description>LA infants received MenACWY at 2, 4 and 6 months of age; and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, pneumococcal conjugate vaccine, and rotavirus vaccine. Around 12 months of age, these infants were recommended to receive pneumococcal conjugate vaccine, HAV, and MMR-V. At 16 months of age, these subjects received the fourth dose of MenACWY along with concomitant DTaP and Hib.</description>
          </group>
          <group group_id="O2">
            <title>LA3B (Men ACWY-CRM + Infant Vaccines)</title>
            <description>LA infants received MenACWY at 2, 4 and 6 months of age; and as part of routine infant vaccination schedule received, DTaP-IPV-HBV, Hib, pneumococcal conjugate vaccine, and rotavirus vaccine. Around 12 months of age, received pneumococcal conjugate vaccine, HAV, and MMR-V. At 16 months of age, these subjects received DTaP and Hib. At 17 months of age, these subjects received the fourth dose of MenACWY.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroresponse Rates to DTaP and Hib Antigens at 1 Month After Toddler Vaccination - LA Subjects</title>
          <description>Immunogenicity as measured by Percentage of Subjects with predefined seroprotective antibody titers against DTaP and Hib Antigens</description>
          <population>Per Protocol</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Diphtheria (≥1.0 IU/mL) (N=118, N=101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="94" upper_limit="100"/>
                    <measurement group_id="O2" value="98" lower_limit="93" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tetanus (≥1.0 IU/mL) (N=118, N=101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="94" upper_limit="100"/>
                    <measurement group_id="O2" value="98" lower_limit="93" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PT (≥4 fold rise) (N=113, N=99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89" lower_limit="82" upper_limit="94"/>
                    <measurement group_id="O2" value="84" lower_limit="75" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FHA (≥4-fold rise) (N=113, N=99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87" lower_limit="79" upper_limit="92"/>
                    <measurement group_id="O2" value="88" lower_limit="80" upper_limit="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertactin (≥4-fold rise) (N=113, N=99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89" lower_limit="82" upper_limit="94"/>
                    <measurement group_id="O2" value="88" lower_limit="80" upper_limit="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hib (≥0.15 μg/mL) (N=117, N=101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="96" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hib (≥1.0 μg/mL) (N=117, N=101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O2" value="99" lower_limit="95" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Diphtheria (percentage difference (LA3A - LA3B))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA3A over LA3B, The lower limit of the two-sided 95% CI for the difference (PLA3A–PLA3B) in percentages of subjects with seroresponse against diphtheria, tetanus, Hib and pertussis antigens (except FHA for ≥4 fold rise) was greater than -10%</non_inferiority_desc>
            <param_type>Percentage difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.2</ci_lower_limit>
            <ci_upper_limit>5.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Tetanus (percentage difference (LA3A - LA3B))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA3A over LA3B, The lower limit of the two-sided 95% CI for the difference (PLA3A–PLA3B) in percentages of subjects with seroresponse against diphtheria, tetanus, Hib and pertussis antigens (except FHA for ≥4 fold rise) was greater than -10%</non_inferiority_desc>
            <param_type>Percentage difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.2</ci_lower_limit>
            <ci_upper_limit>5.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PT (percentage difference (LA3A - LA3B))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA3A over LA3B, The lower limit of the two-sided 95% CI for the difference (PLA3A–PLA3B) in percentages of subjects with seroresponse against diphtheria, tetanus, Hib and pertussis antigens (except FHA for ≥4 fold rise) was greater than -10%</non_inferiority_desc>
            <param_type>Percentage difference</param_type>
            <param_value>6</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.6</ci_lower_limit>
            <ci_upper_limit>15.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>FHA (percentage difference (LA3A - LA3B))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA3A over LA3B, The lower limit of the two-sided 95% CI for the difference (PLA3A–PLA3B) in percentages of subjects with seroresponse against diphtheria, tetanus, Hib and pertussis antigens (except FHA for ≥4 fold rise) was greater than -10%</non_inferiority_desc>
            <param_type>Percentage difference</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.2</ci_lower_limit>
            <ci_upper_limit>8.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pertactin (percentage difference (LA3A - LA3B))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA3A over LA3B, The lower limit of the two-sided 95% CI for the difference (PLA3A-PLA3B) in percentages of subjects with seroresponse against diphtheria, tetanus, Hib and pertussis antigens (except FHA for ≥4 fold rise) was greater than -10%</non_inferiority_desc>
            <param_type>Percentage difference</param_type>
            <param_value>2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.2</ci_lower_limit>
            <ci_upper_limit>10.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hib (≥ 0.15 μg/mL) (percentage difference (LA3A - LA3B))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA3A over LA3B, The lower limit of the two-sided 95% CI for the difference (PLA3A–PLA3B) in percentages of subjects with seroresponse against diphtheria, tetanus, Hib and pertussis antigens (except FHA for ≥4 fold rise) was greater than -10%</non_inferiority_desc>
            <param_type>Percentage difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.1</ci_lower_limit>
            <ci_upper_limit>3.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hib (≥1.0 μg/mL) (percentage difference (LA3A - LA3B))</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess non-inferiority of LA3A over LA3B, The lower limit of the two-sided 95% CI for the difference (PLA3A–PLA3B) in percentages of subjects with seroresponse against diphtheria, tetanus, Hib and pertussis antigens (except FHA for ≥4 fold rise) was greater than -10%</non_inferiority_desc>
            <param_type>Percentage difference</param_type>
            <param_value>1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.2</ci_lower_limit>
            <ci_upper_limit>5.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With hSBA ≥1:8 at 1 Month After 1st (LA2) or 2nd (LA4) Toddler MenACWY Vaccination - LA Subjects</title>
        <description>Immunogenicity as measured by the percentage of subjects with serum bactericidal activity using human complement (hSBA) ≥ 1:8, directed against N.meningitidis serogroups A, C, W and Y.</description>
        <time_frame>12 or 15 months of age (one month post 1st or 2nd toddler vaccination)</time_frame>
        <population>The analysis was done on per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>LA2 (Infant Vaccines Only)</title>
            <description>LA infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. These infants received one dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months; and a second dose of MenACWY at 15 months of age.</description>
          </group>
          <group group_id="O2">
            <title>LA4 (Infant Vaccines Only)</title>
            <description>LA infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, pneumococcal conjugate vaccine, and rotavirus vaccine at 2, 4 and 6 months of age. These infants received one dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months and a second dose of MenACWY along with DTaP and Hib vaccines at 15 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With hSBA ≥1:8 at 1 Month After 1st (LA2) or 2nd (LA4) Toddler MenACWY Vaccination - LA Subjects</title>
          <description>Immunogenicity as measured by the percentage of subjects with serum bactericidal activity using human complement (hSBA) ≥ 1:8, directed against N.meningitidis serogroups A, C, W and Y.</description>
          <population>The analysis was done on per protocol population</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A Pre-vaccination (78, 101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="5"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A Post-vaccination ((78, 101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74" lower_limit="63" upper_limit="84"/>
                    <measurement group_id="O2" value="97" lower_limit="92" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C Pre-vaccination (78, 102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="1" upper_limit="11"/>
                    <measurement group_id="O2" value="1" lower_limit="0.025" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C Post-vaccination (78, 102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91" lower_limit="82" upper_limit="96"/>
                    <measurement group_id="O2" value="100" lower_limit="96" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W Pre-vaccination (70, 98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="1" upper_limit="12"/>
                    <measurement group_id="O2" value="5" lower_limit="2" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W Post-vaccination (70, 98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79" lower_limit="67" upper_limit="87"/>
                    <measurement group_id="O2" value="100" lower_limit="96" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Y Pre-vaccination (71, 95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="0" upper_limit="10"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Y Post-vaccination (71, 95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72" lower_limit="60" upper_limit="82"/>
                    <measurement group_id="O2" value="100" lower_limit="96" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean hSBA Titers at 1 Month After 1st (LA2) or 2nd (LA4) Toddler MenACWY Vaccination - LA Subjects</title>
        <description>Immunogenicity as measured by Serum bactericidal activity using human complement (hSBA) GMTs, directed against N. meningitidis serogroups A, C, W and Y.</description>
        <time_frame>12 or 15 months of age (one month post 1st or 2nd toddler vaccination)</time_frame>
        <population>The analysis was done on per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>LA2 (Infant Vaccines Only)</title>
            <description>LA infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. These infants received one dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months; and a second dose of MenACWY at 15 months of age.</description>
          </group>
          <group group_id="O2">
            <title>LA4 (Infant Vaccines Only)</title>
            <description>LA infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, pneumococcal conjugate vaccine, and rotavirus vaccine at 2, 4 and 6 months of age. These infants received one dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months and a second dose of MenACWY along with DTaP and Hib vaccines at 15 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean hSBA Titers at 1 Month After 1st (LA2) or 2nd (LA4) Toddler MenACWY Vaccination - LA Subjects</title>
          <description>Immunogenicity as measured by Serum bactericidal activity using human complement (hSBA) GMTs, directed against N. meningitidis serogroups A, C, W and Y.</description>
          <population>The analysis was done on per protocol population</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A Pre-vaccination (78, 101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.02" lower_limit="1.7" upper_limit="2.4"/>
                    <measurement group_id="O2" value="2.02" lower_limit="1.74" upper_limit="2.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A Post-vaccination (78, 101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" lower_limit="18" upper_limit="34"/>
                    <measurement group_id="O2" value="128" lower_limit="97" upper_limit="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C Pre-vaccination (78, 102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.18" lower_limit="1.73" upper_limit="2.74"/>
                    <measurement group_id="O2" value="2.05" lower_limit="1.68" upper_limit="2.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C Post-vaccination (78, 102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45" lower_limit="34" upper_limit="60"/>
                    <measurement group_id="O2" value="501" lower_limit="391" upper_limit="643"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W Pre-vaccination (70, 98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.34" lower_limit="1.79" upper_limit="3.05"/>
                    <measurement group_id="O2" value="2.33" lower_limit="1.86" upper_limit="2.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W Post-vaccination (70, 98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22" lower_limit="16" upper_limit="28"/>
                    <measurement group_id="O2" value="394" lower_limit="313" upper_limit="497"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Y Pre-vaccination (71, 95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" lower_limit="1.7" upper_limit="2.84"/>
                    <measurement group_id="O2" value="2.04" lower_limit="1.64" upper_limit="2.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Y Post-vaccination (71, 95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="11" upper_limit="20"/>
                    <measurement group_id="O2" value="329" lower_limit="254" upper_limit="426"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>US1+US3</title>
          <description>Groups MenACWY-CRM + Infant Vaccines (US1 +US3) pooled. US infants received MenACWY at 2, 4 and 6 months of age along with routine infant vaccines, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccine. These infants either received a fourth dose of MenACWY concomitantly with pneumococcal, HAV, and MMR-V vaccines at 12 months of age (US1A and US3) or received pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months and a fourth dose of MenACWY at 13 months of age( US1B).</description>
        </group>
        <group group_id="E2">
          <title>US2+US4A+US4B</title>
          <description>Groups Infant Vaccines only (US2, US4A, and US4B) pooled.
In both groups US infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. These infants received:
One dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months; and a second dose of MenACWY at 15 months of age ( US2 and US4A).
Concomitant pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months and one dose of MenACWY at 13 and a second dose of MenACWY at 15 months of age (US4B)</description>
        </group>
        <group group_id="E3">
          <title>US4C</title>
          <description>US infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines, at 2, 4 and 6 months of age. These subjects received concomitant pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months and one dose of MenACWY at 18 months of age.</description>
        </group>
        <group group_id="E4">
          <title>LA1+LA3+LA5</title>
          <description>Groups Men ACWY-CRM + Infant Vaccines (LA1, LA3 and LA5) pooled
LA infants received MenACWY at 2 and 6 months of age; and DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. These infants received at 12 months of age pneumococcal conjugate vaccine, HAV, and MMR-V and concomitant third dose of MenACWY (LA1A) or a third dose of MenACWY at 13 months of age (LA1B).
LA infants received MenACWY, DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. At 12 months of age these infants received pneumococcal conjugate vaccine, HAV, and MMR-V and received:
Fourth dose of MenACWY concomitantly with DTaP and Hib at 16 months of age (LA3A)
DTaP and Hib at 16 months and fourth dose of MenACWY at 17 months of age (LA3B).
Concomitantly the fourth dose of MenACWY (LA5).</description>
        </group>
        <group group_id="E5">
          <title>LA2+4+6AB</title>
          <description>Groups Infant Vaccines only (LA2, LA4, LA6A and LA6B) pooled. In all groups LA infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines at 2, 4 and 6 months of age. These infants either received: one dose of MenACWY concomitantly with pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months and a second dose of MenACWY at 15 months of age (LA2 and LA4) or received concomitant pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months and one dose each of MenACWY at 12 and 15 months of age (LA6A); or one dose each of MenACWY at 13 and 15 months of age (LA6B).</description>
        </group>
        <group group_id="E6">
          <title>LA6C</title>
          <description>LA infants received as part of routine infant vaccination schedule DTaP-IPV-HBV, Hib, rotavirus, and pneumococcal conjugate vaccines, at 2, 4 and 6 months of age. These infants received concomitant pneumococcal conjugate vaccine, HAV, and MMR-V at 12 months; and one dose of MenACWY at 18 months of age</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="173" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="84" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>IRON DEFICIENCY ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>LYMPHADENITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>CYANOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>PULMONARY VALVE STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>ATRIAL SEPTAL DEFECT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>FALLOT'S TETRALOGY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>HYPOSPADIAS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>OPTIC NERVE HYPOPLASIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>PYLORIC STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>HAEMATOTYMPANUM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>BLEPHARITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>DIARRHOEA HAEMORRHAGIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>HAEMATOCHEZIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>INTUSSUSCEPTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>PERITONITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>STOMATITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>DRUG HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>FOOD ALLERGY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>HYPOGAMMAGLOBULINAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ABSCESS LIMB</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>ABSCESS NECK</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>ABSCESS ORAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>ACARODERMATITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>ACUTE SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>ARTHRITIS BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>BACTERAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>BACTERIAL DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>BOTULISM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>BRONCHIOLITIS</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>BRONCHITIS VIRAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>BRONCHOPNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>CROUP INFECTIOUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>DENGUE FEVER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>ENTERITIS INFECTIOUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>EXANTHEMA SUBITUM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>FEBRILE INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS VIRAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>IMPETIGO</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>INFECTIOUS MONONUCLEOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>LOWER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>LUNG INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>OSTEOMYELITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>OTITIS MEDIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>OTITIS MEDIA ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>PERIORBITAL CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>PERTUSSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>PNEUMONIA BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>PNEUMONIA PRIMARY ATYPICAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>PNEUMONIA RESPIRATORY SYNCYTIAL VIRAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>PNEUMONIA VIRAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>RESPIRATORY SYNCYTIAL VIRUS BRONCHIOLITIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>RESPIRATORY SYNCYTIAL VIRUS INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION VIRAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL SKIN INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>SUBCUTANEOUS ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>VARICELLA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>VIRAL DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>VIRAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>VIRAL PHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>VULVAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ACCIDENTAL DRUG INTAKE BY CHILD</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>ACCIDENTAL EXPOSURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>BURNS SECOND DEGREE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>FOREIGN BODY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>HEAD INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>LIMB TRAUMATIC AMPUTATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>RIB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>ROAD TRAFFIC ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>SKULL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>THERMAL BURN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>TRAUMATIC BRAIN INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>UPPER LIMB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>COW'S MILK INTOLERANCE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>DIABETIC KETOACIDOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>HYPOGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>HYPONATRAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>SYNOSTOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>ACUTE MYELOID LEUKAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>BRAIN NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>COMPLEX PARTIAL SEIZURES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>CONVULSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>FEBRILE CONVULSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>GRAND MAL CONVULSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>PSYCHOMOTOR SKILLS IMPAIRED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>SUBARACHNOID HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>TONIC CONVULSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>NEPHROTIC SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>APNOEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>BRONCHIAL HYPERREACTIVITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>BRONCHOSPASM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>CHOKING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>FOREIGN BODY ASPIRATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>HYPOXIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>LARYNGOSPASM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>PULMONARY HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>RESPIRATORY DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>SLEEP APNOEA SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>STATUS ASTHMATICUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>TACHYPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>WHEEZING</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>RASH</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>URTICARIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>INTESTINAL OPERATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>KAWASAKI'S DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="957" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="279" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="202" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1946" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="795" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="178" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>CONJUNCTIVITIS</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="68" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="28" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="289" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="91" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="78" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="597" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="287" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="57" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>FLATULENCE</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="53" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="29" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>TEETHING</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="217" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="486" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="228" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="39" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>INJECTION SITE ERYTHEMA</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="280" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="108" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="100" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1245" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="548" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="117" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>INJECTION SITE INDURATION</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="204" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="101" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="78" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="745" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="333" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="90" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>INJECTION SITE PAIN</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="651" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="196" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="147" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1592" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="698" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="164" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>IRRITABILITY</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="800" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="240" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="171" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1120" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="474" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="110" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>MALAISE</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="136" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="73" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="296" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="94" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="74" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="748" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="341" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="74" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BRONCHIOLITIS</sub_title>
                <counts group_id="E1" subjects_affected="108" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="180" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="52" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="36" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="219" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="95" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="17" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>CROUP INFECTIOUS</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="48" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="35" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="375" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="192" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="27" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>OTITIS MEDIA</sub_title>
                <counts group_id="E1" subjects_affected="258" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="62" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>OTITIS MEDIA ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="163" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="71" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="340" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="108" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="74" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>VIRAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="44" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="28" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CRYING</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="558" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="154" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="124" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="927" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="419" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="98" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>SOMNOLENCE</sub_title>
                <counts group_id="E1" subjects_affected="676" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="184" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="141" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1198" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="513" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="110" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>EATING DISORDERS</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="425" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="122" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="93" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="607" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="263" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="69" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>BRONCHOSPASM</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="38" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="41" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="24" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>NASAL CONGESTION</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>DERMATITIS ATOPIC</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>DERMATITIS DIAPER</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>ECZEMA</sub_title>
                <counts group_id="E1" subjects_affected="105" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="154" subjects_at_risk="995"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="323" subjects_at_risk="2026"/>
                <counts group_id="E5" subjects_affected="136" subjects_at_risk="824"/>
                <counts group_id="E6" subjects_affected="32" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccines and Diagnostics</organization>
      <email>RegistryContactVaccinesUS@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

